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Abstract 
Measurement of gene expression profiles represents a snapshot of cellular 
metabolism or activity at the molecular scale. This involves measurement of 
messenger (m)RNA employing techniques such as reverse transcription 
quantitative polymerase chain reaction (RT-qPCR). To truly assign biological 
significance to associated findings, researchers must consider the idiosyncrasies of 
this method and associated technical error, termed measurement uncertainty. 
Significant error can occur at sample source, RNA extraction, RT and qPCR levels. 
This thesis explores the steps which may introduce potential bias. It is 
hypothesised that error in mRNA measurement can be partitioned across different 
experimental stages. Within this thesis, RNA measurement from sample source to 
qPCR has been analysed at each stage to delineate variability contributions 
attributed to specific steps using synthetic and validated endogenous reference 
genes, single cell lines, 3D models and complex bone tissue. These data determined 
that total RNA yields remained consistent between treatment (2D cell 
mineralisation, 3D co-culture mechanical loading) and control groups (p > 0.06). 
Sample complexity was positively correlated with RNA extraction yield variability. 
Evaluation of different extraction methods demonstrated that total RNA yields 
differed between methods (p < 0.001). Assessing total RNA quantity and quality, 
different metrics (Bioanalyzer, Nanodrop and Qubit) generated different yield 
estimates (p < 0.05), although quality estimates from different metrics were found 
to be comparable. In addition, different cell batches (cultures of the same cells 
from different cryo vials) generated disparate total RNA yields (p < 0.02), with 
variable quality estimates, despite normalisation for cell count. RT-digital PCR 
analysis revealed quantification differences and detection sensitivity biases 
between different RT enzymes (p < 0.0001), suggesting cDNA prepared using 
different RT enzymes cannot be meaningfully compared. The ERCC synthetic 
targets were variable under the model conditions assessed and therefore not 
suitable as normalisers in these circumstances. This work provides a guide for the 
approaches necessary to reduce error, improve experimental design and minimise 
uncertainties.   
  
 
 
Chapter 1 
 
Introduction 
 
Chapter 1 Introduction  
Page 1 
1 Introduction 
This chapter is adapted from the peer-reviewed publication: Considerations for 
accurate gene expression measurement by reverse transcription quantitative PCR 
when analysing clinical samples. Sanders R, Mason DJ, Foy CA, Huggett JF. Anal 
Bioanal Chem. 2014 May 25. doi: 10.1007/s00216-014-7857-x.  
1.1 Introduction to Metrology 
Metrology is the science of measurement. A theme in constant flux and 
development, metrological challenges are fundamental to every scientific field. The 
primary goal for all forms of measurement is accuracy, to address the question 
whether the measured value is a true representation of the actual value. These 
queries can be partially satisfied by the assignment of uncertainty values to 
express the confidence in a result. Methodological and technological innovations 
fuel an ever-progressing capability to improve measurement accuracy and 
precisely assign values to measurands of otherwise unknown quantities.  
1.1.1 The Need for Standardisation 
Throughout the history of civilisation, as modern societies evolved each developed 
their own unique numbering systems. For as long as these measurement systems 
have been in place, standardisation practices have been developed in order to aid 
social development through trade and commerce. An agreed set of measurement 
units recognised throughout the world was essential for the evolution of 
international trade. Since 1670, when a comprehensive decimal measurement 
system was proposed, modern society has been on a journey towards the 
development of a globally recognised metric system. However, it was not until 
1790, in the midst of the French Revolution, when the National Assembly of France 
requested the French Academy of Science to ‘deduce an invariable standard for all 
the measures and all the weights’, that a simple and scientific system was put in 
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place. The consequence of this development came to fruition in 1960, when the 
General Conference on Weights and Measures revised the system and established 
seven base units: the metre (for length); the kilogram (for weight); the second (for 
time); the ampere (for electric current); the kelvin (for thermodynamic 
temperature); the mole (for amount of substance); and the candela (for luminous 
intensity). Together, these base units form the foundation of the Système 
International d’Unités – the international metric system of units known throughout 
the world as SI. A further 22 derived units complete the complement of the SI 
system [1,2]. The metric system is widely used in science, engineering and 
medicine. Today, standardisation of measurement is fundamental to all facets of 
civilisation and is particularly well established within the scientific and 
engineering communities.  
The National Measurement Institutes (NMIs) that lie within many of the countries 
throughout the world develop and maintain national measurement standards. LGC, 
the UK’s NMI for chemical and bioanalytical measurement, supports the 
measurement infrastructure in the UK by producing reference materials which 
allow other laboratories to ensure the traceability of measurement results through 
instrument calibration and method validation.  
This level of measurement standardisation is crucial to almost all aspects of 
modern-day life. Architecture; superconductors; GPS; transport systems; finance; 
the internet; all these endeavours would be unsuccessful without modern 
metrology standards. Failure to meet these standards can be very costly, 
financially and otherwise. Human health and safety depend on reliable 
measurements in medical diagnosis and therapy. The reliability of these 
measurements must be beyond reproach, because errors can have devastating 
consequences. These factors taken together necessitate sustained efforts to 
improve the reliability of such measurements and play a key role in the continual 
development of effective healthcare systems. 
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1.1.2 Accuracy and Measurement Uncertainty 
Accuracy is essentially how close the measurement is to the truth and is influenced 
by both precision and bias [3]. The challenge when measuring patient samples is 
that the truth is often a moving target that can vary from patient to patient and 
within patient, over time. As measurement systems improve they may often lead to 
increased measurement precision. The added danger with high precision is that it 
can lead to considerable bias. This can manifest results that are difficult to 
reproduce, either simply as a result of repeat measurements providing different 
estimations of the truth or, potentially worse, results that are reproducible but still 
biased and therefore all incorrect; this situation is problematic because agreement 
between laboratories leads to further confidence that the wrong result is correct.  
To further understand measurement accuracy, considerations of uncertainty 
should be applied to indicate scientific confidence. Uncertainty has two 
components: systematic and random variation. Systematic errors lead to bias in 
the measurement. These error components are fixed and predictable and may be 
inherent to various instruments and methods. Random variation occurs when 
making repeated measurements (related to precision; a measure of the degree of 
agreement between replicate measurement results obtained for the same sample). 
Contributing factors are multitude and include issues of sampling, different 
analysts as well as each stage of the stepwise protocol necessary for a 
measurement [4].  
The concept of accuracy includes the effect of both precision and bias and 
describes how close a single result is to the true value. While it cannot be given a 
numerical value, measurement results are said to be ‘more accurate’ when 
measurement errors are reduced. Results with a small bias that are also very 
precise are considered highly accurate, i.e., the average result is close to the true 
value and the data spread (standard deviation) is small. Equally, methods 
generating data with a large bias (large difference between true value and average 
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value of results), or imprecision (large variance), or both, would be considered 
inaccurate.  
It is also prudent to introduce and define precision terms (Figure 1.1). 
Repeatability represents the tightest extreme of independent precision 
measurements, describing the sort of precision one might expect from a set of 
replicate measurements made one after the other, in a single laboratory, by a 
single analyst on a single instrument, with a short time interval [3,5]. Over such 
conditions, one would not expect results to be affected by drift. Intermediate 
precision represents mid-range precision, where a single laboratory uses several 
analysts or equipment sets for a particular method, over different days, and may 
give the most appropriate precision value for setting quality control limits [3,5]. 
Various combinations of conditions are user defined. Reproducibility represents 
the widest extreme of precision, describing the variation that one might expect 
within a set of measurements made on a sample over an extended time period, in 
several laboratories, by a number of different analysts and different instruments 
[3,5]. One would expect reproducibility to reflect variation in the method from all 
possible sources, i.e. the sort of variation expected in a method used to measure a 
sample in several different laboratories.  
As discussed in subsequent sections, the science of measurement is well 
established in the fields of physics and chemistry. In molecular analysis however, 
the concept of ‘true value’ is relatively new and hampered by the fact that there is 
no agreement on how such a value might be obtained [4]. Despite this, bias must 
still be considered in the form of standardisation and mechanisms put in place to 
ensure the robustness of results between laboratories can be assessed. 
Accordingly, variability at each stage of an experimental process needs to be taken 
into account. This allows a comprehensive assessment of the confidence in a result 
and enables inter- and intra-laboratory comparison of data, especially if different 
measurement equipment and/or methods are utilised.   
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Figure 1.1 Effect of varying conditions on precision measurement. In general, the more 
conditions you vary within a particular method the larger the precision value will become. 
Thus you will normally expect repeatability precision to be smaller (i.e. more precise) than 
intermediate precision, which will in turn be smaller than reproducibility. To get a 
representative estimate of the precision of an analytical method, the replicate determinations 
made must be sufficiently independent. A failure to analyse replicates that are appropriately 
independent will lead to misleadingly good precision data. Figure modified from [5].  
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1.2 Reference materials 
 “Reference materials are important to ensure the necessary sensitivity, 
specificity and level of reproducibility of intra- and inter-laboratory test 
results. The best approach to achieve consistent and comparable 
quantitative data amongst laboratories is by the use of internationally 
established reference reagents.” 
Dr Karen Mann, President of the Association of Molecular Pathology, in her testimony before Congress 
(Feb 24, 2010). Source: http://www.amp.org 
To obtain highly accurate results, sample unknown measurements should be 
properly correlated to appropriate standards with a well-defined value and 
uncertainty [3]. The establishment of accurate and practical measurement 
standards linked to fundamental constants, having also the range and diversity 
required for the whole of modern science and technology is a major undertaking. 
Measurement standards, also known as reference materials, are not static. They 
evolve continually to reflect advances in science and in response to changing 
industrial and other needs [1,6,7]. 
A reference material (RM) is defined as “a material or substance one or more of 
whose property values are sufficiently homogeneous and well established to be 
used for the calibration of an apparatus, the assessment of a measurement method, 
or for assigning values to materials” [8,9]. A certified reference material (CRM) is 
defined as a “reference material, accompanied by a certificate, one or more of 
whose property values are certified by a procedure which establishes its 
traceability to an accurate realisation of the unit in which the property values are 
expressed, and for which each certified value is accompanied by an uncertainty at a 
stated level of confidence” [9,10].  
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In any long-term programme to observe small changes in critical parameters, such 
as monitoring viral loads in disease states, the measurements made at the 
beginning of the study must be compatible with those made at the end, i.e. the 
measurement standards used to calibrate them must have long-term stability [1].  
1.2.1 Traceability 
A given result obtained in terms of measurement units that are linked by an 
unbroken chain of calibrations or comparisons to national measurement 
standards, in practical terms to SI units, is known as traceability of measurement 
results [1]. The uncertainty of the calibration or comparison must be given at each 
link of the chain. An appropriate uncertainty of the final measurement in terms of 
SI units can then be achieved. Only when the uncertainty has been properly 
calculated is it possible to estimate the measurement’s reliability and decide 
whether or not it is suitable for the application in hand [1], or its ‘fitness for 
purpose’. In this way, measurement traceability facilitates appropriate data 
comparison.  
1.2.2 Accurate Measurement in Molecular Biology 
When used appropriately, RMs and CRMs allow value assignment for a measurand 
in SI units [9,11]. However, molecular biology is a comparatively new discipline, 
particularly in terms of the development of measurement standards. This is 
additionally hindered by the fact that, while some biological methods may be 
traceable to the SI via the Mole (for example, accurate estimation of total DNA 
mass concentration, e.g. ng/μL) [12], current SI units and their derivatives may in 
fact not be apposite for the description of all biological measurement as indirect 
conversions and various assumptions are necessary for reporting according to SI. 
For example, whilst estimation of total DNA mass concentration by UV 
spectrophotometry may be converted to the Mole, this method does not take into 
account presence of intact target or the capacity of any given target to undergo 
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successful PCR amplification. These are assumptions that must be made in order to 
assign a value. An inability to measure directly to SI affects traceability and 
uncertainty considerations. Several studies have highlighted the lack of standards 
in this discipline, which leads to difficulties in comparing results from different 
laboratories or between different methods [13-16]. 
The three central components of molecular biology measurement encompass DNA, 
RNA and proteins. In these terms, a development of an appropriate RM may 
require the application of non-SI derived standardised measurement; such as 
based on enumeration principles, for example DNA copy number (such 
enumeration units can be linked back to SI, but several assumptions must be made 
that may compromise uncertainty estimates). An international unit (IU), officially 
defined by the International Conference for Unification of Formulae, is an 
internationally accepted amount of a substance. This arbitrary measure may be 
used to standardise measurements where the amount of a substance cannot be 
traced back to SI. The IU is utilised for fat-soluble vitamins (such as vitamins A, D 
and E) and certain hormones, enzymes, and biologicals (such as vaccines and viral 
RMs [17]). DNA RMs certified for their DNA mass concentration, with an estimated 
measurement uncertainty and traceable to the SI, are beginning to emerge for the 
purpose of measurement standardisation in molecular biology. Current examples 
include human cytomegalovirus [18], BCR-ABL [19] and GMO analysis [20]. 
However, appropriate CRMs are necessary for effective comparison of quantitative 
measurements, method validation, and quality control in routine analysis [12]. To 
improve biological measurement capabilities, DNA (or RNA) reference materials 
are required which have been certified for total DNA (or RNA) concentration [12]. 
Over the last ten years, international measurement institutes have collaborated to 
build an improved support infrastructure for biological measurement. This work is 
coordinated by the Nucleic Acids (formerly Bioanalysis) Working Group, part of 
the CCQM (Consultative Committee for Amount of Substance — Metrology in 
Chemistry [21]) of the International Committee for Weights and Measures. This 
relatively new field of science is referred to as biometrology and has applications 
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in fields as diverse as agricultural biotechnology, diagnostics, forensic science, 
pharmaceutics and speciation.  
The real-time quantitative polymerase chain reaction (qPCR) [22], developed from 
the revolutionary method of PCR pioneered by Kary Mullis in the 1980s [23-25], 
has emerged as a widely used method for biological investigation because it can 
detect and precisely quantify very small amounts of specific nucleic acid 
sequences. This is coupled to an inherent simplicity that makes qPCR assays 
straightforward to design and perform. The characterisation of gene expression 
patterns through quantification of messenger RNA (mRNA), by coupling reverse 
transcription with PCR, as a surrogate of cell metabolism is a major application of 
this technology. Reverse transcription quantitative PCR (RT-qPCR) enables rapid 
and precise assessment of changes in mRNA levels as a result of physiology, 
pathophysiology or development [26]. However, for RNA analyses to be clinically 
informative, reliable measurements that are reproducible between laboratories 
are essential. As much as 30% of the costs of medical care budgets are in 
measurements and tests related to diagnosis [1]. This necessitates sustained 
efforts to improve the reliability of such measurements and tests, which play a key 
role in the continual development of effective healthcare systems.  
In research studies, RT-qPCR has been used to measure bacterial mRNA levels 
[27,28] or RNA viral loads [29-32], to evaluate cancer status or to track disease 
progression and response to treatment [33-35]. As a consequence, this method is 
being applied to the discovery and development of putative biomarkers. An 
example of successful translation of an RT-qPCR method to patient is the 
OncotypeDx assay, which predicts the potential benefits of chemotherapy and 
likelihood of cancer recurrence [36-39] and thus can be used to stratify patients to 
different treatment regimens [40]. Furthermore, viral load monitoring using RT-
qPCR is now routine for a number of RNA viruses [41].  
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1.3 RNA Molecular Measurement 
As with other approaches, accurate quantification of RNA demands a 
comprehensive assessment of uncertainty. To facilitate this, we must first 
undertake a consideration of those factors within the measurement process that 
may contribute variability to that measurement. Only then can we proceed with 
the assignment of uncertainty.  
1.3.1 Sources of Variability 
The route from sample to accurate quantification of mRNA levels is a multi-
component process each with its own experimental uncertainty. There can be 
numerous factors that need to be considered (Figure 1.2) [42]. Such cause and 
effect diagrams are widely used in measurement uncertainty and the field of 
metrology [43,44]. There are several sources of bias in an RNA measurement by 
RT-qPCR, the main culprits are summarised in Table 1.1 [42].  
RT-qPCR techniques have the ability to quantify nucleic acids over a wide dynamic 
range (at least eight logarithms) and are precise (DNA and RNA measurements can 
typically be optimised to have a coefficient of variation of < 5% or < 10%, 
respectively [45]). Routine detection of fewer than five target copies make it 
possible to analyse small samples such as clinical biopsies or miniscule lysates 
from laser capture microdissection [7,26,46]. But measurements using this precise 
technique are only as robust as the upstream processes used to sample, store and 
prepare the RNA. Precision is a measure of the degree of agreement between 
replicate measurement results obtained for the same sample [3,4]. However, what 
is often overlooked is that the whole stepwise procedure contributes to the 
experimental precision.  
Variability in qPCR results obtained from identical samples assayed in different 
laboratories is a problem [46-48]. The use of distinct instruments, software,   
Chapter 1 Introduction  
Page 11 
 
Figure 1.2 Cause & Effect: Uncertainty Contributions for mRNA Analysis. The central arrow represents the experimental process from RNA to 
quantification. Branches feeding into experimental progression characterise sources of variability that contribute to uncertainty at various stages of 
the process. There are numerous methodologies available for the final quantification step. Concentration (conc), quantification (quant).  
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Table 1.1 Factors Contributing Bias to an RT-qPCR Measurement 
Source of Bias Details/Solution 
Sample Sampling. Inhomogeneous samples (e.g. whole tissue biopsies 
comprising multiple cell populations) may lead to an average 
mRNA profile across multiple cell types. Particularly important for 
disease states such as cancer where only the tumour itself should 
be processed. Optimise sample collection, using cellular separation 
where appropriate. Care should be taken to obtain samples when 
multiple factors can be controlled for (e.g. time of collection, time 
post treatment, gender, race, age, etc.). 
RNA not 
efficiently 
extracted  
Will limit the amount of RNA available. May bias towards more 
abundant targets making minority target measurement 
difficult/impossible. Optimise sample collection and extraction 
process.  
RNA degraded Bias cDNA production and detection sensitivity. May affect some 
targets more than others. Avoid multiple freeze-thaw cycles. Use 
RNase/DNase free plastics or DEPC treated labware and RNase 
decontaminating solutions and sprays. Use RNase inhibitors during 
sample preparation. Change gloves frequently. Sample analysis by 
gel electrophoresis or a lab-on-a-chip platform can reveal RNA 
degradation before the RT step.  
RNA storage Optimise storage conditions to preserve RNA integrity 
Non-linearity of 
method 
Caused by inhibition, enzyme inefficiency (e.g. resulting in not all 
RNA being converted to cDNA in RT reaction), etc. Choose an RTase 
that is more tolerant of inhibitors typically found in RNA 
preparations (e.g., salt, phenol, proteins, etc.). Validate RTase for 
sample type. Include appropriate controls. Too little or too much 
RNA or widely varying amounts of RNA in RT reactions will result 
in inefficient or biased results (non-linearity), with saturation at 
the extremes. Quantify the amount of RNA in each sample and add 
the same amount to each RT reaction.  
Inappropriate 
calibrator 
For example, DNA standard is used when measuring RNA. 
Calibrator prepared in different background material/matrix to 
unknown samples. Where possible, ensure that calibrators are 
validated as appropriate for sample type and are spiked into 
sample matrices.  
Instrument bias Ensure instrument maintenance and calibration is up to date.  
Operator Different operators can introduce significant bias. Where possible, 
ensure operator consistency throughout an experimental protocol. 
When analysing data from different operators, the appropriate 
consideration of intermediate precision and/or reproducibility 
should be made. Operator bias can be tested by comparing different 
operators.  
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reagents, plates or seals can often lead to underestimated run-to-run differences 
that need to be compensated in order to allow data reproducibility [49]. Indeed, 
the single most likely source of data variation is due to variability introduced by 
the analyst [46-48]. Since there are so many steps involved in taking a tissue 
sample to a ‘quantitative’ result (Figure 1.2), it is not surprising that this variation 
is problematic [47] and factors that more comprehensively estimate error will lead 
to a better estimation of the variation and increase the likelihood of making 
accurate measurements. 
1.3.1.1 Sample Source and Storage 
Samples may be obtained from a wide variety of biological sources: from animal 
and plant material, to bacteria and viruses. Each sample type will have its own 
qualities, which will contribute to variability. For example, extraction of high 
quality RNA is particularly challenging in bone as it contains low cell numbers 
embedded within a highly mineralised tissue [50]. It is important to recognise and 
account for these differences in order to correctly design experiments that will 
generate meaningful data.  
The surgical removal of tissue or the collection of cells from a plate can introduce 
variability. The transcriptome is dynamic [51] and highly sensitive to 
environmental factors [52] such as tissue removal, washing plated cells, or tissue-
handling methods [53]. Harvesting samples via a highly reproducible method in 
the shortest possible time frame will minimise transcriptional changes induced by 
the manipulation of the samples, and can dramatically reduce the expression 
variability between biological replicates. Flash freezing of tissue samples in liquid 
nitrogen immediately upon isolation is typically recommended. For cell-based 
assays, the initial RNA extraction buffer should be added from a kit directly to the 
washed cells on the plate with scraping and mixing to form a stable homogenate 
that can be frozen at –20ºC or –80ºC [53].  
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1.3.1.1.1 Cell Line Treatment 
Treating cells, tissue, or animals with intervention can be a common source of 
error due to the varying post-treatment incubation times [51,53]. Transcription of 
mRNA is dynamic such that a treatment-induced transcriptional effect can be 
observed only during a particular time frame. Thus, sampling a series of time 
points maybe the difference between valid results, less than optimal data, or no 
data at all [53].  
Due to the dynamic nature of the transcriptome, many researchers plan 
experiments to sample different time points; however, some may fail during 
implementation [53]. A good example is the addition of a compound to several 
plates of cells that will be used in a time-course study in which all the plates are 
treated at precisely the same initial time. Under this circumstance, it would be 
difficult, or impossible, to stop the treatment for several replicates at each time 
point due to the time required to manipulate each replicate plate of cells. A more 
accurate approach is to stagger the treatments between each replicate to allow 
enough time to stop treatment at precisely the same time for each plate in a 
replicate group [53].  
1.3.1.2 RNA Extraction 
RNA is extremely labile compared with DNA, which is mainly due to its 
susceptibility to RNase degradation. RNases are very stable and RNA isolation must 
therefore be carefully performed to ensure both RNA integrity and the removal of 
contaminating nucleases, genomic DNA (gDNA) and RT or PCR inhibitors. This can 
be a problem with any sample source, but clinical samples are of special concern 
because of their complexity and potential inconsistencies in sample size, collection, 
storage and transport can lead to variable quality of RNA templates [26]. The 
mRNA used for clinical diagnostics and research may be derived from various 
tissues including biopsies, lumbar puncture, blood, urine or buccal swabs: each 
posing their own challenges for accurate measurement. In each case, the 
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limitations of sample handling in real life clinical situations will be different. It is 
well known that RNA is sensitive to degradation by post-mortem processes and 
inadequate sample handling or storage [6,54].  
As with other molecular biology processes (e.g. DNA or protein extraction), there 
are a multitude of kits and protocols available on the market. While this availability 
of choice has undeniable benefits, it also creates problems that can only be solved 
by experimental compliance with the utilisation of appropriate RMs. By definition, 
RMs are designed to enable researchers to identify and account for these 
differences in data interpretation. The impact these variabilities can exert should 
not be taken lightly.  
1.3.1.3 Reverse Transcription Quantitative PCR 
When performing RT-qPCR it may be widespread practice to focus on technical 
replication at the qPCR stage of the process. However, many studies have shown 
that variability attributed to reverse transcription is far greater than the variability 
contribution of qPCR alone [47,48,55,56], (Figure 1.3). This increased variance 
may be caused by factors such as RT enzyme efficiency, RNA integrity and 
secondary structure [47]. The RT step is therefore critical for accurate RNA 
quantification [56,57]. Reverse transcriptase linear dynamic range is another 
crucial consideration for successful RT-qPCR [47] and should be demonstrated 
empirically. However, often it is the PCR rather than the RT step that is replicated. 
This has the danger of appearing to produce highly precise data, but could in fact 
proffer bias by masking true measurement variability. Consequently, true, 
meaningful and clinically significant measurement, particularly of small expression 
fold changes, ideally requires a discussion of the potential different sources of 
variance and bias.  
Several factors can influence a result. For example, multiple reverse transcriptase 
enzymes with different characteristics exist and unintended endogenous priming   
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Figure 1.3 Schematic representation of variability observed between cDNA and RNA 
standard curves. Green points: standard curve. qPCR variability is relatively low when 
compared to reverse transcription variability. As a result, a standard curve generated from the 
dilution of cDNA indicates the variability associated with the qPCR step alone and does not 
represent variability associated with the RT step. Alternatively, a standard curve generated 
from an RNA dilution series incorporates the variability accountable to the RT step, which is 
intrinsically more variable than qPCR. Consequently, the range within which the unknown 
sample measurement can reliably lie is greater when using an RNA-based standard curve and 
smaller when using a DNA-based standard curve. The RNA curve will therefore provide a more 
accurate estimate of uncertainty, offering greater confidence in a result. Sample fold changes 
discerned when utilising this approach more likely represent ‘true’ measurement differences 
rather than insufficiently apportioned uncertainty.   
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can occur regardless of which primers are used to prime the RT reaction. Such 
non-specific priming can lead to lowered and/or variable signal in the subsequent 
PCR assay [26,48]. Each strategy may exert different efficiency influences over the 
RT reaction and as such experimental designs should be harmonised to reflect this. 
Equally, total RNA concentration should be similar in every sample to minimise 
bias. In addition, the purity of RNA can be the cause of variable Cq values from 
contaminants that can affect reaction efficiency [58].  
RT-qPCR is used extensively in clinical research investigating putative biomarkers 
for disease diagnosis as well as for predictive and prognostic monitoring. However, 
on review of the literature, articles published reporting RT-qPCR data frequently 
do not report all experimental details relating to RT-qPCR experiments [59]. 
Fundamental experimental details are often omitted when reporting mRNA 
measurements, including information pertaining to RNA quality, rational for choice 
of normalisation strategy, location of amplicon or detailed descriptions of the 
reverse transcriptase and PCR assay conditions [60,61].  
1.3.1.3.1 Reverse Transcription Priming 
Broadly three strategies exist for priming during cDNA synthesis. Random primers 
prime non-specific cDNA synthesis at multiple transcript sites and may include 
rRNA templates in total RNA samples. Given that total RNA contains only 3-5% 
mRNA [62], the potential for non-protein coding synthesis is large, which may 
create inconsistencies if the target of interest is present at low levels as ineffective 
priming will lead to non-quantitative amplification. If bias is consequently 
introduced, this becomes exaggerated during qPCR amplification. For low target 
levels it may be preferable to prime using oligo d(T)16 as this will specifically 
amplify polyadenylated (poly(A)) tail targets, i.e. mRNA, preventing out-
competition of low level targets by rRNA fractions. Target-specific primers 
synthesize specified cDNA sequences. However, this requires separate priming 
reactions for each target and gene-specific variation may be introduced [48].  
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1.3.1.3.2 Reverse Transcription Enzymes 
Reverse transcriptase’s (RT enzymes) are RNA-dependent DNA polymerases 
encoded by retroviruses, which convert their RNA genome into DNA prior to host 
genome infiltration. These RT enzymes have two functions; firstly as a DNA 
polymerase utilising RNA as a template in the viral life cycle, although capable of 
using ssDNA as an equally efficient template in the laboratory. This is due to the 
fact that DNA-dependent DNA polymerase activity is also present to allow 
synthesis of the complementary DNA strand after synthesis of the first strand 
using the RNA template. This intrinsic DNA-dependent DNA polymerase activity 
also explains in part the importance of performing efficient DNase treatment of all 
RNA extracts prior to the RT. Its second function is RNase H activity, or 
ribonuclease H activity, whereby the RNA moiety of an RNA-DNA duplex or hybrid 
formed following RT of an RNA template is degraded [62].  
Commercially available RT enzymes are derived from one of two sources; Moloney 
murine leukemia virus (MMLV) or Avian myeloblastosis virus (AMV), either 
purified directly from the virus or expressed in E. coli. Fundamentally, both RT 
enzymes possess the same activities. However, differences include optimal 
experimental conditions for temperature and pH, as well as RNase H activity, 
which is much stronger for AMV than MMLV-derived enzymes [62].  
The AMV-derived enzyme has a powerful RNase H activity that can cleave the 
template near the 3’ terminus of the growing DNA strand if reverse transcriptase 
pauses during synthesis [63,64]. Thus, the high level of RNase H activity associated 
with the avian RT tends to supress the yield of cDNA and restricts its length. The 
murine enzyme may be better suited for RT-qPCR because its RNase H activity is 
comparatively weak [65]. However, the MMLV enzyme reaches maximum activity 
at a lower temperature (37ºC) than the avian enzyme (42ºC), which may be a 
slight disadvantage if the RNA template has a high degree of secondary structure 
[64].  
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Variants of MMLV RT that lack RNase H activity have been engineered [64]. Several 
such enzymes are sold commercially (for example, Superscript from Life 
Technologies and StrataScript from Stratagene). The modified RTs transcribe a 
greater proportion of the template molecules and synthesize longer cDNA 
molecules than the WT enzyme [63,65,66]. In addition, they are capable of cDNA 
synthesis at higher temperatures (up to 50ºC in some cases), which is an 
advantage when the template RNA is rucked into secondary structures [64].  
Thermostable Tth DNA polymerase (or recombinant Tth, rTth), which is encoded 
by the thermophilic bacterium Thermus thermophilus, exhibits RT activity in the 
presence of Mn2+ [67]. The chief advantage of using Tth polymerase in RT-qPCR is 
that both stages of the reaction (RT and qPCR) are carried out in the same reaction 
tube [68]. As a disadvantage, the average size of the cDNA synthesised by the Tth 
polymerase is only ~1-2 kb, far less than can be achieved with MMLV RT (~10 kb) 
[64]. In addition, the use of Mn2+ is of concern because of the lowered fidelity of 
DNA synthesis in the presence of this cation. Finally, Tth cannot be used with 
oligo(dT) or random hexamers as primers, since the hybrids will be unstable at 
temperatures at which the thermostable DNA polymerase is active [64].  
As for PCR enzymes for use in RT-qPCR, RT enzymes require efficiency over a wide 
dynamic range. This facilitates efficient conversion of both high and low 
abundance transcripts into cDNA and as such is one of the most crucial steps in a 
quantitative study [62]. RT efficiency may be influenced by total RNA content in 
the RT reaction [56,57], where quantification of both high and low abundance 
targets is positively correlated with total RNA background present in the RT 
reaction. In this capacity, background RNA may act as a chelator of inhibitors. 
When dilutions are performed at the RNA stage, in order to maintain RT reaction 
linearity it is suggested that a carrier RNA should be included in the reaction mix to 
ensure the total RNA concentration for each reaction is constant. This is 
particularly important for generation of standard curves for qPCR analysis.  
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1.3.1.4 Inhibition 
Several studies have also shown that RT components may have an inhibitory effect 
on the subsequent qPCR reaction, the magnitude of which depends on the RT 
system [47,62,69-72]. This is particularly noticeable for low abundance targets 
within undiluted cDNA and in the absence of carrier. The inhibitory effect of 
reversible inhibitors decreases upon dilution of the cDNA samples for calibration 
curve analysis. Therefore, this should be considered when performing RNA 
standard curves. However, when using RNA standard curves, all standards will 
consequently have the same amount of RT components when used in the qPCR 
reaction and so the inhibitory effect should be equal across all samples. When 
performing a cDNA standard curve, the lowest standards are subject to the highest 
level of dilution and therefore more efficient in the qPCR. This disparity between 
samples creates a non-linear relationship between standards, which may yield a 
theoretical reaction efficiency of over 100%. Furthermore, if samples are 
compared at different dilutions, measurement differences may in part be due to 
variable inhibition of the PCR by RT components [62], rather than true biological 
variability. Sellner et al. [70] suggest that maintaining an RT:PCR enzyme ratio less 
than 3:2 alleviates the PCR inhibition caused by the RT enzyme. Moreover, this 
study also showed that adding non-homologous RNA improved PCR enzyme 
sensitivity by up to 100 fold. This reliance on unit ratios suggests an interaction 
between the two enzymes at a molecular level, which may take the form of direct 
binding between the two enzymes. The alleviation of this inhibition by the addition 
of extra non-homologous RNA may be due to the RNA providing an alternative 
binding substrate for the RT enzyme [70]. These observations strengthen the case 
for using RNA, rather than cDNA, dilutions in RT-qPCR experiments and this 
approach is recommended by the author.  
Contrary to independent findings for low abundance targets [56,57], Levesque-
Sergerie et al. [62] suggested that the presence of background does not alleviate 
the inhibitory effects of RT components. In fact, in those samples with higher 
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background concentrations, the auspicious effect of RT component dilution on PCR 
inhibition was muted. As different enzymes may have different reaction 
efficiencies, the RT component inhibitory effect may be enzyme dependent. 
Dilution may therefore change the efficiency ranking of compared qPCR enzymes.  
Understanding the impact of sample matrix on different targets helps to identify its 
influence on the accuracy of analytical results [73]. In this context, matrix refers to 
components of a sample other than the analyte. The presence of RT or PCR enzyme 
inhibitors has the potential to increase measurement error, reduce assay precision 
and sensitivity, and produce false negative results in both quantitative and 
qualitative RT-qPCR assays [74]. Inhibitors can come from many sources including 
co-purified cellular or tissue components, carry over components from storage 
buffers and the extraction process and the RT reaction. For example, biological 
samples from different sources (human tissue from two different organs) may 
comprise distinct protein profiles. The inconsistency between these different 
‘background matrices’ may alternately influence experimental outcomes. Studies 
show that PCR inhibition can be assay specific and PCR inhibitors co-purified 
during nucleic acid extraction may affect different assays to variable degrees. This 
highlights the importance of matched sample matrices when evaluating potential 
reference genes to ensure both the reference and the target gene assay are subject 
to the same reaction conditions [74]. Furthermore, calibration curves that are 
prepared in a reaction that is not affected by the inhibitor may yield biases.  
All this may contribute to variation in measurement, particularly if samples are 
obtained and analysed periodically during a successive long-term study. 
Recognising the importance of matrix-specific standards helps to identify influence 
of sample matrix on the accuracy of analytical results [73] and ensures that 
temporally separated measurements may be compared meaningfully. 
Consequently, sampling and subsequent storage should be carefully controlled and 
documented in order to preserve the quality and abundance of the RNA material. 
This is especially important in clinical studies [75-78]. Both biological and 
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technical replicates are recommended for good experimental design [79], (Figure 
1.4). The potential for the introduction of variability is greatest at the first stages 
in experimental process, i.e. biological variability at sample source.  
1.3.1.4.1 One-Step versus Two-Step RT-qPCR 
While conventional methods partition the RT and qPCR steps of the process, recent 
years have seen an abundance of one-step processes, where both RT and qPCR 
occur in the same reaction, come into common use. Using the conventional two-
step method, where RT and qPCR steps are temporally and spatially separated, 
researchers can replicate at either or both the RT and qPCR levels. Additionally, 
extra handling stages are required in order to transfer the newly synthesised cDNA 
into the qPCR reaction mixture. This also results in a further dilution of sample and 
dilution of the RT reaction components before commencement of qPCR. Dilution of 
both potential sample/extraction contaminants and/or RT components may 
alleviate inhibition of the qPCR reaction. In contrast, one-step processes ensure 
that any sample dilution is performed at the RNA level, any replicate analyses 
consequently replicate the RT step; the sample does not undergo further dilution 
(when cDNA proceeds to qPCR amplification) and no additional handling steps are 
involved. This may be particularly valuable when low copy number targets are 
analysed. When using one-step processes, the influence of RT components and 
RNA contaminants on the efficiency of the qPCR reaction should be investigated to 
apportion these variabilities.  
One-step RT-qPCR systems may circumvent the issue of RT component inhibition 
of PCR since equal bias introduced by RT components is maintained, as 
components are not attenuated in any of the standard dilutions. Thus qPCR 
reactions should also remain linear within the dynamic range. Furthermore, by not 
requiring cDNA dilution by transfer into a qPCR reaction, one-step processes may 
also enhance sensitivity of low abundance targets. However, to obtain highly 
accurate results, sample unknown measurements should be properly correlated to   
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Figure 1.4 Schematic representation of different experimental designs representing 
biological versus technical replication. Generally, data variability increases, as replication is 
included from higher stages within the experimental process. For example, to ascertain true 
patient variability, replicate biological samples must be analysed (different samples from one 
patient, samples from different tissues from the same patient, or samples from different 
patients). The RNA extraction and reverse transcription components of the process may 
contribute more variability to the final measurement than qPCR alone. Definition of all sources 
of technical variability enables the actual biological variability to be discerned and as such, 
more confidence can be conferred to the results when this variability is included.  
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appropriate measurement standards, or RMs, with a well-defined value and 
uncertainty [1,6,7].  
Significant differences in one-step versus two-step RT-qPCR quantification 
sensitivities may be observed for low copy targets or low concentration samples 
such as single cells [71,72,80,81]. In such observations, one-step methods display 
up to a 32-fold (5 Cq) increase in sensitivity for transcript copy number compared 
to two-step reactions. This sensitivity difference has been attributed to gene-
specific priming in one-step protocols (as opposed to random hexamers or oligo 
(dT) commonly used in two-step protocols). Alternatively, there may be increased 
opportunity for the generation of mRNA secondary structures with some two-step 
RT temperature conditions. Target availability for primer annealing and the RT 
enzyme is diminished (random hexamers require a lower pre-incubation 
temperature of 25ºC to aid target binding) [80,82]. Indeed, further studies show 
increased qPCR linearity of template dilutions when using gene-specific primers 
for RT rather than random hexamers [48].  
Searching for the key words ‘gene expression’ and ‘clinical diagnostics’ in Pubmed 
(http://www.ncbi.nlm.nih.gov/pubmed/) yielded an approximate 579% increase 
in publications in 2014 compared to 2004 (364% increase from 2005 to 2015). 
However, upon reviewing several recent articles reporting RT-qPCR data, few 
articles reported all RT-qPCR experimental details [59]. The majority were 
deficient of several fundamental experimental details when reporting gene 
expression measurements, including 65% without information pertaining to RNA 
quality and 85% with no reference to data normalisation. Furthermore, only 20% 
of those articles assessed provided complete descriptions of the RT, with only 10% 
detailing complete PCR reaction conditions. In order to stand up to scientific 
rigour, key aspects of RT-qPCR experimental processes must be reported. There 
had been a growing consensus developing around the need to improve published 
information with relevant experimental detail that covers every aspect important 
to the qPCR assay itself, as well as issues relating to pre- and post-assay 
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parameters [83]. However, poor qPCR data obtained amongst a catalogue of 
mistakes, inaccuracies and inappropriate analysis methods as well as 
contamination and poor assay performance [84,85], promoted the now retracted 
claim of a link between the triple measles mumps and rubella (MMR) virus vaccine, 
gut pathology and autism [83]. It was these MMR papers and subsequent court 
case that were the final inspiration for the development of the MIQE guidelines 
(Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments), which propose a minimum standard for the provision of 
information for publications utilising qPCR experiments [86]. These cover key 
aspects including sample acquisition, assay design and validation as well as details 
about data analysis, enabling other scientists to easily assess and, if necessary, 
repeat the experiment [55,86].  
These issues highlight the importance of including appropriate RMs, designed to 
enable researchers to identify and account for these differences, and for 
harmonisation of experimental design. RMs enable data normalisation to alleviate 
technical variabilities. This can also be advanced by the application of standardised 
procedures, such as those outlined by the International Organization for 
Standardization (ISO) [87].  
1.3.1.4.2 Reagents and Equipment 
Other sources of RT-qPCR variability include ability of the thermocycler to 
maintain a consistent temperature across all sample wells, as any deviations in 
temperature may lead to different RT and/or PCR amplification efficiencies 
[26,88,89] and thus contribute to the overall variability in measurement. This 
extends to differences between different thermocycler platforms, with differences 
observed in timing and heat transfer capabilities [89]. Expectation of lot-to-lot 
consistency may be reason for selecting commercially available kits rather than 
preparing mixes in-house. In addition, maintenance of primer/probe stabilities is 
often assumed between different syntheses or suppliers. However, while the 
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multitude of commercial kits and protocols available offer undeniable benefits, 
reagent preparations from distinct batches have been shown to contribute 
significant experimental variability with up to seven-fold differences in calculated 
mRNA quantities observed [47,90].  
For numerous commercially supplied primers and probes, the location of the 
amplicon selected for mRNA detection is omitted; a fact that makes it difficult to 
adhere to the MIQE guidelines. The problem with not providing this information 
means the reader does not know which part of a given transcript is being detected. 
This information is important for any hope of reproducibility due to transcript 
differences including alternative splicing, polyadenylation and alternative 
promoters. An amendment to the MIQE guidelines [91] offered a compromise to 
commercial vendors who do not disclose this information by alternatively 
requiring a context sequence to enable the researcher to locate which portion of a 
given sequence was being detected [55,86,91]. Where neither primer information 
nor context sequence is provided, researchers using such commercial assays are 
strongly advised to sequence the PCR products to obtain the location of the 
transcript being measured.  
1.3.1.4.3 Estimating Copy Number 
RT-qPCR is typically performed either by estimating copy number using a 
calibration curve or simply assessing the fold change without considering the 
absolute abundance of the respective RNAs; the latter is termed the delta (Δ)Cq (or 
ΔCt) method (Livak [92] and Pfaffl [93]). Considerations around what is accurate 
differ between the two methods. The former has the added challenge of how 
appropriate and transmutable the choice of calibrator is. A calibration curve 
provides an estimation of the magnitude and dynamic range of a given 
measurement, but can reduce or increase bias of the estimated copy number 
(depending on the initial value assignment).  
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A calibration curve also provides an estimation of the PCR efficiency, which is an 
important source of bias both when estimating copy number as well as fold 
change. Consequently, while the ΔCq method ignores magnitude, PCR efficiency 
must be estimated [93] to avoid biases. Where PCR efficiency is not routinely 
estimated, which is most common for the ΔCq method [92], biases could be avoided 
by factoring in additional uncertainty to account for the unknown PCR efficiency. 
This would reduce the chance of measuring a significant difference, but increase 
the chance that when a difference is significant, it is real.  
Assay efficiencies may also be estimated using amplification curve fitting 
algorithms, which are dependent on the number of cycles over which there is an 
increase in fluorescence, and several such approaches have been proposed [94-
97]. These are most likely to succeed when the measurement is made using a DNA 
binding dye since these assays yield a greater change in fluorescence [98]. While 
these approaches offer an alternative to the implementation of a standard curve, 
the latter is still the more commonly used method for assay evaluation as it 
additionally provides information about working range and is conceptually easy to 
apply [98,99].  
The evaluation of background-normalised qPCR data can be subjective, for 
example, assessing the quality of a curve, determining the perfect starting point of 
the exponential phase and where to assign the threshold for Cq generation. These 
elements are subject to personal judgment. For this reason, digital PCR is seen as a 
promising alternative, where a digital output is produced (presence or absence of 
target) [36,100] and the ambiguity associated with Cq measurement is negated. For 
RT-qPCR measurements, calibration curve estimated copy number or fold changes 
should be reported rather than Cq, which is an arbitrary measure, and assay 
efficiency should always be taken into account.  
Experimental replication serves to improve confidence as it provides a better 
estimation of the mean provided by a given technique. Nevertheless, replication 
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cannot assist where systematic errors are present and may serve to make matters 
worse by increasing the confidence in the biased result. For RNA measurement, 
bias can be reduced by aiming to replicate the experimental steps that afford the 
highest variance from sample to analysis (Figure 1.2). This will reduce precision 
but will also reduce bias. Another essential method for reducing measurement 
uncertainty is to apply normalisation.  
1.3.1.5 Other Molecular Methods  
There are many methods in molecular biology for measuring quantities of target 
nucleic acid sequences. However, most of these methods exhibit one or more of the 
following shortcomings: they are time consuming, labour intensive, insufficiently 
sensitive, non-quantitative, require the use of radioactivity, or have a substantial 
probability of cross contamination [26,101]. These methods include, but are not 
limited to; Northern and Southern hybridisations, HPLC, scintillation proximity 
assay, PCR-ELISA, RNase protection assay, in situ hybridisation, and various gel 
electrophoresis PCR end-point systems [26], (see also Figure 1.2).  
The measurement of phosphorus content of nucleotides and DNA by high-
performance inductively coupled plasma optical emission spectroscopy (HP-ICP-
OES) has been reported for quantifying nucleic acids. This method can provide an 
accurate measurement, which is traceable to the SI [14,102] provided that the 
material contains no other sources of phosphorus, such as contaminating RNA. 
However, this approach requires large amounts of material (1 to 2 mg) and sample 
purity is critical [12,102]. Furthermore, complete destruction of target is required 
in order to liberate the constituent phosphorous. Consequently, subsequent 
analysis of the same sample is not possible for most methods.  
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1.3.1.5.1 Digital PCR  
Digital PCR (dPCR) is a relatively new technology which can measure both absolute 
and relative copy numbers of template DNA independent of external calibrators 
and, hence, has the potential to be used as a reference method for quantifying DNA 
amount (copy number) concentration (copies/μL) required for certification of RMs 
[103-105]. dPCR is based on the principle that an absolute count of amplified 
targets can be achieved. Single molecules are isolated by dilution and individually 
amplified by PCR; each product is analysed separately [103]. This process requires 
only small amounts of material when compared to phosphorus analysis or next 
generation sequencing (NGS), although the cost of dPCR analysis may be higher 
than some other techniques [12,106]. dPCR may also be utilised for the 
measurement of RNA, RT-dPCR [107-111]. The same difficulties with RT efficiency 
will present themselves with RT-dPCR as they do for RT-qPCR, but dPCR may be 
better placed as a tool to measure such variability more precisely.  
Despite the commonly held belief to the contrary, several studies have shown that 
dPCR is subject to inhibition affects that may change the measurement result [112-
115]. Increased inhibition has been shown to slow down the reaction considerably. 
In dPCR, inhibitors or slow starting reactions may result in misclassification as 
partitions fail to reach the fluorescence threshold while still containing at least one 
initial target copy [112]. Resulting false negatives hence reduce sensitivity for the 
detection of positive partitions.  
1.3.1.5.2 Next Generation Sequencing (NGS) 
NGS platforms share the common technological feature of being capable of 
massively parallel sequencing on clonally amplified or single cDNA molecules [36]. 
NGS technologies offer the possibility of hypothesis-neutral discovery of novel 
transcripts and isoforms in a fraction of the time required for genome-wide 
analysis performed by Sanger sequencing [116,117]. However, multiple template 
preparation stages, diverse sequencing chemistries and complex data processing 
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of NGS experiments may impact on the verification of bona fide nucleic acid 
biomarkers [36,116]. When applied to sequencing transcriptomes, NGS is known 
as RNA-seq.  
RNA-Seq is the first sequencing-based method that allows a more comprehensive 
transcriptome to be surveyed in a very high-throughput and quantitative manner 
[117]. This method uses recently developed deep-sequencing technologies. In 
general, a population of RNA (total or fractionated, such as poly(A)+) is converted 
to a library of cDNA fragments with adaptors attached to one or both ends. Each 
molecule, with or without amplification, is sequenced in a high-throughput manner 
to obtain short sequences from one end (single-end sequencing) or both ends 
(pair-end sequencing) [117]. The reads are typically 30–400 bp, depending on the 
DNA-sequencing technology used. Following sequencing, the resulting reads are 
either aligned to a reference genome or reference transcripts, or assembled de 
novo without the genomic sequence to produce a genome-scale transcription map 
that consists of both the transcriptional structure and/or level of expression for 
each gene [117].  
RNA-Seq has an upper limit for quantification, which correlates with the number of 
sequences obtained [117]. Consequently, it has a large dynamic range of 
expression levels over which transcripts can be detected: a greater than 9,000-fold 
range was estimated in a study that analysed 16 million mapped reads in 
Saccharomyces cerevisiae [118], and a range spanning five orders of magnitude 
was estimated for 40 million mouse sequence reads [119]. RNA-Seq has also been 
shown to be accurate for quantifying expression levels, as determined using qPCR 
[118] and spike-in RNA controls of known concentration [119]. The results of 
RNA-Seq also show high levels of reproducibility, for both technical and biological 
replicates [117,118,120].  
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1.3.1.6 Normalisation 
Normalisation is an essential component of a precise mRNA measurement. Its 
purpose is to remove technical error. However, as with the measurement of the 
genes of interest (GOI), normalisation strategies are also influenced by variance 
and bias, so must be used with caution. Current normalisation methods include 
standardising tissue weight, tissue volume, cell count, RNA concentration, or using 
reference genes and external reference panels [7,121-123]. A standard approach 
relies on reducing gross variation by ensuring samples are of comparable size with 
more subtle variation (crucial to fine measurements) being further removed using 
(preferably multiple) internal reference genes, and/or synthetic internal positive 
controls.  
Challenges associated with representative sampling of clinical samples are 
discussed in detail below, but ensuring samples are comparable can be a further 
challenge. Under controlled conditions of reproducibly extracted, good-quality 
RNA, initial gene transcript number is ideally standardised to cell number, but 
accurate enumeration of cells is often precluded when starting with solid tissue 
[7]. Following RNA extraction, quantity and quality of extracts may be measured 
[55,122,124].  
1.3.1.6.1 RNA Mass Quantity 
A frequently applied normalisation scalar is RNA concentration [7]. There are a 
number of methods for RNA quantification. Following RNA extraction, both 
quantity and quality of extracts should be measured [55] using metrics such as UV 
absorbance at 260 nm (A260), RiboGreen RNA quantification assay and ‘Lab-on-a-
chip’ based capillary electrophoresis. Each method has associated limitations. 
Common extraction contaminants, such as proteins, DNA/RNA and salts, can 
increase A260 nucleic acid quantity estimation [12,125,126]. Furthermore, 
measurement by A260 cannot discriminate between single-stranded DNA, double-
stranded DNA or RNA in solution, or between target sequence and other 
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potentially contaminating sources of nucleic acid. In addition, it cannot indicate 
target quality or the ability of PCR to successfully amplify a DNA sample. 
Furthermore, small changes in the pH of the solution will cause the 260/280 
absorbance ratio to vary [127]. Acidic solutions will under-represent the 260/280 
ratio by 0.2-0.3, while a basic solution will over-represent the ratio by 0.2-0.3. 
Together, these factors may contribute to inaccuracy in nucleic acid concentration 
estimates [12,47,103,125,126,128].  
In addition to these considerations, the five nucleotides that comprise DNA and 
RNA exhibit widely varying 260/280 ratios (Adenine: 4.50, Cytosine: 1.51, 
Guanine: 1.15, Thymine: 1.47 and Uracil: 4.00) [129]. The 260/280 ratio will 
therefore depend on the composition of the nucleic acid being measured. RNA will 
typically have a higher 260/280 ratio due to the higher ratio of Uracil compared to 
that of Thymine. 
Alternatively, fluorescent dyes have been used for quantifying total RNA. 
RiboGreen (Life Technologies) RNA quantification exploits the fluorescence 
enhancement seen upon nucleic acid-dye association. Reagent literature states that 
RiboGreen reagent does not detect significant sample contamination by free 
nucleotides and thus more accurately measures the amount of intact RNA in 
potentially degraded samples than A260. Despite the general assumption that A260 is 
less accurate than RiboGreen analysis, studies have shown that both methods 
generate comparable results when RNA concentration exceeds a minimum of 100 
ng/μL, albeit with RiboGreen measurements registering marginally lower 
concentrations than spectrophotometer results. While A260 analysis becomes less 
reliable at lower RNA concentrations [47] it should be remembered that methods 
that use fluorescent dyes typically require a calibration curve and that the 
calibrator used for this must also be assigned a value (usually by A260 
measurement). However, neither of these methods provides reliable RNA quality 
information, a key consideration when quantitating mRNA levels in fresh tissue 
[47].  
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When using RNA concentration to normalise, RNA quality is also an important 
consideration. Methods for estimating RNA quality based primarily on the 
detection of ribosomal (r)RNAs are very popular. Agarose gels or ‘Lab-on-a-chip’ 
based capillary electrophoresis platforms allow RNA sample quality assessment 
with the latter offering the integration of RNA sample quantification with a quality 
assessment in one rapid step [47]. rRNA ratios, with additional electrophoretic 
trace features, are used to calculate total RNA integrity (e.g. RIN: RNA integrity 
number, RQI: RNA quality indicator). However, it should be noted that rRNAs 
yielding similar RIN/RQI numbers generated by these instruments can contain 
mRNAs that differ significantly in their integrity [130], so good quality rRNA is not 
necessarily indicative of good quality mRNA. In some instances it is impossible to 
quantify this parameter, for example, when minimal RNA is available from 
microdissected tissues [7]. Further drawbacks to the use of 18S or 28S rRNA 
molecules as standards are their absence in purified mRNA samples and their high 
abundance compared to target mRNA transcripts. The latter makes it difficult to 
accurately subtract the baseline value in RT-qPCR data analysis [7].  
In some cases, the validity of normalising to total RNA has been confirmed when 
comparing results between individuals [47]. However, there are several arguments 
against the use of mass quantity. Normalisation to total RNA content first requires 
accurate quantification of the RNA sample and as discussed above, methods 
utilised for this purpose have various limitations. Another important consideration 
when using this approach is the lack of internal control for RT or PCR inhibitors 
[13] and as such, the variability attributed by these factors cannot be monitored.  
1.3.1.6.2 Internal Reference Genes 
RT-qPCR analysis of mRNA should also be normalised using internal reference 
genes. While manuscripts that evaluate the stability of candidate reference genes 
under certain experimental conditions might provide helpful guidelines for other 
researchers, it is has long been undisputed that the utility of chosen reference 
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genes must be confirmed by each research group for every experimental setup 
[6,86,131]. Although this may seem laborious and time-consuming in the short-
term, it is key to the generation of truly meaningful data that will hold-up against 
scientific scrutiny. Their suitability must be validated experimentally for particular 
tissues or cell types on an experimental-specific basis [132].  
Ideally, normalisation should be performed against validated multiple reference 
genes. Multiple reference genes rely on comparative expression measurements 
between a number of targets to estimate the error induced trends that are 
introduced by the experimental process; this is reported to provide considerably 
increased precision [7,55,133-136]. While the latter are considered the gold 
standard, some advocates of this approach state that it is assumption free. This is 
erroneous as the technical assumptions are that all RTs and PCRs are equal and we 
have already seen that this is not the case. A multiple reference gene approach 
validated on a study-specific basis should alleviate the use of inappropriate 
normalisers.  
Further support for reference gene selection may be found using algorithms such 
as geNorm [7], NormFinder [137] or BestKeeper [138]. The validated geNorm 
approach utilises the geometric mean of multiple, carefully selected, candidate 
genes. The BestKeeper algorithm uses a pair-wise correlation analysis method and 
NormFinder uses the estimate of inter-group and intra-group values. In general, 
using fewer than three reference genes is not advisable [7,46,86,131,139]. Single 
reference genes may be used if the measurement of small differences is not 
necessary, but the chosen target must be validated across the range of 
experimental conditions under investigation [140]. Crucially, any difference that is 
measured would need to be sufficiently greater than the inherent variation of the 
single reference gene measurements (incorporating all the steps from sampling to 
measurement) used to normalise that data, to be sure the observation is due to the 
gene of interest and not the reference gene or a combination of both.  
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It is increasingly evident that a number of classically designated reference genes 
demonstrate inconsistent expression between different tissues and treatment 
regimens [7,86,121,132,136,139,141,142]. For example, despite continuing 
reports for more than a decade that emphasise the problems associated with its 
use, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) continues to be utilised 
as a normaliser [47,143-145]. It is well documented that GAPDH mRNA levels are 
not constant [131,142,146] and it contributes to diverse cellular functions such as 
nuclear RNA export, DNA replication, DNA repair, exocytotic membrane fusion, 
cytoskeletal organisation and phosphotransferase activity [147]. It is 
pathologically implicated in apoptosis and neurodegenerative disease [148] and its 
mRNA levels are highly heterogeneous even in cellular subpopulations of the same 
pathological origin [47,149]. There are some instances when normalisation to 
GAPDH may be valid, but for most experimental conditions its use is inappropriate 
and should be discontinued [47]. Although studies continue to be published using 
one or more reference genes that have not been specifically validated for the 
measurement in question [59], it is encouraging that in recent years (and generally 
since the publication in 2009 and implementation by some of the MIQE guidelines), 
there has been an increase in publications directly evaluating reference gene 
validation [133-135,141,150-152]. However, more work is needed to ensure such 
guidelines are adhered to, particularly from Journals and reviewers who could 
make it a requirement for publication [153].  
A recently described alternative normalisation technique targets expressed 
repetitive elements, ERS (expressed Alu repeats, or EARs) [130] that are abundant 
in the human genome (~1 million copies). This strategy uses Alu repeat sequences 
embedded in the UTRs (untranslated regions) of mRNAs, to estimate the global 
mRNA quantity. As a result, it has the potential to be used as a ‘universal’ internal 
target, i.e. suitable to use for normalisation in all human RT-qPCR experiments. 
However, further work is needed to assess the validity of this proposed method.  
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1.3.1.6.3 External Standards 
An external standard comprises a target sequence that is present at a defined 
quantity and may be analysed independently of the test samples or spiked into test 
samples and used for value assignment and/or normalisation purposes. External 
standards differ from reference genes, which are usually internal targets with 
consistent expression levels. However, these expression levels can only be 
determined thorough comparison to a standard curve of external standards of 
defined concentration, or relative fold change measurements.  
All quantitative methods assume that the RNA targets are reverse transcribed and 
subsequently amplified with similar efficiency [47]. The risk with normalisation 
against external standards (such as RMs) is that a proportion of the samples might 
contain some inhibitor that significantly reduces the RT-PCR efficiency, resulting in 
inaccurate quantification. This does not apply to reference genes as they are 
internal targets and so are subject to the same matrix affects as the unknown 
target genes. It is therefore necessary to develop universal well-defined and 
characterised standards for spiking into biological samples pre-RNA extraction 
[47]. This format would enable an assessment of the variability inherent to each 
step in the experimental process post-lysis. In contrast to internal 
standards/reference genes, external standards can be quantified before inclusion 
in test samples and so provide a means by which to absolutely quantify targets 
using a calibration curve. Furthermore, they also offer traceability. However, a 
disadvantage of external standards is their lack of commutability. They may not 
readily transfer from a research to a clinical setting and so therefore would not 
easily slot into diagnostic markets. Further research and development would be 
required in order to fulfil this role. It would be preferable to develop external 
standards that may be spiked into biological samples and measured alongside GOI 
targets so that (1) external spikes are subject to the same matrix effects as GOI and 
(2) no additional reaction wells need be accommodated, keeping costs down and 
improving commutability.  
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For this purpose, the External RNA Control Consortium (ERCC) panel of synthetic 
RNA oligonucleotides have been developed in collaboration with the American 
National Institute of Standards and Technology (NIST). The ERCC is an adhoc 
group with approximately 70 members from private, public, and academic 
organisations, initiated in 2003 to develop a set of external RNA control transcripts 
that can be added to assess technical performance in gene expression assays. They 
have been designed to evaluate data consistencies with defined performance 
criteria. All ERCC work is intended to apply to RT-qPCR assays as well as one-
colour and two-colour microarray experiments [154].  
The use of synthetic standards raises the questions: “How similar to a ‘real’ 
molecule is a synthetic one?” and “Will they behave the same during analysis?” 
Once again, the value of experimental-specific RM validation is clear. It may 
potentially require a trade-off between synthetic molecule stability and trueness to 
‘real life’ endogenous targets. ERCC standards have been designed to mimic 
endogenous mammalian mRNA targets, for example, through possession of 
secondary structure motifs and a poly(A) tail. The panel comprises unique control 
sequences inserted in common plasmid DNA engineered to be readily in vitro 
transcribed to make RNA controls. Endogenous mRNA species undergo 
modification to include a 5’ cap, which is important for export from the nucleus, 
excision of introns and stabilisation of the RNA. The synthetic ERCC transcripts 
lack this 5’ cap. While the related functions of nuclear export and splicing are not 
important for these exogenous species, transcript stabilisation is. However, using 
stabilising storage solutions as a diluent, storing at -80ºC and making aliquots to 
avoid multiple freeze thaw cycles all act to maintain target stability and integrity.  
It should be noted that while external RNA standards spiked into biological 
samples may provide an assessment of the variability within the proceeding 
experimental steps, they cannot account for any variability upstream (e.g. 
sampling or cell lysis). Also, purified RNAs may not always be compatible with a 
given extraction method. Consequently, application of external standards needs to 
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be validated empirically and a combined approach in conjunction with validated 
reference genes may be most effectual.  
1.3.1.6.4 Measurement Controls 
Studies show that PCR inhibition can be assay specific with an inhibitor completely 
inhibiting one assay while having no effect on another [74] so where internal 
positive controls are used they need to be representative of the targets of interest. 
The SPUD assay has been developed to estimate the extent of qPCR inhibition by 
measuring an external spike-in from potato (Solanum tuberosum) in control 
(water) vs. target samples [155]. This can be applied as DNA or RNA [156]. 
Analysis of Cq and assay efficiency between control and target samples for the 
SPUD assay indicates the extent of matrix inhibition [36,155]. Another method for 
evaluating inhibition is to perform a serial dilution of the sample of interest. A 
reduced delta Cq at the higher concentrations is suggestive of reversible inhibition.  
External positive controls can be used more extensively to evaluate biases 
associated with the extraction step. In clinical virological load monitoring, control 
viruses can be added to the sample prior to extraction [157,158]. Extraction 
methods can purify different amounts of template with different variances, so this 
is an important step to replicate [159,160]. Quantifying total RNA is a simple 
method for controlling for varying yields when measuring mRNA, with the 
accepted potential problems discussed above. However, if further rigour is 
required then external RNA standards can be used. An example of such a resource 
is the ERCC panel of synthetic RNA oligonucleotides, which has been developed for 
this purpose [154].  
It is also important to include negative control samples in order to evaluate the 
potential for contamination [79]. No template controls (NTCs) are commonly 
employed in RT-qPCR studies. There are no guidelines on how to report positive 
NTC results, although proposals have been made [48], namely that NTCs with high 
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Cq values, far removed from sample unknown positive results, can be legitimately 
ignored but should be reported when publishing data. Any Cq that differs by more 
than 5 from the NTC may be regarded as probably not caused by any contaminant, 
especially when the replicate wells also record positive, similar Cq values. 
However, if an NTC records a Cq less than 30, high levels of contamination are 
indicated.  
It should be noted that false positive amplification may not always be the result of 
contamination, but maybe attributable to badly designed assays resulting in 
primer-dimer formation, amplification of pseudo genes and/or primers binding to 
carrier molecules. One technique to counteract contamination from previous PCR 
products is the application of uracil N-glycosylase (UNG). The dTTP is substituted 
by dUTP in the PCR mastermix, generating dUTP-containing amplicons. UNG 
enzyme is activated before the normal reaction thermocycling and any 
contaminating PCR products (containing dUTP) are digested. This is a proactive 
method to prevent contamination from future reactions, but will not help with a 
pre-existing contamination problem of standard dTTP-containing PCR products 
[161]. 
1.3.1.7 Other Considerations 
In order to facilitate good repeatability (measurement made by the same operator, 
instrument, and conditions over a short period of time) and reproducibility (by 
different operators, instruments, and/or conditions) [3], key aspects of RT-qPCR 
experimental processes need to be reported, as outlined in the MIQE guidelines 
[55,86]. This is fundamental if findings are to be corroborated, which is in turn 
crucial for the observation to be translated into a clinically useful tool.  
The MIQE guidelines encourage the use of a sample maximisation strategy, i.e., 
analysing as many samples as possible in the same experiment, as opposed to a 
gene maximisation strategy that analyses multiple genes in the same experiment 
Chapter 1 Introduction  
Page 40 
[55,86]. This is because it minimises any technical, run-to-run variation between 
different samples for the comparison of mRNA levels. If not all samples can be 
analysed in the same run, identical samples that are tested in both runs (inter-run 
calibrators, or IRCs) must be analysed. Measuring the difference in Cq or the 
normalised relative quantity between the IRCs in different runs allows the 
calculation of a correction or calibration factor to remove run-to-run differences 
[86,162].  
RNA measurement on a complex biological sample (like a tissue biopsy) requires a 
series of steps, each of which contributes error that is often several fold greater 
than the difference in the mRNA to be measured. Consequently, determining 
differences in mRNA levels in real scenarios requires consideration of the sources 
of error and appropriate normalisation mechanisms to control for them. Yet 
measurement claims of biologically significant mRNA level differences are 
routinely made without apparent consideration (or reporting) of such technical 
factors [59]. Consequently, while often statistically significant, these results may 
not be due to the biological phenomenon under investigation and/or may not be 
reproducible. Without assessment and consideration of the technical variability 
introduced at each stage of the experimental process, findings may be of limited 
practical use in the clinic because they are difficult to reproduce.  
Simple measures that will help to facilitate effective measurement capabilities 
include spacial separation of individual aspects of the experimental procedure. 
Designating separate areas for nucleic acid extraction/preparation, PCR set-up 
(template negative area), template addition and finally PCR (PCR positive area) 
will go a long way to minimise potential contamination, increasing confidence in 
measurement results [79].  
The issues described above highlight the importance of including appropriate 
controls, designed to enable researchers to identify and account for these 
differences, and harmonisation of experimental design [122,163]. There are a 
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number resources that support experimental design both as basic guides [98], 
extensive repositories of information [164], as well comprehensive software tools 
including GenEx [165], qbase [166] and RealTime StatMiner ® [167].  
1.4 Clinical Relevance 
RT-qPCR is an important tool in the understanding of the molecular events 
underlying human diseases but also identifies unique biomarkers for the 
identification and stratification of a range of diseases [6,47]. Studies have reported 
applying these methods for the identification of micrometastases or minimal 
residual disease in colorectal cancer [168], neuroblastoma [169], prostate cancer 
[170] and leukaemia [171]. It has been employed to distinguish different types of 
lymphoma [172], for the analysis of cellular immune responses in the peripheral 
blood [173,174], the detection of bacterial [175] and viral [176] RNA signatures in 
clinical samples and for monitoring the response of human cancer to treatment 
[33]. Other clinically relevant applications include its use for the analysis of tissue-
specific mRNA levels [177], identifying cytokine mRNA levels upon ex vivo 
stimulation of peripheral blood mononuclear cells [178] and for cytokine mRNA 
profiling [179]. Novel gene expression approaches are constantly being evaluated 
for diagnostic purposes for numerous human diseases.  
These developments may ultimately lead to the implementation of truly 
personalised medicine, whereby the course of treatment chosen, response and 
prognosis may centre on molecular measurements. Yet what is ominous is that 
despite the vast amount of published clinical research using RT-qPCR to measure 
putative mRNA biomarkers, few tests have as yet been transferred to the clinic for 
routine use. Where RNA measurements are routinely used, such as monitoring 
viral loads in disease states or response to a particular treatment regime, the 
measurements made at the beginning of the study must be compatible with those 
made at the end, i.e. the measurement standards used to calibrate them must have 
long-term stability [1]. These considerations apply equally to gene expression 
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biomarkers and collectively contribute to measurable improvements in the quality 
of analytical results.  
In terms of clinical measurement, different capabilities will be required depending 
on the measurement need. For example, viral load and specific gene signatures, 
such as the BCR-ABL fusion transcript, require differentiation between gross 
changes of target, whereas cellular mRNA levels are more subtle and much more 
challenging to measurement reproducibly. For example, clinicians will not usually 
alter therapy when measuring HIV viral load unless there is a change of around 
one order of magnitude (log10 scale). However, research that measures normalised 
mRNA levels by RT-qPCR frequently presents much smaller significant differences 
(e.g. frequently less than three-fold).  
1.4.1 Biological Variability 
Biological variability is one of the principal unknown entities in terms of the 
aforementioned considerations and represents the final determining factor 
whether a given RNA measurement will be of clinical value, i.e. once the technical 
factors are resolved the measurement is still dependent on biology. Previously, it 
has been assumed that the findings of randomised controlled trials (RCTs) were 
applicable to all patients. However, it is becoming increasingly apparent that this is 
not the case [180,181]. Treatment outcomes as well as disease progression and 
manifestation have been shown to vary between patient groups, with women and 
ethnic minorities being under-represented in vascular surgery RCTs [182], or 
patient chronotype and its relationship with cancer treatment schedules [183]. 
The underlying cause for these findings will be due to physiological differences 
many of which will manifest in the mRNA profiles, suggesting that many putative 
surrogate mRNA biomarkers are likely to be similarly variable between different 
patient groups.  
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mRNA profiles may change on a cyclical basis, influenced by circadian rhythms, 
growth and development, and other environmental factors such as stress, 
sustenance/nutrition, physical activity and infection, in conjunction with 
variability attributable to gender, race, age and time of sample collection, to name a 
few. These factors must additionally be considered over and above general 
experimental issues such as choice of procedure, sources of error and sample 
contamination, in order to select a useful biomarker that can yield reproducible 
results. Unpicking the sources of biological verses technical variance represent a 
crucial yet frequently neglected step in translating a measurement to the clinic.  
The mRNA used for clinical diagnostics and research may be derived from various 
tissues including biopsies, spinal taps, blood, urine or buccal swabs. As a 
consequence, sample handling has to be carefully controlled and regulated in order 
to preserve the quality and integrity of the RNA material [6,54].  
1.4.2 Tissue Variability 
As described above, sample source is a major contributor to measurement 
variation. RNA extractions and subsequent analyses performed from whole tissue 
biopsies with little regard for the different cell types contained within that sample, 
inevitably result in the averaging of the expression of different cell types and the 
mRNA profile of a specific cell type may be masked, lost or ascribed to and 
dismissed as incorrect measurement [184] because of the bulk of the surrounding 
cells [47,185]. When working with versatile tissues such as blood, cell number and 
composition may vary within two samples (even from the same patient); 
consequently blood volume may not be an appropriate metric to begin with and 
separation of the different cell types is often performed. However, it should be 
remembered that any processing of live cells will impact on the cellular physiology 
and may directly alter the expression of the genes of interest.  
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Cellular separation is more difficult to achieve when analysing solid tissue samples 
but may be important, as significant differences have been detected in the mRNA 
profiles between microdissected and bulk tissue samples [185,186]. This is 
particularly relevant when comparing mRNA profiles in complex tissue with 
multiple, phenotypically distinct cell types, within a given tumour or between 
normal and cancer tissue where phenotypically normal cells adjacent to a tumour 
may exhibit altered mRNA profiles due to their proximity to the tumour [47,187]. 
It may be possible to alleviate these pressures of sample source/cell type by 
performing single cell analysis. This rapidly growing field has much to offer but 
also comes with a multitude of unique challenges associated with sample 
processing, low mRNA abundance and data normalisation [188-191]. It should also 
be remembered that cell sizes may vary between different samples (such as tumor 
biopsies or where tissues are undergoing hypertrophy as part of normal 
physiology), which adds an additional challenge to data interpretation.  
1.4.3 Patient Variability 
The greatest contribution to variability in clinical measurement will be observed 
between different subjects (patient-to-patient). While fundamental similarities in 
expression may be observed, demographic, genetic and environmental factors 
ranging from; age; sex; and ethnicity to smoking, nutrition and medication [121] 
will exert considerable influences on biological flux. Expression may also be 
modified by disease state, during cellular proliferation, due to cellular composition, 
circadian fluctuations and by mitogenic stimuli (e.g. growth factors) [6,142,192].  
1.4.4 Musculoskeletal Disease 
The World Health Organization (WHO; http://www.who.int/en/, accessed May 
2011) in collaboration with the Bone and Joint Decade Initiative has completed a 
ten-year study investigating the “Burden of Musculoskeletal Conditions at the Start 
of the New Millennium" [193]. Joint diseases, rheumatoid arthritis and 
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osteoarthritis, osteoporosis, spinal disorders, low back pain, and severe trauma are 
among 150 musculoskeletal conditions affecting millions of people globally. These 
conditions are the most frequent cause of disability severely affecting individuals’ 
ability to carry out their activities of daily living. WHO estimates that several 
hundred million people already suffer from bone and joint diseases, with dramatic 
increases expected due to a doubling in the number of people over 50 years of age 
by 2020.  
Diseases of the musculoskeletal system can affect the body’s muscles, bones, joints, 
tendons, ligaments and nerves. They mostly encompass functional disorders or 
motion discrepancies, and those of or pertaining to the joints are the most 
common. The numbers of those affected are set to rise over the next few decades. 
In the developing world, successful treatment of communicable diseases, 
combined with a rapid increase in road traffic accidents, will lead to an increase in 
the burden of musculoskeletal conditions. In industrialised countries, the 
increasing numbers of elderly people is a key factor in this rise. As these conditions 
represent an increasingly substantial health problem, it is essential that good 
molecular tools are developed to provide confident measurement for the 
development of research as well as diagnostic and prognostic tools.  
Standardisation of RNA measurement, which represents one of the greatest 
challenges of its type in biological measurement, is particularly difficult when 
studying expression in musculoskeletal tissues, especially bone and cartilage, due 
to difficulties in sample sourcing and RNA extraction. Obtaining intact, high quality 
RNA is an essential step in analysing mRNA levels. This step is particularly 
challenging in bone, which contains low numbers of cells embedded within a 
highly mineralised tissue [50]. The physical and chemical characteristics of bone 
hinder the access of reagents in the nucleic acid extraction process [194-196] and 
predispose to co-extraction of PCR inhibitory compounds [194,197-200]. 
Consequently, relatively specialised techniques are required for successful nucleic 
acid extraction from bone. Major approaches, with innumerable variations, include 
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organic extraction methods involving phenol/chloroform and silica-binding 
methods where guanidinium-based chaotropic salts are used both to disrupt 
proteins, as well as mediate highly specific binding of nucleic acid to silica particles 
via ionic salt bridges [194,201-203]. A suitable cell line model alleviates the 
difficulties of RNA extraction from whole bone. Osteoblastic cell lines such as SaOS-
2 offer the additional benefit of being able to mineralise in culture [204,205].  
1.4.4.1 Important Clinical Questions in the Musculoskeletal System 
Mechanical loading regulates the shape, repair and regeneration of the skeleton. 
Mechanical signals are transduced through the extracellular matrices, modify cell–
matrix and cell–cell interactions, and impact on transcriptional responses [206]. 
Mechanical behaviour of whole bone is often studied in order to obtain a greater 
understanding of the relationship between bone structure and functions during 
physiological loading. These insights can help identify areas of peak stresses that 
are more likely to fracture during intense activity, and allow the prediction of 
effects of various genetic defects, disease processes and drug treatments [207]. 
The complexity of bone architecture itself makes such studies difficult, as 
differences in for example mineralisation, can vary within a sample as well as 
between samples. However, load transfer between bones through joints and the 
implications of long-term mechanical loading may be studied by elucidating the 
coinciding changes in mRNA levels (mechanoresponsive signalling) and may 
subsequently aid patient diagnosis, treatment and tissue engineering approaches 
[208].  
It is well established that mechanical loading is a critical factor in the maintenance 
of adequate bone mass in the skeleton, where various signals have been 
implicated. One such signal is glutamate; a major excitatory neurotransmitter in 
the central nervous system (CNS) [208,209]. The excitatory amino acid 
transporter, EAAT1 (also known as SLC1A3: solute carrier family 1 (glial high 
affinity glutamate transporter), member 3, or GLAST1: glutamate/aspartate 
Chapter 1 Introduction  
Page 47 
transporter1, the rat homologue) terminates glutamatergic signalling and was first 
implicated in mechanotransduction [208]. GLAST1 was originally discovered in a 
gene screening experiment looking for mechanoresponsive genes in osteocytes in 
vivo [210]. This led to the idea, later confirmed, that glutamate signals in bone 
[209]. Furthermore, several studies have shown evidence that glutamate release, 
receptors and transporters are expressed and functional in several bone cells, 
including osteoblasts, osteocytes and osteoclasts [209,211]. Glutamate and 
associated signalling mechanisms provide potential therapeutic targets in 
connective tissue and musculoskeletal disorders.  
1.4.4.2 Additional Cell Lines 
The hepatocyte-derived cell line Hep-G2 is a commonly employed in vitro model. 
Cells maintain in large part a number of cellular functions similar to those of 
normal hepatocytes such as expression of hepatocyte-specific cell surface 
receptors and synthesis and secretion of plasma proteins [212-214]. Furthermore, 
because of the high degree of morphological and functional differentiation in vitro, 
the Hep-G2 cell line is a suitable model to study intracellular trafficking, 
heptocarcinogenesis, drug targeting and toxicogenomics in vitro [214-217]. These 
cells are relatively uncomplicated to cultivate and as such, make a useful model 
system.  
The Hs 683 cell line, of oligodendroglial origin, has been extensively characterised 
and display similar expression patterns to oligodendrogliomas [218]. These cells 
are also known to express factors involved in glutamate signalling, and so may 
augment such signalling in cells of osteoblastic origin [219,220].  
1.4.5 Practical Clinical Challenges  
In certain clinical situations, for example where surgical sampling is required, 
some of the points detailed here will reflect a utopian view that will not be 
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practical to implement. For instance, tissue-sampling methods may vary among 
institutes and even across individuals within the same institution. This can be very 
challenging to standardise with respect to the time-span of surgery, how long it 
takes for a sample to be fixed or frozen, etc. To ensure data comparability and 
increased clinical impact within such challenging circumstances, it is crucial that 
such conditions are defined as accurately as possible and the associated limitations 
are fully considered within the discussions around a given finding.  
A particular mRNA result may only be possible under a very specific sampling 
procedure that is not easily repeatable (due to specialist skill and/or equipment). 
Such findings may reveal new biological mechanisms, but unless they can be 
corroborated they will be of questionable value. An example by which this can be 
performed could be that the samples are re-analysed (ideally including re-
extraction) by a different laboratory to confirm the measurement. However, such 
analysis may never be translated to routine clinical care as biomarkers and as 
mRNAs are frequently measured as surrogates for protein driven physiology, 
additional confirmatory experiments considering the proteins and/or physiology 
in question is essential.  
It is also crucial that other factors within the protocol (Figure 1.2) that can be 
controlled are detailed within a given study. Factors that frequently vary but which 
are easily controlled, and easily reported, like storage conditions and duration may 
vary among laboratories, e.g. type of freezer, storage in liquid nitrogen by 
immersion or by vapour phase, etc. and so they must be comprehensively 
described. Documentation of such factors will facilitate identification of any 
associated discrepancies that might arise, a fact that is particularly pertinent to 
biobanking, which may comprise large numbers of samples that may have been 
stored for different durations.  
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1.5 Conclusion 
Accurate RT-qPCR analysis and reporting could improve clinical diagnosis as well 
as predictive and prognostic monitoring. Furthermore, improved analytical 
measurement sensitivity may offer tools to detect and quantify disease markers at 
earlier stages of progression, facilitating earlier treatment and improved outcome. 
Moreover, diagnostic tests conferring superior accuracy and analytical confidence 
may change treatment regimens patients are offered. For example, several 
expensive and highly toxic cancer therapies are only effective in treating certain 
oncogene genotypes. As such, they are offered only to those patients that have 
definitive molecular proof they harbour the associated specific mutation. HER2 
(human epidermal growth factor 2) status in breast cancer is one such DNA 
measurement example and is used as a predictive therapy-selection factor for the 
humanised monoclonal antibody trastuzumab (Herceptin®; Genentech) [221]. 
Current diagnostic methods, including fluorescent in-situ hybridisation (FISH) and 
immunohistochemistry (IHC), can be subjective and insensitive. Advances in 
accurate molecular quantification of RNA [222,223], could offer enhanced 
analytical power for this and many similar clinical challenges, and may in the 
future become gold standards in clinical diagnostics.  
Yet for RT-qPCR to make an impact when applied to preclinical research, accuracy 
must be seen as more than just good precision. Accurate clinical measurement 
must also include considerations of both potential bias and good technical 
reproducibility. By applying this to the whole stepwise process for preparing the 
RNA sample and subsequent methods for normalisation, RT-qPCR will become 
more reproducible, which in turn will improve the impact and likelihood that 
findings will be translated to routine clinical use.  
The accomplishment of such standardisation measures as detailed in this review 
may be problematic in practice, particularly in clinical laboratories. The key is to 
implement a standardised approach, to be aware of (and define) limitations and to 
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include appropriate calibrators or reference materials, which will allow 
appropriate data normalisation.  
1.6 Scope 
The overall objective for RMs and standardisation is to provide an appropriate and 
versatile solution to measurement bias. Correct interpretation of results and 
appropriate use of statistics will increase confidence in experimental findings and 
clinical relevance, aiding scientific understanding and medical innovation.  
Bone represents one of the most difficult tissues in which to make accurate 
molecular measurements as a consequence of varying and complex matrices. 
However, it is included here due to its fundamental role in musculoskeletal disease 
and glutamate signalling crossover between mechanical loading, inflammation and 
brain signalling mechanisms.  
Liver and brain tissues are extensively studied due to their central involvement in 
body homeostasis and are relatively uncomplicated to work with due to high RNA 
yields with straightforward extraction procedures. These will be utilised here as an 
additional experimental challenge.  
Figure 1.5 outlines the major components of this investigative strategy. Starting 
with a bottom-up approach, i.e. from the end of the process (qPCR measurement 
and data normalisation and interpretation) through to the start (sample source 
and extraction of RNA), this study aims to characterise the variability inherent to 
various aspects of the experimental path.  
1.7 Aims and Hypothesis 
This thesis is based on the hypothesis that error in mRNA measurement can be 
partitioned across different stages of the experimental procedure. This project   
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Figure 1.5 Proposed experimental strategy for investigating contributors to variability. 
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aims to define such error in a range of samples to improve experimental design 
and minimise uncertainties, alongside providing a guide on how to approach 
apportioning error, standardisation and validation. An ERCC RNA panel has been 
developed for use as an external (synthetic) RM, which was evaluated alongside 
validated endogenous reference genes. This thesis employs multiple bone models 
of differing complexity (2D cell culture model, 3D gel co-culture model and clinical 
samples) for the assessment of variability introduction and error propagation for 
RT-qPCR measurements and compares this with glial and hepatic variabilities. 
Additionally explored are potential clinical applications for this method.  
Aims:  
1. To define the experimental sources of variation during the key stages required 
for RNA measurement.  
2. To use synthetic RNA standards, namely an ERCC RNA panel, to elucidate 
sources of variability in RT-qPCR measurement of mRNA levels.  
3. To use human-derived cell lines as background material and as a source of 
endogenous reference targets and GOI for the preparation of a pilot reference 
material to test process variabilities and normalisation approaches.  
4. To use three bone models of increasing complexity to evaluate variability 
contributions attributable to sample source.  
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2 Materials & Methods 
2.1 Materials 
Human genomic DNA (gDNA; Promega P/N G304A) and/or human universal 
reference RNA (Stratagene P/N 740000) was used in qPCR assay development. 
LoBind® safe-lock PCR clean tubes were employed throughout this study 
(Eppendorf 1.5 mL P/N 0030 108.116 and 0.5 mL P/N 0030 108.035). Primer and 
probe sequences for qPCR and dPCR designed in-house using Primer Express, 
software version 3 (ABI) and ordered from Sigma, with purification by HPLC. Some 
experiments were performed using assay-on-demand (ABI). Sequences, gene 
accession numbers and assay concentrations are outlined in 9.1 Appendix 1 – 
Assay Information. Total yeast RNA [from baker’s yeast (Saccharomyces 
cerevisiae), Sigma P/N 26750] at 25 ng/reaction was used as carrier in this study. 
All samples were diluted using RNA Storage Solution, RSS (ABI P/N AM7001), 
unless otherwise stated.  
2.1.1 Synthetic RNA Transcripts 
Eight synthetic (ERCC developed targets; External RNA Control Consortium) RNA 
transcripts (ERCC-00013, -00025, -00042, -00084, -00095, -00099, -00113, and -
00171) were selected for investigation (supplied in plasmid DNA format, courtesy 
of Dr Marc Salit, NIST, USA). For brevity, the ERCCs shall be subsequently identified 
without the preceding zeros. Concentrations of plasmid were assigned by the 
supplier using UV spectrophotometry and converted to copy number using 
published methods [224]. Copy number conversions were performed using the 
appropriate extinction coefficient values for dsDNA (50 ng-cm/µL) or RNA (40 ng-
cm/µL). Plasmid DNA was used as template for in vitro transcription (IVT).  
Chapter 2 Materials & Methods 
 
Page 55 
2.1.2 Cell Lines 
Hep-G2-derived RNA (organ: liver, disease: hepatocellular carcinoma) was used for 
RNA stability experiments (ATCC P/N HB-8065). Three human cell lines were 
employed for production of complex background material for endogenous target 
selection: Hep-G2; SaOS-2 (organ: bone, disease: osteosarcoma, ATCC P/N HTB-
85); and Hs683 (organ: brain, disease: glioma, ATCC P/N HTB-138).  
Subculturing and propagation was performed as per manufacturer’s instructions, 
with appropriate culture medium and serum additionally supplied from ATCC 
(Hep-G2: Eagle's Minimum Essential Medium (P/N 30-2003), 10% fetal bovine 
serum (P/N 30-2020). SaOS-2: McCoy's 5a Medium Modified (P/N 30-2007), 15% 
fetal bovine serum. Hs683: Dulbecco's Modified Eagle's Medium (P/N 30-2002), 
10% fetal bovine serum). Prior to sub-culturing of cells in T-175 flasks (Corning, 
Sigma P/N CL S431079), culture medium was aspirated from cell monolayer at 
approximately 90% confluency, which was washed briefly in room temperature 
Hanks Balanced Salt Solution (HBSS; PAA Laboratories P/N H15-009) to remove 
serum. Five mL Trypsin/EDTA (Sigma P/N T4049) solution was added to each 
flask and incubated at 37ºC for 5 min. After incubation, cell detachment was 
monitored under a light microscope until all cells had detached. Adding an equal 
volume of the appropriate culture media subsequently quenched trypsin activity. 
Cells were pooled together and re-seeded into fresh T-175 flasks containing 30 mL 
of the appropriate cell culture media, according to their splitting ratio. For 
propagating cells in culture, 100% of the media was replaced every second day. 
2.1.2.1 Carrier Options 
Inclusion of carrier nucleic acid (DNA or RNA not containing the target sequence) 
may increase experimental precision when evaluating low target copy number 
samples [56,69,103]. Carriers utilised in this study include: 50 ng total Hep-G2 
RNA (produced in-house); 50 or 250 ng total yeast RNA; 50 or 250 ng sonicated 
salmon sperm DNA (Agilent P/N 201190); and no carrier (water). All were diluted 
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using RSS (RNA carriers) or 1 TE pH 8 (DNA carriers; Sigma P/N 93283), unless 
otherwise stated.  
2.2 Production of RNA 
2.2.1 ERCC RNA: Plasmid DNA Digest & IVT 
ERCC plasmid DNA (from standards ERCC-13, 25, 42, 84, 95, 99, 113 and 171) was 
linearized using BamHI; 0.5 µg plasmid DNA was digested with 40 U restriction 
endonuclease, as per manufacturer’s instructions (New England Biolabs P/N 
RO1365). Samples were purified according to manufacturer’s instructions 
(QiaQuick DNA purification; Qiagen P/N 28104), with an elution volume of 32 µL.  
IVT was performed using MEGAscript® T7 Kit (ABI P/N AM1333). Briefly; 8 µL 
linearized plasmid DNA template was subjected to IVT in 20 µL total reaction 
volume (according to manufacturer’s instructions), with an overnight incubation of 
37ºC. Samples were treated with Turbo DNase (as per MEGAscript® T7 kit 
protocol, Ambion P/N AM1907M) at 37ºC for 15 min, before purification using 
RNeasy kit (Qiagen P/N 74104) and further on-column DNase treatment (Qiagen, 
as per optional method in RNeasy kit protocol). The two DNase treatments were 
performed due to previous experience of residual DNA remaining when only one 
treatment was performed. However, for the pilot RM production, an alternative 
DNase treatment was validated. IVT ERCC RNA concentrations and insert sizes 
were subsequently estimated using Nanodrop UV spectrophotometry (Thermo 
Scientific) and 2100 Bioanalyzer (Agilent), respectively. Samples were diluted to 
approximately 1 ng/µL in RSS and stored at -80ºC. Concentrations and copy 
number estimates are reported in Table 9.6.  
An aliquot of each of the same IVT ERCC RNA transcript samples were additionally 
heat-treated (70ºC for 2 min, before being placed on ice) before re-analysing using 
2100 Bioanalyzer to test for secondary structure denaturation. 
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2.2.1.1 Secondary Structure Prediction 
ERCC RNA sequences were subjected to in-silico secondary structure prediction 
using the online tool, MFOLD (http://mfold.rna.albany.edu/, accessed 2011 and 
2015). Folding predictions were performed at 45ºC (temperature of RT step). 
Predicted structures with the lowest energies (most stable) were chosen as the 
most probable configuration for the majority of transcript molecules within a 
sample (9.2 Appendix 2 –Endogenous and ERCC Transcript Predicted 
Secondary Structures). 
2.2.2 Cell Line RNA Production for Complex Background 
Total RNA derived from SaOS-2, Hep-G2 and Hs 683 cell lines were used for 
production of the complex background material. Based on confluency and cell size, 
eight to fourteen flasks were prepared for each cell type, as outlined above. 
Medium was removed, cells washed in HBSS and TRIzol (Sigma, P/N 15596-018) 
added directly to cell monolayers (17.5 mL per T-175 flask, 1 mL per 10 cm2) and 
passed three times over the entire surface of the flask to ensure cell lysis. Lysates 
were transferred to 50 mL round-bottomed Falcon tubes (VWR P/N 21008-951) 
and stored at -80ºC until RNA extraction. Replicate T-175 flasks (one per cell line 
used) generated at the same time and under the same conditions were used for cell 
enumeration and viability estimates using a Vi-Cell (Beckman Coulter). For cell 
counting, cells were detached post HBSS wash using 5 mL Trypsin/EDTA for 5 min 
at 37ºC and neutralised with 5 mL culture medium before Vi-Cell analysis.  
Total RNA was extracted from cell lysates by following a standard TRIzol protocol 
(Invitrogen). Briefly, TRIzol lysates were thawed and incubated for 5 min at room 
temperature and harvested by centrifugation (12,000 × g for 10 min at 4ºC) to 
pellet DNA and cell debris. Chloroform (Sigma P/N 472476-1L) was added to the 
supernatant (200 µL of chloroform for every 1 mL of TRIzol). Following phase 
separation using centrifugation (12,000 × g for 15 min at 4ºC), RNA was collected 
in the upper aqueous phase and precipitated using 0.5 mL isopropyl alcohol 
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(Sigma P/N 59304) per 1 mL TRIzol. The RNA pellet was washed with 75% 
ethanol (Sigma P/N E7023) before resuspension in 50 µL nuclease-free water (ABI 
P/N AM9937). Total RNA solutions were treated with recombinant (r)DNase I (ABI 
P/N AM2235), as per manufacturer’s protocol (1 U rDNase I reagent added per 4 
µg of total RNA, incubated at 37ºC for 30 min). These preparations were purified 
using RNeasy midi kit (Qiagen P/N 75144) and the total RNA eluted in varying 
volumes of nuclease-free water (depending on expected yield, following kit 
protocol), assessed for quantity (yield; Nanodrop), and subsequently pooled (per 
cell-type).  
Following total RNA extraction, DNase treatment and purification, pooled cell line 
RNA samples were subjected to standard quality metrics for concentration and 
integrity (Nanodrop and 2100 Bioanalyzer, respectively). Neat samples 
(resuspended following purification in nuclease-free water, between 110-700 
ng/µL) were stored at -80ºC. 
2.3 Preparation of Transcriptomic Calibration Material (TCM) 
Ideally the expression ratio of two reference genes should be the same in all 
samples, regardless of the experimental condition or cell type, with increasing 
ratio variation corresponding to decreasing expression stability of one (or both) of 
the tested genes [7]. Based on this principle, pilot RMs were prepared using a 
combination of six validated synthetic and three endogenous reference genes. 
Different mixed ratios of the three chosen cell lines were prepared to comprise the 
three distinct pilot RMs, each offering a different experimental challenge, with 
scope for applicability to standardisation. These pilot RMs are assigned as 
Calibrant, Unknown 1 and Unknown 2. The unit types Unknown 1 and Unknown 2 
are referred to as ‘Unknown’ materials, despite the fact that their composition is 
known to us, as their ultimate purpose is as a prototype reference material for 
molecular measurements, helping to determine measurement capabilities and 
validate measurement claims of laboratories.  
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Each ERCC IVT RNA stock solution was diluted to 1.0E+09 copies/µL (Calibrant) or 
1.0E+08 copies/µL (Unknown 1 and Unknown 2) in RSS and three, 100 ERCC 
solutions (synthetic-only TCM, sTCM) for Calibrant, Unknown 1 or Unknown 2 
containing all six ERCC transcripts at different concentrations was prepared 
(Table 3.7). Pooled cell line RNA stocks were diluted in RSS to 250 ng/µL (Hep-G2 
and Hs683) or 100 ng/µL (SaOS-2), and three solutions for Calibrant, Unknown 1 
or Unknown 2 prepared by mixing different proportions of each cell line RNA to a 
final concentration of 50 ng/µL (9.4 Appendix 4 – Pilot Reference Material 
Composition). The respective 100 ERCC solution was spiked into the 
corresponding mixed ratio cell line solution to produce Calibrant, Unknown 1 or 
Unknown 2 materials. The solutions were aliquoted (150 L) to generate 245 
replicate units for each Calibrant, Unknown 1 and Unknown 2 prior to storage at -
80ºC. These pilot RMs comprised the test material for determining uncertainty 
contributions at each stage of the experimental process. 
2.3.1 Endogenous Target Selection 
2.3.1.1 Reference Genes 
A panel of 32 control genes were evaluated as candidates for endogenous 
reference genes shared between the three cell lines (ABI P/N 4391590. See 9.1 
Appendix 1 – Assay Information for candidate reference gene assay details). 
Reference genes with consistent/least variable expression across the three 
different cell types were selected for continuation, as determined by RefFinder 
[225] analysis.  
RefFinder, accessed via the Cotton EST Database, is a web-based comprehensive 
tool developed for evaluating and screening reference genes from extensive 
experimental datasets. It integrates three computational programs (GeNorm [7], 
Normfinder [137], BestKeeper [226] and the comparative ΔΔCt (Cq) method [227]) 
to compare and rank the tested candidate reference genes. Based on the rankings 
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from each program, it assigns an appropriate weight to an individual gene and 
calculates the geometric mean of their weights for the overall final ranking.  
2.3.1.2 Genes of Interest 
A selection of 29 candidate genes was assessed for GOI suitability. The expression 
of each potential target gene in each of the three cell lines (Cq values) were used to 
model fold changes based on different options for composition of Unknown 1 and 
Unknown 2 materials. See 9.1 Appendix 1 – Assay Information for candidate GOI 
assay details. Based on these predictions, mixed ratio model units of the three cell 
lines were mocked up and tested for applicability using a subset of the GOI assays. 
For our purposes, GOIs simply required differential expression in each of the three 
cell lines and assays that performed reproducibly with high efficiency.  
2.3.2 Assay Design 
When designing primers for ERCC TCM targets, assays were positioned across 
different RNA secondary structure motifs (predicted using MFOLD [228,229]), 
representing both tightly folded and more open regions, depending on the target 
(9.2 Appendix 2 –Endogenous and ERCC Transcript Predicted Secondary 
Structures). 
ERCC RNA concentration and copy number estimates are summarised in Table 
9.6. Assay positions within the respective transcripts are detailed in Table 9.4.  
After initial endogenous target selection, the amplicon region of both Reference 
and GOI assays, as detailed by the commercial assay manufacturer, was identified 
and used to redesign assays in-house. Assays were designed to this same region 
and amplification conditions optimised. These assays underwent validation as 
performed previously, including primer/probe concentration optimisation and 
cross-reactivity tests with ERCC RNA standards, before application to pilot RM 
evaluation. 
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2.3.3 Measurement Uncertainty Budget 
A260 was used for initial quantification of ERCC stock concentration. The 2100 
Bioanalyzer was employed for the assignment of purity to ERCC stock solutions. 
These factors were additionally used for calculation of the pilot RM assigned values 
and associated uncertainty budgets for each ERCC transcript. Furthermore, other 
contributions to uncertainty calculations included volumetric dilutions of the stock 
solution and sample homogeneity and stability. Since all study materials were 
prepared from the same stock ERCC solution, transcript concentration and purity 
terms were the same when measuring relative expression ratios. Therefore, the 
associated measurement uncertainty is composed of precision terms related to the 
independent dilution steps performed for each Unknown unit type (Unknown 1, 
Unknown 2) preparation, plus sample homogeneity and stability.  
Measurement uncertainty was calculated using the root sum of squares rule for 
combining standard uncertainties for independent variance components: 
𝑈𝑐 = √𝑢12 + 𝑢22 
Where:  Uc = combined uncertainty 
un = uncertainty (SD) of a contributing factor 
2.4 Reverse-Transcription Quantitative PCR Analysis 
RT-qPCR experiments were performed under either one-step or two-step reaction 
conditions. Taqman 96-well optical plates (ABI P/N 4306737) and Taqman 96-well 
optical plate adhesive covers (ABI P/N 4311971) were employed for all RT-qPCR 
experiments.  
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2.4.1 Two-step RT-qPCR 
For two-step RT-qPCR, the RT reaction was performed using TaqMan reverse 
transcription reagents (ABI P/N N8080234). Reactions performed according to 
supplier recommendations (final reaction concentrations given); TaqMan RT 
buffer, 5.5 mM MgCl2, 500 µM each dNTP, 2.5 µM oligo d(T)16, 0.4 U/µL RNase 
Inhibitor, 1.25 U/µL Multiscribe RTase and 5 µL RNA at various quantities (20, 2 or 
0.2 ng, diluted in RSS). Sample reactions were incubated at 25ºC for 10 min, 48ºC 
for 30 min and 95ºC for 5 min. Triplicate reactions per sample were performed in 
parallel.  
Subsequent qPCR analysis employed hydrolysis probes or intercalating dye 
(Power SYBR Green PCR Master Mix; ABI P/N 4367659, or EvaGreen; Biotium P/N 
31003-1) in a 96 well plate format with the Prism 7900 HT real-time PCR system 
(ABI). Reactions of 10 or 25 µL consisted of TaqMan® Universal Master Mix (ABI 
P/N 4304437) or Power SYBR Green Buffer or 2 Fast EvaGreen Master Mix (final 
concentration 1), sequence-specific gene assay (9.1 Appendix 1 – Assay 
Information), 2-5 µL cDNA at various concentrations (20, 2 or 0.2 ng, RNA 
equivalent) (Table 9.5) and ROX (Biotium P/N 99939, EvaGreen reactions only, 
final concentration 1). Level and stage of replication can also be found in Table 
9.5. The qPCR reaction was performed using the following parameters: 50ºC for 2 
min (TaqMan assays only), 95ºC for 10 min (2 min EvaGreen reactions only), 40-
45 cycles of 95ºC for 15 s and 60 ºC for 1 min. SYBR Green and EvaGreen assays 
additionally included a dissociation step (60 to 95ºC) to assess for non-specific 
products and/or primer-dimers (Alu assay). Only single product peaks were 
observed.  
2.4.2 One-step RT-qPCR 
Unless otherwise stated, one-step RT-qPCR utilised AgPath-ID one-step RT-PCR 
reagents (Ambion P/N 4387391) and the Prism 7900 HT real-time PCR system, in 
a 96 well plate format. Reactions of 10 or 25 µL comprised RT-PCR buffer/master 
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mix, RT enzyme (1), sequence-specific gene assay (9.1 Appendix 1 – Assay 
Information, RT priming gene-specific due to one-step process), 25 ng/reaction 
carrier (unless otherwise stated) and 1-2.5 µL RNA at 50 ng/µL (unless otherwise 
stated). Samples were analysed in triplicate. Thermal cycling conditions: 55ºC for 
10 min (RT step), 95ºC for 10 min, 40 cycles of 95ºC for 15 s and 60ºC for 45 s. 
PCR efficiency estimates were derived from curves encompassing six-point (or 
seven-point, GAPDH assay), ten-fold serially diluted standards (incorporating 
triplicate measurements per dilution), utilising: ERCC IVT RNA transcripts (ERCC 
assays, one-step); human gDNA (Alu assay, qPCR only); complex background 
material (mixed cell line-derived total RNA from each Hep-G2, SaOS-2 and Hs 683 
cells, endogenous assays, one-step), or human universal reference RNA (GAPDH 
assay, two-step, RT replicates).  
2.4.3 qPCR Analysis 
For all experiments performed on the Prism 7900 HT real-time PCR system, 
analysis was performed utilising SDS software (ABI), version 2.3. Assays included 
in this analysis typically exhibited efficiencies between 90 and 110% as a selection 
criterion. Systematic limit of quantification (LOQ) was not performed for all assays, 
however, standard curve analysis showed good linearity within the experimental 
range. 
2.4.4 dPCR Analysis 
dPCR experiments were performed using the Fluidigm Biomark platform. Both 
12.765 (P/N BMK-M-12.765) and 48.770 (P/N BMK-M-48.770) chip formats were 
utilised. Assays were first optimised using the qPCR platform before transfer to the 
Biomark. Analysis was performed utilising dPCR analysis software (Fluidigm), 
version 3.0.2. Each chip contains 12 panels with 765 reaction chambers or 48 
panels with 770 reaction chambers, respectively (Figure 2.1A). Master reactions, 
which additionally included GE sample loading reagent (1, Fluidigm P/N   
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A 
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Figure 2.1 Fluidigm Biomark chips. (A) 48:770 digital PCR array. Each chip contains 48 
panels, with 770 reaction chambers/partitions. Reaction mix is loaded into sample inlets and 
delivered to 0.86 nL chambers by an integrated fluidic circuit controller. 12:765 digital PCR 
arrays (not pictured), consist of 12 panels each with 765 reaction partitions; 6 nL per partition. 
(B) 48:48 Dynamic array. Each chip can analyse up to 48 different samples with 48 different 
assays. Assay and sample mixes are loaded into respective inlets and delivered to 9 nL reaction 
chambers by an integrated fluidic circuit controller.   
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85000735), were loaded into sample inlets and delivered to 6 nL or 1 nL chambers 
respectively, by an integrated fluidic circuit controller. Thermal cycling conditions 
as for qPCR. Analysis was performed utilising dPCR analysis software (Fluidigm), 
version 3.0.2. A count of partitions showing positive amplification can be made and 
an absolute target concentration elucidated [103]. dPCR calculations are explained 
in further detail below. MIQE guideline required information [230] is presented in 
9.6 Appendix 6 – Digital MIQE.  
2.4.4.1 dPCR Calculations Explained 
A count of partitions showing positive amplification can be made and an absolute 
target concentration elucidated. “Estimated copies” or “copies per panel” refer to 
the number of targets on the panel following a Poisson correction, to account for 
the fact that some positive partitions will contain more than one molecule. As the 
number of positive partitions increases, so does the probability that some 
partitions will contain more than one target molecule. The number of partitions in 
the dPCR chips used is sufficiently large to use Poisson probabilistic analysis to 
broadly estimate the mean concentration of the RNA sample using the following 
Excel formula [100]: 
λ = -ln(1- k/n)  or  λ = m/n 
№ Copies on the panel = (LN((C – k)/n))*(-n) 
k = n-((EXP(№ copies in the panel/-n))*n) 
*Target copies/µL = (№ copies on the panel)/(proportion loaded per panel) 
Proportion loaded per panel = (volume loaded per panel)/(volume loaded per inlet) 
Volume loaded per panel = (Partition volume)  (n)  
Where:  
λ = the mean number of molecules per partition 
k = the number of positive partitions 
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n = the number of partitions analysed per panel 
m = the estimated copy number in the total volume of all partitions 
№ Copies in the panel ≡ estimated copies 
Inlet = individual well for sample loading (discrete for each panel) 
*Target copies/µL is the concentration of sample as it is added to master mix. If dilutions have 
been made to get to this point, these also need to be considered in your calculation of target 
copies/µL in your original sample.  
Table 2.1 dPCR Specifications 
 12.765 48.770 
№ panels 12 48 
n 765 770 
Master reaction volume prepared per inlet 8 µL 4 µL 
Volume of master reaction loaded per panel 4.6 µL 0.65 µL 
Proportion loaded per panel 0.575 0.1625 
Partition volume 6 nL 0.84 nL 
 
 So for example, for a sample with 500 positive partitions (amplifications), 
using a 48.770 dPCR chip: 
№ Copies on the panel = (LN((770 – 500)/770))*(-770) = 806.9358 
 Then:  
Target copies/µL in dilution used = 806.9358/0.1625 = 4965.759 
 Original sample was diluted 1:1000 for experiment. Therefore:  
Original sample concentration = 4965.759  1000 = 4965759 copies/µL 
  = 4.97E+06 copies/µL 
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Lamda (λ), defined as the number of molecules per partition or true concentration, 
may be determined with the least amount of relative error when there are 
approximately 1.6 target molecules per partition, which corresponds to 
approximately 80% positive partitions [231]. That equates to approximately 612 
or 616 positive partitions per panel and 1231 or 1239 copies/panel, for 12:765 or 
48.770 dPCR chips respectively.  
2.5 Experimental Details – RT-qPCR Kit Comparison 
Details pertaining to assay, replication, RT-qPCR experimental format (one-step or 
two-step) and sample and carrier concentrations can be found in Table 9.5, for 
each experiment.  
2.5.1 One-Step RT-qPCR Kit Comparison by dPCR  
Initially, quantification was assessed for two synthetic (ERCC-25 and ERCC-99) 
targets in both uniplex and duplex formats, between the three commercial one-
step RT-qPCR kits: AgPath-ID one-step RT-PCR reagents, Quantitect Probe one-
step RT-PCR Kit (Qiagen P/N 204443) and Superscript III Platinum one-step RT-
qPCR system w/ROX (Invitrogen P/N 11745-100). Reactions were prepared as 
outlined for AgPath-ID kit in 2.4.2 One-step RT-qPCR.  
RT-dPCR was performed using Fluidigm Biomark 12.765 dPCR chips, n = 1 panel, 
plus three replicate experiments. Sample was diluted to approximately 1896 
copies per panel (or 2062 copies/µL added to master mix), based on UV estimates. 
Thermocycling conditions were as follows: (RT) 45ºC for 30 min, (RT 
inactivate/denature) 95ºC for 15 min, (PCR) 40 cycles 95ºC for 15 s and 60ºC for 
60 s. Yeast total RNA carrier was included at 25 ng/reaction. Following this, ERCC-
25 and ERCC-99, plus two endogenous (UBC and MMP1) targets were compared 
between the kits. These assays were analysed in duplex: ERCC-25 with ERCC-99 
(duplex A), UBC with MMP1 (duplex B), and ERCC-25 with UBC (duplex C). Sample 
was diluted to approximately 1886 copies per panel (or 1640 copies/µL added to 
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master mix, for ERCC targets), based on UV estimates. RT-dPCR was performed 
using Fluidigm Biomark 12.765 dPCR chips, n = 3 replicate panels, plus two 
replicate experiments.  
2.5.2 Comparison between dPCR and UV Measurement  
Measurement variability of six ERCC targets was tested using RT-dPCR evaluated 
as above (AgPath-ID kit). ERCC targets were spiked into cell line-derived total RNA 
at approximately 1.0E+06 copies/μL (estimated by UV), enabling evaluation of 
potential assay bias. Sample was diluted to approximately 200-400 copies per 
panel. RT-dPCR was performed using Fluidigm Biomark 48.770 dPCR chips, n = 3 
replicate experiments, on different days. Assays were analysed in uniplex.  
2.5.3 Linearity and Sensitivity of RT-dPCR  
An evaluation of RT-dPCR quantification sensitivity was performed using ERCC-25 
and ERCC-99 assays. Based on UV estimated values, sample was diluted in 0.5% 
Tween 20 (Sigma P/N P9416) to approximately 500, 250, 100, 50, 25, 10 and 5 
copies per panel (equivalent to 3077, 1538, 615, 308, 154, 62 and 18 copies/µL, 
respectively). Volumetric dilutions were performed independently for each 
dilution, rather than sequentially, to avoid volumetric error propagation during 
dilution steps. RT-dPCR was performed using Fluidigm Biomark 48.770 dPCR 
chips, n = 6 panels per dilution, plus three replicate experiments. Assays were 
analysed in duplex.  
2.6 Experimental Details – Extraction Kit Comparison 
2.6.1 Lysate Preparation  
Cell lysates of 17.5 mL were collected from T-175 flasks in aliquots for each cell 
line (Hs 683 and SaOS-2) and lysate buffer (for TRIzol, RNeasy and MasterPure 
extraction kits). Four flasks per cell line were produced; one flask per each of three 
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different lysis buffers plus one flask for cell enumeration. The TRIzol experiment 
was repeated three times for an analysis of batch variability. Seven mL of lysate 
were aliquoted and stored at - 80ºC.  
To assess the linearity of each extraction method, lysates were extracted at 
different dilutions: neat, 1:2 and 1:5. Prior to total RNA extraction, the 7 mL lysate 
aliquots were thawed, thoroughly mixed and dilutions prepared using the 
appropriate lysis buffer as diluent. Aliquots of total RNA were reserved for 
quantification and all extracts were stored at - 80ºC before DNase treatment.  
2.6.2 Total RNA Extraction using TRIzol Reagent 
Total RNA was extracted from cell lysates by following a standard TRIzol protocol 
(Invitrogen). See 2.2.2 Cell Line RNA Production for Complex Background.  
2.6.3 Total RNA Extraction using RNeasy Mini Kit  
Total RNA was extracted from cell lysates by following the “Purification of Total 
RNA from Animal Cells” protocol in the kit handbook (Qiagen P/N 74104). RLT 
buffer (containing 1% beta-mercaptoethanol, Sigma P/N M7154) lysates were 
homogenized using a QIAshredder spin column. One volume of 70% ethanol was 
mixed with the eluate and transferred to an RNeasy spin column. After separation 
using centrifugation (8,000 × g for 15 s), the silica membrane-bound RNA was 
washed with 700 µL of RW1 buffer followed by 500 µL of buffer RPE (both at 8,000 
× g for 15 s). A further 500 µL of buffer RPE was used to wash the membrane (30 s) 
and the membrane spun dry for 2 min at full speed. Total RNA was eluted in 50 µL 
nuclease-free water.  
2.6.4 Total RNA Extraction using MasterPure RNA Purification Kit  
Total RNA was extracted from cell lysates by following the manufacturers’ protocol 
(Epicentre, CamBio, P/N MCR85102). Fifty μg Proteinase K (Epicentre P/N 56-
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0002 and Qiagen P/N 19131) was added to Tissue and Cell Lysis Solution lysates 
and incubated at 65ºC for 15 min with frequent vortexing, before placing samples 
on ice for 3-5 min. Addition of 175 μL MPC Protein Precipitation Reagent preceded 
centrifugation (10,000 × g for 10 min at 4ºC). Total RNA was precipitated from the 
supernatant using 0.5 mL isopropyl alcohol. The RNA pellet was washed with 70% 
ethanol before resuspension in 35 µL of TE Buffer. Samples were incubated at 26ºC 
for 15 min to assist resuspension of the pellet. 
2.6.5 Post-Extraction Treatment  
Total RNA solutions were treated with rDNase I, as per manufacturer’s protocol (1 
U rDNase I reagent added per 4 µg of total RNA, incubated at 37ºC for 30 min). 
These preparations were purified using RNeasy midi kit, assessed for quantity 
(yield; Nanodrop). Neat samples (resuspended following purification in nuclease-
free water) were stored in aliquots at -80ºC.  
2.6.6 RNA Quality Metrics 
Following total RNA extraction, DNase treatment and purification, total RNA 
samples were subjected to several quality metrics for concentration and integrity.  
2.6.6.1 Nanodrop 
Sample concentration in ng/µL is based on absorbance at 260 nm. Volumes of 1.4 
µL were measured on a NanoDrop 1000 Spectrophotometer (Thermo Scientific) in 
triplicate per sample. 260/280 and 260/230 absorbance ratios were also obtained 
and used in assessment of sample quality.  
2.6.6.2 Bioanalyzer 
A 2100 Bioanalyzer (Agilent) was used to assess quality and quantity of RNA 
samples employing both the RNA 6000 Nano kit (P/N 5067-1511) and the RNA 
6000 Pico kit (P/N 5067-1513), following the manufacturers protocol. Samples 
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were measured once each. Instrument generated RIN (RNA Integrity Number) 
values provided an estimate of sample quality.  
2.6.6.3 Qubit 
A Qubit 2.0 Fluorometer (Invitrogen) and RNA Broad Range (BR) Assay kit 
(Invitrogen P/N Q10210) was employed as an additional quantity metric 
comparison. A 1:200 working solution of Quant-iT reagent was prepared with RNA 
BR Buffer. The high and low standards provided in the kit were prepared by a 1:20 
dilution using the working solution. RNA samples were prepared in a similar 
manner to the standards, before incubation in the dark for 2 min. Triplicate 
readings per sample were measured on the Fluorometer.  
2.6.6.4 Alu PCR 
The Alu assay was utilised for the detection of gDNA contamination of cell line-
derived RNA pre- and post-DNase treatment, plus post RT. In addition, total RNA 
concentration as estimated by Alu PCR may be used for normalisation [130]. DNase 
untreated, DNase treated and post RT was analysed for neat SaOS-2 sample 
triplicates only (post RT samples were performed using RT triplicates). All other 
samples analysed post DNase only. RTs for Alu PCR analysis were performed using 
the Taqman Reverse Transcription Kit and 100 ng/µL SaOS-2 (neat lysate) RNA 
post DNase treatment. Twenty-five µL reactions were prepared and analysed as 
outlined in 2.4.1 Two-step RT-qPCR.  
Alu PCR was performed using EvaGreen chemistry (not hydrolysis probe), due to 
universality of Alu sequence [130]. Ten µL reactions consisted of 2 Fast EvaGreen 
Master Mix, 10 ROX, 250 nM (final concentration) of each forward and reverse 
primer (9.1 Appendix 1 – Assay Information) and 2 µL RNA at 10 ng/µL, on a 
randomised 96-well plate format. Samples were measured in triplicate. A six point 
standard curve of human female gDNA was used with 10-fold dilutions starting at 
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10 ng/µL. Reaction conditions: 95ºC for 2 min, 45 cycles of 95ºC for 15 s and 60ºC 
for 60 s.  
2.7 Experimental Details - Sample Source and Type 
Samples were spiked pre-extraction with synthetic-only transcriptomic calibration 
material (sTCM), to obtain an estimated 1.0E+06 copies/µL of each ERCC target in 
the resulting total RNA post extraction.  
2.7.1 2D Culture Model – SaOS-2 Mineralisation 
Two different passages of SaOS-2 cells (p33 and p36) were subcultured and 
propagated as per manufacturer’s instructions (2.1.2 Cell Lines). Cells were 
maintained at 37 ºC, 5% CO2 for three days. In total, 7 T25 flasks (Corning, Sigma 
P/N CL S430372) were prepared per passage: three replicate flasks per condition, 
treatment (differentiation) versus control, and an additional flask for each passage 
was prepared alongside the experimental flasks for cell enumeration, as 
previously. This was repeated twice to generate two time points: D1 (24 hrs) and 
D7 post-treatment. On reaching confluency, the time point was designated day 0 
(D0) and 10 mL treatment media was added to the flasks. Differentiation media 
consisted of 98.8 mL propagation media, 1 mL of 0.2 M β-Glycerophosphate (Sigma 
P/N G9422, dissolved in dH20, Gibco P/N 15230-089), 100 mL of 50 mg/mL 
Ascorbic acid (Sigma P/N A4544-25G, dissolved in dH20) and 100 mL of 10-3 M 
Dexamethasone (Sigma P/N D4902, dissolved in Ethanol, Fisher P/N 
E/0650DF/17). Control media consisted of propagation media and 1:1000 ethanol. 
All media was filtered through a sterile 0.2-micron filter (Corning P/N 431229) 
and incubated at 37ºC before use. Treatment media was renewed on the cells after 
24 hrs. Cells were maintained at 37 ºC, 5% CO2 until D1 or D7 following onset of 
differentiation. On D1 and D7, cells were rinsed and collected in 2.5 mL TRIzol lysis 
buffer, as described in 2.2.2 Cell Line RNA Production for Complex 
Background. 2.5 mL lysates were stored at -80ºC as 2 1 mL aliquots.  
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2.7.2 3D Co-Culture Model 
Dr Cleo Bonnet (Cardiff University) performed all work preceding total RNA 
extraction.  
2.7.2.1 Cell Lines 
MLO-Y4 osteocyte-like cells were kindly donated by Prof. Lynda Bonewald 
(University of Missouri, USA) to Dr Deborah Mason’s group, part of the 
pathophysiology and repair division at Cardiff University. These cells have been 
shown to behave like primary osteocytes as they express high amounts of 
osteocalcin (OCN), low amounts of alkaline phosphatase (ALP) and type I collagen 
protein (ColI) and they have complex cytoplasmic processes expressing CD44, 
CX43 and ONP [232].  
MLO-Y4 cells were grown (until 70-80% confluent) in alpha-MEM (Life 
Technologies P/N 22561-021) supplemented with 100 U/mL penicillin (PenStrep 
combined, Life Technologies P/N 15140-122), 100 µg/mL streptomycin, 2.5% heat 
inactivated fetal bovine serum (HIFBS, Life Technologies P/N 10270-106) and 
2.5% heat inactivated newborn calf serum (HINBCS, Life Technologies P/N 
26010074). Heat inactivation was performed following Cambrex company 
protocol. Bottles of sera were thawed in a water bath at 56ºC for 30 min before 
use.  
SaOS-2 cells were grown in DMEM GlutaMAXTM (Life Technologies P/N 31966-
021) supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin and 5% 
dialysed FBS (DFBS, Sera Laboratories P/N EU-000-HD) until 100% confluent.  
2.7.2.2 3D Collagen Co-Cultures 
Rat tail tendon type 1 collagen (2.5 mg/mL in 7 mM glacial acetic acid, Sigma P/N 
C3867) was mixed on ice in a 4:1 ratio with 5 MEM containing 11 g/L sodium 
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bicarbonate (NaHCO3, Sigma, S-6297) and neutralised to pH 7.4 with 1 M Tris 
(hydroxymethyl)aminomethane (Tris) base (pH 11.5, Sigma P/N T1378) to give a 
2 mg/mL collagen solution. MLO-Y4 cells (1.5E+06 cells/mL gel) were diluted in 
their alpha MEM medium (less than 10% of the total gel volume) and mixed 
thoroughly into the collagen solution on ice. The collagen-cell mix was dispensed 
into wells in silicone plates (250 µL/well), which had been previously coated 
overnight with the Sigma collagen and incubated at 37ºC in 5% CO2 for 1 hr for 
polymerisation. Each well in the silicone plates has the same dimensions as a 
standard 48-well plate. Eight hundred µL of DMEM GlutaMAX medium was added 
on top of the gels before incubation overnight at 37ºC in 5% CO2. Media was 
removed the next day and SaOS-2 cells (1.0E+05 cells/well) were layered on top of 
the collagen gels in DMEM GlutaMAX medium (Figure 2.2). Co-cultures were 
incubated for 5 days prior to loading and subsequent termination. Media was 
changed every 2-3 days. Three gels were prepared per plate, with one plate per 
condition: loaded and control. The experiment was repeated three times on 
different days with cells of different passage.  
2.7.2.3 Mechanical Loading of 3D Co-cultures 
Preparation and validation of the mechanical loading system and software, 
including the silicon plate, was prepared and described previously by Vazquez et 
al. [233,234].  
On D5 of incubation the media was replaced (DMEM GlutaMAX) 1 hr before 
loading. The silicone plate for loading was attached to a BOSE EletroForce® 
loading instrument by a custom-made device in order to stretch the plate on one 
side only causing cyclic compression and tension forces at the same time but in 
perpendicular directions in all wells. A 250 N load cell was used to apply a loading 
regime of 5 min, 10 Hz, 2.5 N to the 3D collagen co-cultures. Mechanical loading of 
cultures in the silicone plate was performed using a BOSE ElectroForceController 
Software ® 3200 instrument (Kent, UK) and controlled   
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Figure 2.2 Schematic representation of 3D gel co-cultures. (A) Each well contained a 3D 
collagen gel matrix seeded with MLO-Y4 cells (osteocytes). A surface layer of SaOS-2 cells 
(osteoblasts) was seeded on top of the 3D matrix. The 3D co-culture was topped with the 
appropriate media. (B) An illustration of the mechanical loading experiments, with the 
inclusion of a control plate that was not loaded. A 250 N load cell was used to apply an 
osteogenic loading regime of 5 min, 10 Hz, 2.5 N to the 3D co-cultures, generating cyclic 
compression and tension forces at the same time but in perpendicular directions in all wells. 
  
Chapter 2 Materials & Methods 
 
Page 76 
with WinTest® Software 4.1 with TuneIQ control optimisation (BOSE) [233,234]. 
The control plate was left on the bench next to the loading machine during loading 
of the test plate. Both silicone plates were returned to the incubator for 4 hrs prior 
to TRIzol treatment.  
2.7.2.4 TRIzol Treatment of 3D Co-cultures 
To retrieve the SaOS-2 osteoblastic layer of cells from the 3D gel matrix, the media 
was removed and 800 µL TRIzol was added to the top of each gel for 10 seconds 
before transferring to a 1.5 mL Eppendorf. MLO-Y4 cells in the gel were treated 
with 1 mL of TRIzol until the gel dissolved before transferring to a 1.5 mL 
Eppendorf (if required for future work). Samples were stored at -80ºC. SaOS-2 cell 
lysates were extracted and DNase treated as described in 2.2.2 Cell Line RNA 
Production for Complex Background. RNA pellets were resuspended in 40 µL 
nuclease-free water.  
2.7.3 Clinical Samples – Total Knee Replacement Bone Cores 
Clinical samples were collected by the Arthritis Research UK Biomechanics and 
Bioengineering Centre (Andrea Longman, Helen Roberts, Deborah Mason, Cleo 
Bonnet) and surgeons (Rhys Williams, Chris Wilson and Sanjeev Argawal) under 
their ethical approval (Research Ethics Committee for Wales, reference number 
10/MRE09/28). Surgical staff collected bone cores during total knee replacement 
(TKR) surgery from five female patients aged between 44 and 75 years (one 
patient had a bilateral TKR and so samples were obtained from both the right and 
left knees, giving six ‘patient’ samples in total). These samples were used to 
compare positional mRNA profiles. Each patient set consisted of TKR cores 
collected in theatre using bone biopsy needles from four different positions, 1 cm 
below the tibial plateau (Figure 2.3). Samples were maintained in RNAlater 
(Sigma P/N R0901) on dry ice during surgery and stored at -80ºC. Samples 
required thawing to remove excess RNAlater before being frozen on dry ice and 
subjected to the standard dismembration protocol.   
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Figure 2.3 Positional schematic of clinical sample regions. (A) Schematic representation of 
the human knee. (B) Positional schematic of sample sites from the tibial plateau. The four 
sample sites (blue cores) for each patient included anterior medial (AM), posterior medial 
(PM), anterior lateral (AL) and posterior lateral (PL). Anterior: toward the front of the body. 
Posterior: toward the back of the body. Medial: a structure toward the midline of the body. 
Lateral: away from that median plane.   
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2.7.3.1 Dismembrator 
It is notoriously difficult to extract nucleic acids from bone material, and special 
protocols are required [194,201-203]. Clinical bone cores were disrupted using a 
dismembrator before storage in TRIzol, ready for total RNA extraction. 
Unprocessed samples were maintained on dry ice. A steel-shaking flask with 
matching grinding ball were cleaned using 1 M sodium hydroxide (Fisher P/N 
S14920160) and rinsed with molecular grade water (Sigma P/N W4502) before 
use. The shaking flask and grinding ball were pre-cooled in liquid nitrogen. An 
individual bone core sample was placed in the bottom half of the shaking flask with 
the grinding ball and immediately immersed (alongside the flask top) in liquid 
nitrogen. After allowing the sample to freeze for 5-10 s, everything was removed 
from the liquid nitrogen and 600 μL of TRIzol was added on top of the sample. The 
shaking flask was sealed and the sample homogenised using a Mikro-
Dimembrator-U, B.Braun (Biotech International) at 200 rpm for 2 min. Sample 
appearance is powdery until melted, so to aid sample collection 400 μL of TRIzol 
was added before transferring the whole volume (1 mL) into a fresh Eppendorf. 
Samples were maintained on dry ice until all samples were processed. Between 
samples, the shaking flask and grinding ball were rinsed in water, and cleaned first 
with 1 M sodium hydroxide followed by absolute ethanol. Lysates were stored at -
80ºC.  
Samples were spiked with sTCM pre-extraction and processed using the TRIzol 
protocol and DNase treated, as described in 2.2.2 Cell Line RNA Production for 
Complex Background. Total RNA was resuspended in 50 μL nuclease-free water.  
2.7.4 Quality Metrics 
As described in 2.6.6 RNA Quality Metrics, all DNase treated samples for both the 
3D gel co-culture model and clinical bone cores were subjected to Nanodrop and 
Bioanalyzer assessment, plus evaluation by Alu PCR. All samples were analysed 
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using the Alu assay in triplicate against a six-point, ten-fold, human gDNA standard 
curve, starting at 10 ng/μL (also in triplicate). 
2.7.5 Dynamic Array 
Fluidigm Biomark Dynamic 48.48 Arrays (P/N BMK-M-48.48) were utilised for the 
high throughput analysis of both clinical bone core and 3D gel co-culture samples. 
This enabled an assessment of all samples with 27 different assays. Details of the 
assays analysed in this experiment are given in 9.1 Appendix 1 – Assay 
Information.  
Due to the low volume capacity (9 nL), and therefore reduced physical sensitivity 
of the dynamic array partitions, it is recommended by the manufacturer to 
perform a preamplification reaction prior to analysis on the dynamic array. This 
ensures that even minority targets are in sufficient abundance for analysis and 
detection. As a result of this additional step, RT-qPCR reactions on the dynamic 
array are performed in a three-step process: RT; preamplification; qPCR. Twenty 
ng/µL of RNA was used in each RT reaction. Six out of the 42 samples had 
concentrations lower than 20 ng/µL and so were used in the RT reaction neat. 
Triplicate RTs per sample were performed as described previously in 2.4.1 Two-
step RT-qPCR. Alongside the samples, triplicate RTs were also performed for the 
Calibrant unit. The Calibrant standard curve consisted of four points in 10-fold, 
RNA serial dilutions.  
2.7.5.1 Preamplification 
Preamplification (Taq amplification based on 14 cycle PCR) was performed using 
TaqMan PreAmp master mix (ABI P/N 4391128). All 27 assays were combined in 
equal volumes to generate a final concentration of 0.2 for each gene expression 
assay. A separate preamplification reaction was performed for each of the 
triplicate RTs. Ten µL reactions consisted of 2 TaqMan PreAmp master mix, 
pooled assay mix (final concentration 0.2, each assay) and cDNA (final 
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concentration 10 ng/µL). Reaction conditions: 95ºC for 10 min, 14 cycles of 95ºC 
for 15 s and 60ºC for 4 min. Preamplified products were stored at -20ºC. Before 
proceeding further, all preamplified products were diluted 1:5 using TE, as per 
manufacturer's protocol.  
2.7.5.2 Dynamic Array Analysis 
Fluidigm Dynamic Arrays are performed much like Fluidigm Digital Arrays except 
that the assay and sample components are prepared separately. Five µL assay mix 
comprises 20 forward and reverse primers and probe mix, plus 2 DA assay 
loading reagent (Fluidigm, Biomark GE 48.48 Dynamic Array Sample and Loading 
Reagent Kit P/N 85000800). Five µL sample mix comprises 2 TaqMan Universal 
master mix, 12.5 GE sample loading reagent and 2 µL pre-amplified product. Both 
assay and sample mixes were prepared in excess and 10 µL was subsequently 
loaded into corresponding inlets on the dynamic array chip (Figure 2.1B). Three 
replicate Dynamic Array chips were analysed, one for each of the RT replicates per 
sample. ERCC assays were performed as single replicates; all other assays were 
performed in duplicate. Each sample, including the Calibrant dilutions were 
performed as single replicates per chip.  
The Calibrant was also used to test the linearity of the preamplification reaction. 
Six point curves of 10-fold serial dilutions were prepared for both preamplified 
and non preamplified Calibrant. These were analysed in replicates of four using the 
same assays as above.  
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3 Production & Validation of Novel Transcriptomic 
Calibration Material 
3.1 Introduction 
Accurate normalisation of mRNA level is an absolute prerequisite for reliable 
results, especially when the biological significance of subtle differences in mRNA 
levels is studied [7,235]. As detailed in the introduction to this thesis, there are 
several strategies employed for the normalisation of RT-qPCR data; the most 
frequently employed of which is the measurement of internal reference genes. 
While the best approach maybe to use multiple validated internal reference genes 
[86], to enable meaningful data comparisons, internal RNA control genes must 
show constitutive, stable expression across all control groups [236].  
Normalisation to externally spiked RNA controls offers an alternative to 
endogenous reference genes [236-239]. This approach allows normalisation of 
mRNA level data without the assumption of stably expressed endogenous 
reference genes [236]. As discussed in the introduction to this thesis, such external 
controls should be spiked into test samples so that any inhibitory matrix effects for 
example, are also conferred to the control RNA measurement, otherwise, a 
difference in such conditions may limit the effectiveness of this strategy.  
Indeed, several studies have concluded that external RNA controls are suitable for 
normalisation of RT-qPCR data [235,236,238,240,241] and that they are able to 
compensate for inadequate internal RNA reference genes, which may in fact 
increase the variability associated with the measurement result. Such variation 
adds to the already complex multiple sources of variation attributed to biology and 
technology [235,237-239]. Normalisation using external RNA controls should 
allow for comparisons of mRNA levels across different stages of development 
[242] and across different types of tissues [236]. Furthermore, the reliability and 
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impact of external RNA controls would be further strengthened by using multiple 
external RNA control genes and analysing them using geNorm [236,238,243]. 
The focus of this thesis is to deconstruct the factors contributing to RNA 
measurement variability. For that purpose, initial studies detailed in this chapter 
concentrated on the development of a pilot TCM. The aim of this chapter was to 
produce in large quantities, highly characterise and validate the TCM, before use in 
experimental assessment throughout the tenure of this project. It was decided that 
this TCM should contain both synthetic and endogenous RNA species. The 
synthetic targets allowed evaluation of absolute quantification and supplied an 
opportunity to manipulate measurement ratios to challenge methodological 
sensitivities. The synthetic component also provided an opportunity for exogenous 
target spikes to monitor and normalise all sample types measured. The 
endogenous targets provided the opportunity for measurement of biological 
variability and assessment of normalisation strategies.  
3.2 Material & Methods 
All cell culture of Hep-G2, Hs 683 and SaOS-2 cell lines, up to and including lysate 
collection, was performed by Dr Gary Morley and Dr Sabhi Rahman, LGC, 
Teddington. Culture details are described in 2.1.2 Cell Lines and 2.2.2 Cell Line 
RNA Production for Complex Background. Statistical analysis was performed in 
collaboration with Dr. Simon Cowen, Dr. Steve Ellison and Dr. Jesus Minguez, 
Statisticians, LGC, Teddington.  
For successful generation of a suitable calibration material, quality control 
assessments were performed at relevant stages in the preparation of the TCM.  
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3.2.1 DNA Contamination Assessment 
ERCC RNA transcript samples were evaluated for plasmid DNA contamination as 
DNase treatment is not 100% efficient and residual DNA content would give false 
positive results. For this purpose, all eight ERCC RNA samples were serially diluted 
10-fold (from 5E+08 to 5E+03) and the RT-step prior to qPCR excluded, ensuring 
any signal generated should be attributable to contaminating residual plasmid 
DNA (2.4.1 Two-step RT-qPCR).  
Similarly, cell line RNA extracts were tested by qPCR for residual gDNA content 
following rDNase I treatment. The Alu assay was employed for this purpose due to 
the high prevalence of conserved Alu sequence repeats within 3’ UTRs. Alu 
expression was compared in all three cell lines, before and after rDNase I 
treatment, and when performing standard 50 µL as well as larger volume rDNase I 
reaction volumes (used to accommodate complete lysate extraction in one 
reaction, while maintaining manufacturers recommended total nucleic acid 
concentration of 200 ng/µL. Sample volumes treated: SaOS-2 182 µL, Hs 683 452 
µL and Hep-G2 2510 µL). Twenty ng RNA for each cell line and treatment were 
measured in triplicate by qPCR. A standard dilution series of human gDNA was 
additionally assessed, also in triplicate. Due to the frequency of Alu sequence 
motifs, it is usual to expect Alu-specific positive amplification in NTC samples 
[244]. Low-level Alu contamination permeates most reagents. As such, positive 
amplification observed in target samples at the same concentration (Cq) as in NTC 
replicates can be considered background contamination, not attributable to gDNA 
carryover [244]. Amplification of Alu sequences in target samples truly resulting 
from inefficient DNase treatment will be distinguished by a left shift in Cq, i.e., 
higher concentration. Such differences in this study are defined by at least a three 
times standard deviation shift in Cq to be considered different. Less than this and 
the value falls within the 99% level of confidence and so is not significantly 
different. NTC samples were analysed in replicates of six.  
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3.2.2 Assay Cross-Reactivity with Human Targets 
Since the TCM for assessment in this project will comprise both ERCC RNA 
transcripts and human cell line-derived RNA (as disease models and sources of 
endogenous reference genes and GOI), all eight ERCC assays were tested for 
potential cross-reactivity with human samples (2.4.1 Two-step RT-qPCR).  
3.2.3 Carrier Optimisation 
DNA and RNA carriers at different concentrations, as well as no carrier, were 
tested for influence on one-step RT-qPCR efficiency and precision. It is important 
that such carriers have no sequence similarity with ERCC RNA transcripts or 
endogenous targets to prevent false positive results attributable to the carrier. The 
carriers evaluated in this experiment were shown by BLAST analysis to have no 
sequence homology with ERCC RNA transcripts or endogenous targets. Ten-fold 
serial dilutions of ERCC-13 RNA, from 5E+08 to 5E+04 copies/reaction, were 
analysed in triplicate for each carrier condition. A second experiment was 
additionally performed to further define variability between DNA carrier 
(sonicated salmon sperm DNA) and RNA carrier (total yeast RNA), when analysing 
both DNA (plasmid) and RNA (IVT) samples (2.1.2.1 Carrier Options and 2.4.1 
Two-step RT-qPCR). 
3.2.4 RNA Stability Analysis 
To evaluate the effect of storage on both lysate and extracted RNA on the qPCR 
result, lysate was collected from one T-175 flask of Hep-G2 cells and 12 identical 
aliquots made. The 12 lysate aliquots were split into three groups of four aliquots 
and total RNA extracted at monthly intervals; time (T)=0, T=1, T=2 (2.2.2 Cell Line 
RNA Production for Complex Background). Lysates and/or total RNA were 
stored at -80ºC between experiments. Standard quality metrics for quality and 
quantity were performed for each time point. Total RNA extracts were also 
assessed by two-step RT-qPCR (RT: oligo d(T)16 priming) at the point of extraction 
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and at monthly intervals until the end of the three month time course (2.4.1 Two-
step RT-qPCR). Human universal reference RNA (Ambion) was used as a positive 
control/calibrant in combination with GAPDH assay-on-demand.  
3.2.5 RT Variability 
In line with current consensus, an experimental demonstration of RT variability 
was undertaken. A test of linearity for RNA dilutions versus cDNA dilutions at the 
RT stage of RT-qPCR was performed by two-step RT-qPCR (2.4.1 Two-step RT-
qPCR). 
3.2.6 Endogenous Target Selection 
A panel of 32 control genes were evaluated as candidates for endogenous 
reference genes shared between the three cell lines (2.3.1.1 Reference Genes. See 
Appendix 1 – Assay Information for assay details). Following selection of 
reference genes, 29 potential GOI were evaluated for suitability across the three 
cell lines (2.3.1.2 Genes of Interest. See Appendix 1 – Assay Information for 
assay details).  
3.2.7 Transcriptomic Calibration Material Homogeneity and Stability 
The TCM was generated by mixing RNA extracted from Hep-G2, SaOS-2 and Hs 683 
cell lines, following the protocol outlined in 2.3 Preparation of Transcriptomic 
Calibration Material (TCM). The TCM has been produced as a prototype 
reference material for molecular measurements, and the way it has been generated 
was guided by this ultimate purpose. For this reason, the unit types Unknown 1 
and Unknown 2 are referred to as ‘Unknown’ materials, despite the fact that their 
composition is known to us (as we produced them). Their intended use would 
include distributing to laboratories to participate in a trial whereby values are 
assigned to the named targets in Unknown 1 and Unknown 2 through calibration 
curve-based assessments (using the Calibrant unit type) or fold change 
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measurements between the two Unknowns. Completion of this type of study helps 
to determine measurement capabilities (and validate measurement claims) of the 
participating laboratories. 
TCM sample homogeneity (uniform composition) was evaluated using ten 
randomly selected aliquots of each unit type, Calibrant, Unknown 1 and Unknown 
2 (2.3 Preparation of Transcriptomic Calibration Material (TCM)), measured 
in replicates of eight. One randomised 96 well plate was prepared for each sample 
(Calibrant, Unknown 1 or Unknown 2) and each assay. Each plate included an RNA 
standard curve (serially diluted 1:10 from 1.0E+06 to 1.0E+01 copies/µL in 
carrier), plus three no template controls (NTCs). RT-qPCR experiments were 
performed according to one-step conditions, with inclusion of yeast total RNA 
carrier (2.4.2 One-step RT-qPCR). ERCC-99 and HPRT1 assays were employed as 
representative of both external and endogenous target populations (2.3 
Preparation of Transcriptomic Calibration Material (TCM)).  
A short-term stability study was undertaken at a range of temperatures to 
establish the effect of storage time on RNA stability. For each Calibrant, Unknown 1 
and Unknown 2 solution, three replicate units were isochronously tested at -80 ºC, 
on dry ice, +4 ºC, and +40ºC and at time (T) = 0, 7 and 14 days. One-step RT-qPCR 
was performed (2.4.2 One-step RT-qPCR) and the ERCC-99 and HPRT1 Cq values 
for a particular unit type at the different temperatures and time-points were 
compared. A longer-term stability study was also performed. For each Calibrant, 
Unknown 1 and Unknown 2, three replicate units were incubated for one week on 
dry ice (to simulate a shipping period) before being transferred to either -80ºC or -
20ºC (designated T = 0). Measurements of ERCC-99 and HPRT1 were made at T = 0 
and 6 months. 
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3.3 Results & Discussion 
3.3.1 ERCC IVT RNA Quality Control 
Following plasmid sample digestion and IVT of ERCC RNA, transcript sizes, 
concentration and integrity were assessed. ERCC sample concentrations and copy 
number equivalents estimated by UV A260 assessment ranged from approximately 
300 to 1000 ng/µL, equating to 9.3E+08 to 3.7E+09 copies/µL in 1 ng/µL 
preparations (Table 3.1). Samples were additionally evaluated for integrity by 
capillary electrophoresis (Figure 3.1). Initial analysis confirmed correct transcript 
sizes with additional banding patterns (Figure 3.1A). Heat denaturation at 70ºC 
removed the excess banding patterns from the transcript profiles (Figure 3.1B), 
with minimal band smearing.  
The eradication of superfluous banding when heat-treating ERCC RNA transcripts 
prior to integrity assessment suggests that the banding observed on the original 
profile was caused by insufficient denaturation of RNA secondary structure, rather 
than concatemerisation. The profile of the heat denatured transcripts presented 
clear bands at the expected sizes, without significant smearing (which may 
otherwise indicate sample degradation). Additional banding present in Figure 
3.1B suggests some secondary structures remain intact, despite heat denaturation. 
No instrument-derived RIN values were generated associated with ERCC RNA 
transcript analysis due to the lack of 18S and 28S rRNA eukaryotic markers.  
3.3.1.1 Assay Validation 
Several experiments were performed to validate the qPCR ERCC assay conditions 
and sample purity. Individual assays were assessed for efficiency and intermediate 
precision by one-step RT-qPCR, and all, except ERCC-95, were shown to be fit for 
purpose (based on efficiency and intermediate precision, where replicates were 
performed on a different day by the same analyst (Table 3.2). See also 1.1.2 
Accuracy and Measurement Uncertainty). ERCC-95 was therefore no   
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Table 3.1 IVT ERCC RNA standards. Concentration and copy number equivalents following 
initial preparation. 
ERCC- 
Concentration 
(ng/µL) 
Length with poly(A) 
tail (bases) 
Mw 
IVT RNA 
copies/µL 
1 ng/µL equiv 
to: (copies/µL) 
13 318 808 264188 7.26E+11 2.28E+09 
25 491 1994 647955 4.56E+11 9.29E+08 
42 402 1023 330495 7.33E+11 1.82E+09 
84 995 994 323987 1.85E+12 1.86E+09 
95 551 521 168589 1.97E+12 3.57E+09 
99 299 1350 439632 4.10E+11 1.37E+09 
113 958 843 274225 2.10E+12 2.20E+09 
171 394 505 164604 1.44E+12 3.66E+09 
Mw: molecular weight, equiv: equivalent.  
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Figure 3.1 Quality control of ERCC IVT RNA. Analysis of IVT transcript sizes was performed 
using an Agilent 2100 Bioanalyzer. (A) RNA transcripts following RNeasy purification. (B) The 
same RNA transcript samples following heat-induced denaturation revealed additional bands 
were attributable to secondary structure motifs in the non-denatured RNA samples. 2100 
Bioanalyzer quantification for all synthetic targets was comparable to nanodrop concentration 
estimates (p = 0.660, with an average fold change between the two measurements of 1.02, CV 
11.5%).  
   
A                                                         B 
Chapter 3 Production & Validation of Novel Transcriptomic Calibration Material 
Page 91 
Table 3.2 ERCC Assay Efficiencies. Six point RNA standard curve from 5.0E+06 to 5.0E+01 
copies/µL, triplicate measurements.  
Target DNA 
Average 
Efficiency (%) † 
CV (%) † 
Standard Error 
of the Mean † 
ERCC-13 ~109 0.46 0.08 
ERCC-25 ~104 0.60 0.10 
ERCC-42 ~102 0.72 0.11 
ERCC-84 ~99 0.23 0.04 
ERCC-95 ~140* 0.54 0.09 
ERCC-99 ~106 0.51 0.09 
ERCC-113 ~103 0.31 0.05 
ERCC-171 ~95 0.58 0.11 
† As determined by average of three RT-qPCR reactions using the ABI 7900 platform. * An 
efficiency estimate of ~140% for this assay was criterion for exclusion of the associated target 
from the panel of standards to be prepared. Efficiency estimates were averaged over three 
experiments across three months and so this may explain the decrease in precision.  
 
  
Chapter 3 Production & Validation of Novel Transcriptomic Calibration Material 
Page 92 
longer included in future studies. Based on our groups’ extensive work in this field, 
acceptable intermediate precision for one-step RNA measurements is < 10%, and 
for DNA measurements is < 5%, provided > 1000 copies are being quantified. (The 
coefficients of variance, CV, of qPCR on the LightCycler instrument for DNA 
measurements have been shown to be approximately 2-5% [245]). Assays with 
PCR efficiency estimates between 90 and 110% were accepted for this study 
(Table 3.2).  
3.3.1.2 Cell Line RNA Quality  
Total RNA derived from each cell line was assessed for quality and quantity. 
Representative yields (pre- and post-DNase treatment) and cell counts per flask 
are summarised in Table 3.3. Hep-G2 lysates produced the highest total RNA 
yields per T-175 flask (722.25 µg) and SaOS-2 lysates yielded the lowest (46.71 µg; 
Hs 683: 170.52 µg). Following DNase treatment, these yield relationships were 
maintained: Hep-G2 645.52 µg/flask, Hs 683 142.36 µg/flask and SaOS-2 33.84 
µg/flask (Figure 3.3). There was no significant difference observed between pre- 
and post-DNase yields for any of the three cell lines (all p > 0.05). Although cell 
counts per flask correlated with total RNA yields, the yields per cell also showed 
the same relationship with Hep-G2 cells yielding the most RNA and SaOS-2 cells 
yielding the least RNA. All three cell lines, regardless of treatment, produced good 
quality RNA as assessed by capillary electrophoresis and associated generation of 
RIN values, all being > 9.9. Additionally, all cell lines showed strong 18S and 28S 
ribosomal banding, without significant smearing (indicative of non-degraded total 
RNA; Figure 3.4).  
The Hs 683 cells were comparatively large and generated a lower total RNA yield 
per T-175 flask following TRIzol extraction than the other two cell lines. The 
smaller size of the Hep-G2 cells offered an increase in total cell count per T-175 
flask and consequently the largest total RNA yield of the three cell lines following 
TRIzol extraction. The SaOS-2 cells were the slowest growing and displayed by far  
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Table 3.3 Cell line RNA quantity  
Cell line 
Estimated cell 
count per flask 
Av. yield/flask 
pre-DNase (µg) 
Av. yield/cell 
pre-DNase (pg) 
% CV 
Av. yield/flask 
post-DNase (µg) 
Av. yield/cell 
post-DNase (pg) 
% CV RIN 
Hep-G2 5.90E+07 722.25 12 29.95 645.52 11 31.15 9.9 
Hs 683 2.60E+07 170.52 7 35.83 142.36 5 40.94 10 
SaOS-2 1.83E+07 46.71 3 36.06 33.84 2 46.03 10 
 
 
Chapter 3 Production & Validation of Novel Transcriptomic Calibration Material 
Page 94 
 
Figure 3.2 RNA yields pre- and post-DNase treatment. Total RNA yields were measured 
pre- and post-DNase treatment using UV A260 for the three cell lines, HepG2 (n = 8), Hs 683 (n = 
14) and SaOS-2 (n = 11). The data have been normalised for cell count. Error bars: standard 
deviation.  
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Figure 3.3 Quality control of cell line total RNA. Pre- and post-DNase treatment samples 
were compared. Analysis of ribosomal bands was performed using an Agilent 2100 
Bioanalyzer. All cell lines show strong 18S and 28S ribosomal bands without significant 
smearing. Low molecular weight bands in lanes 1-3 may be attributable to low level 
degradation or the 5S precursor.  
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the lowest yields, despite attempts to extract all cell line flasks at approximately 
equal (manufacturer recommended) confluency. 
3.3.2 DNA Contamination Assessment 
Deoxyribonuclease (DNase) enzyme treatment of samples is used to degrade 
contaminating sources of DNA in RNA preparations. This aims to eliminate the 
possibility of DNA signals being detected in lieu of RNA signals in downstream 
applications that measure RNA. As with many enzymatic reactions, achievement of 
100% efficiency is very difficult, if not impossible to achieve. Consequently, the 
purpose of this experiment is to examine the efficiency of the DNase reaction.  
Positive amplification in the absence of RT was observed in ERCC RNA samples 13, 
25, 84 and 171 with 5E+08 and 5E+07 copies/reaction, at high Cq values (> 34-37). 
ERCC RNA samples -42 and -95 displayed positive amplification for 5E+08 
copies/reaction only, (Cq > 37). No positive amplification at any concentration was 
observed in ERCC RNA samples 99 and 113. For those samples that showed 
amplification, ERCC-13, -25, -42, -84, -95 and -171, further dilution removed this 
signal suggesting that DNA contamination was never more than 1 in 5 million 
copies (diluted to 5E+07 copies/reaction and below for ERCC-42 and -95, and to 
5E+06 copies/reaction and below for ERCC-13, -25, -84 and -171). Positive control 
samples (ERCC plasmid DNA at 5E+05 copies/reaction) presented Cq values 
between 15 and 20, dependent on ERCC target/assay.  
The presence of positive amplification in the RT-negative ERCC samples illustrated 
that the DNase treatment was not 100% efficient in the removal of contaminating 
plasmid DNA. Such DNA contamination may lead to an overestimation of the RNA 
A260 absorbance measurement [246] and may affect downstream applications. 
However, the detection of contaminating gDNA indicates the concentration at 
which the ERCC standards may be used to effectively determine RNA 
quantification without being obscured by residual gDNA contamination. 
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Nevertheless, the level of gDNA contamination remaining post-DNase treatment 
was low and for practical purposes, the efficiency of the DNase treatment was 
sufficient for downstream applications.  
Other studies have also demonstrated the inefficiency of DNase treatment 
[47,245,247,248], and suggest a trade-off between the completeness of DNA 
digestion and the preservation of RNA integrity. In this reaction, RNA integrity may 
be affected by RNase contamination and the method of DNase inactivation [247]. 
Conversely, Horstmann et al., when evaluating mRNA levels in bladder tissue using 
laser capture microdissection microscopy, RNA preamplification and qPCR, 
showed that inclusion of a DNase step both improved the integrity of RNA 
(observed through increased RIN values) and decreased the Cq values [249]. The 
observed increase in RIN values was probably because the removal of DNA 
increased the sample purity, which affects RIN estimation, rather than the DNase 
step affecting RNA integrity. The latter observation was most likely due to 
concentration of the sample through a purification procedure post-DNase 
treatment. Furthermore, due to the higher RIN values observed for the DNase 
treated samples, it is likely that the higher proportion of less degraded RNA lead to 
improved preamplification efficiency and thus a decrease in Cq [249].  
These data highlight the need for this validation step and subsequently indicated 
the level at which RNA samples should be assessed for future experiments. In this 
case, ERCC RNA samples quantified at or below 5E+06 copies/reaction should 
allow data interpretation without the contribution of plasmid DNA contamination. 
Of course, it is possible that the DNase used for such experiments may influence 
the outcome and that different enzymes may exhibit different reaction efficiencies. 
In addition, the template type and matrix qualities may influence reaction 
efficiency.  
The Alu PCR metric for estimating gDNA contamination in cell line derived RNA 
samples clearly demonstrated the efficacy of different treatments (Figure 3.4).   
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Figure 3.4 DNA Contamination Assessment. Alu PCR (no RT) evaluation of Hep-G2 derived 
RNA samples, with and without DNase treatment. This plot is representative of all three cell 
lines. Qty: quantity. Log(10) Qty is in pg/reaction.  
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Pre-treatment samples (no DNase) displayed positive amplification between 12 
and 14.5 Cq for all cell lines. Treatment with rDNase I in 50 µL reactions resulted in 
an increase in Cq (average 5.5 Cq shift), which is indicative of an approximate 2-log 
reduction of gDNA. When larger volume rDNase I reactions were performed, there 
was an average increase of 10.6 Cq for all cell lines. This demonstrates that the 
larger volume reaction works better, with a higher DNase reaction efficiency. In the 
50 µL DNase reactions, contaminating gDNA was reduced by 99.67, 91.18 and 
96.84% in Hep-G2, Hs 683 and SaOS-2 RNA samples respectively. This is 
equivalent to 487, 3115 and 725 fg/reaction remaining gDNA contamination. In 
the larger volume DNase reactions (accommodating the complete lysate extraction 
in one reaction, while maintaining manufacturers recommended total nucleic acid 
concentration of 200 ng/µL), contaminating gDNA was reduced by 99.99, 99.97 
and 98.85% in Hep-G2, Hs 683 and SaOS-2 RNA samples respectively. This is 
equivalent to 10, 11 and 264 fg/reaction remaining gDNA contamination; that's a 
further reduction of 0.32, 8.79 and 2.01% in Hep-G2, Hs 683 and SaOS-2 RNA 
samples respectively. Even so, there was still gDNA present and so one should be 
cautious. Furthermore, these data suggest that the efficiency of the DNase reaction 
may be in part dependent on the cell line itself that the RNA is derived from. NTC 
replicates generated the highest Cq values and therefore lowest concentration 
(average 26.7 Cq).  
These findings indicate that the Alu metric is suitable for measuring gDNA 
contamination and may therefore be used as a pre-screen for samples. The fact 
that Alu is a multicopy target gives added confidence to low-level contamination 
results as (gDNA contamination from) target genes are commonly single copy 
genes or indeed have a far lower repeated presence in the genome than the Alu 
element and as such would present at even lower concentrations than Alu 
contamination.  
Despite the substantial decrease in contaminating gDNA following rDNase I 
treatment of cell line derived RNA (between 91 and 99%); these data show the 
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inefficiency of this process. gDNA Alu target continued to be detected at levels 
significantly higher than in background (NTC) samples (NTCs contribute 
approximately 5-6 fg/reaction of gDNA, whereas the best DNase result leaves 
approximately 10 fg/reaction of contaminating gDNA and the least efficient leaving 
approximately 3.1 pg/reaction). Signal in the NTC samples is indicative of gDNA 
contamination of the reagents.  
Based on these data, it is advisable in mRNA studies to dilute RNA samples where 
possible before processing. Dilution of input RNA is one of the simplest and often 
effective solutions to alleviate the effects of reversible carryover reaction 
inhibitors [250]. The ratiometric DNA/RNA would stay the same but by diluting 
the background any contaminating gDNA should be undetectable. This may be 
variable by target and should be empirically assessed for each assay/sample type. 
However, concomitantly, rare mRNA targets may be diluted beyond the limit of 
detection and so target abundance should be considered before any dilution is 
undertaken.  
Moreover, qPCR assays should be designed to specifically target mRNA transcripts 
(i.e., crossing exon-exon boundaries) and analysed in silico to determine specificity 
to the chosen target to the exclusion of similar target sequences, including 
processed pseudo genes [47,48,61,86,122,162,251,252]. These precautions will 
increase RNA quantification accuracy and so has been done for all assays 
presented in this chapter. However, when considering secondary structures, 
designing assays to cover exon-exon boundaries may add too many restrictions. If 
rigorous and controlled DNase treatment has been performed and the amount of 
DNA removal assessed, then these precautions may not be necessary. When 
assessing the abundance of a rare target in a complex background, these tests need 
to be more rigorous. It may be advisable where possible to design an assay within 
a loop structure, which is more open, and therefore more cDNA is produced. Large 
variation is expected for mRNAs with tight structures in which access to primer 
target sites is restricted [56].  
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3.3.3 Assay Cross-Reactivity with Human Targets 
All eight ERCC assays were tested for potential cross-reactivity with human gDNA. 
None of the ERCC assays demonstrated positive amplification with 250 ng human 
gDNA (2.4.1 Two-step RT-qPCR). Positive amplification was however observed 
when ERCC plasmid DNA was assayed (positive controls), as above.  
All eight ERCC assays were demonstrated not to exhibit cross-reactivity with 
human gDNA samples. This was expected following an initial BLAST search 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi, accessed 2011) for ERCC RNA transcript 
and assay sequence homology to the human sequence database. These samples 
and assays are therefore suitable for production of mixed, complex units, as the 
synthetic ERCC targets/assays will not interact with the human RNA background 
material generated by mixing total RNA from human cell line sources.  
3.3.4 Carrier Optimisation 
Nucleic acids can stick to plastic and this can affect the concentration of a sample 
[253,254], particularly low abundance targets. As well as using LoBind® plastic 
ware the use of carrier solutions (for example, glycogen or nuclease-free tRNA) as 
diluents when preparing samples, which prevents low copy number molecules 
from sticking to the plastics, helps preserve integrity and produces greater 
precision of qPCR data where sensitivity is desired.  
All carrier options (including no carrier) exhibited comparable precision (on 
average, 0.22 Cq standard deviation across all carrier options at all dilutions, n=3) 
for 5E+08 to 5E+04 copies/reaction (ERCC-13 RNA, 1:10 serial dilution, one-step 
RT-qPCR reaction) (Table 3.4). Similarly, the mean delta (∆)Cq between 
subsequent dilutions for all experimental parameters was highly consistent at 3.48 
with an average standard deviation of 0.16. A perfectly accurate dilution series 
would   
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Table 3.4 Carrier optimisation. Average, standard deviation and dilution differentials (∆Cq) 
of Cq values generated by one-step RT-qPCR for a dilution series of ERCC RNA with and 
without various carrier types.  
  
Target Quantity (copies/µL)    
5.00E+08 5.00E+07 5.00E+06 5.00E+05 5.00E+04 
∆Cq 
Mean 
∆Cq 
StdDev 
Salmon 
sperm 
250 ng 
Cq Mean 14.91 18.18 21.52 24.99 28.56 - - 
Cq StdDev 0.10 0.13 0.21 0.24 0.10 - - 
∆Cq - 3.28 3.34 3.47 3.57 3.41 0.13 
Salmon 
sperm 
50 ng 
Cq Mean 15.00 18.41 21.62 24.93 28.72 - - 
Cq StdDev 0.07 0.04 0.29 0.07 0.13 - - 
∆Cq - 3.41 3.21 3.31 3.79 3.43 0.25 
Yeast 
RNA       
250 ng 
Cq Mean 15.13 18.44 22.08 25.37 28.95 - - 
Cq StdDev 0.15 0.10 0.04 0.06 0.06 - - 
∆Cq - 3.31 3.65 3.29 3.58 3.46 0.18 
Yeast 
RNA  
50 ng 
Cq Mean 14.92 18.34 21.82 25.39 28.68 - - 
Cq StdDev 0.01 0.11 0.18 0.08 0.30 - - 
∆Cq - 3.42 3.48 3.57 3.29 3.44 0.12 
Hep-G2 
RNA   
50 ng 
Cq Mean 14.39 18.10 21.44 25.19 28.72 - - 
Cq StdDev 0.06 0.18 0.08 0.08 0.28 - - 
∆Cq - 3.71 3.34 3.74 3.53 3.58 0.19 
No 
carrier 
Cq Mean 14.60 18.14 21.58 25.23 28.89 - - 
Cq StdDev 0.05 0.13 0.09 0.06 0.15 - - 
∆Cq - 3.54 3.44 3.64 3.67 3.57 0.10 
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generate ∆Cq values of 3.3 consistently. The difference in these results from the 
theoretically accurate ∆Cq values for dilutions maybe as a result of pipetting errors, 
calibration errors and/or inherent inefficiency of the actual system. There was no 
trend observed between sample concentration and ∆Cq. Two-factor ANOVA 
(carrier versus dilution) of Cq values revealed that carrier type had a significant 
impact on the Cq values generated (p < 0.001), with yeast total RNA at 250 
ng/reaction showing the least variance in Cq values (average Cq variance across all 
dilutions = 8.06E-03) and yeast RNA at 50 ng/reaction showing the most variance 
in Cq values (average Cq variance across all dilutions = 2.79E-02). While dilution 
obviously significantly influenced Cq values (p < 0.001), there was also an 
interaction between carrier type and dilution terms (p < 0.001). While no carrier 
appears to have the least variance, this is only for the standard deviation of ∆Cq 
measurements across all dilutions (final column of Table 3.4, this just tells us that 
the dilutions are consistent), not for the standard deviation of Cq values between 
replicates (values in bold in Table 3.4). It should be noted that reagents 
themselves often contain carrier, which may go some way to explaining the 
consistency of results when comparing ’no-carrier’ options.  
When considering carrier type (250 ng total yeast RNA or 250ng salmon sperm 
DNA) with regards to sample type (RNA or DNA), almost all data were comparable 
(Figure 3.5). However, it was observed that when measuring low copy (5E+01) 
RNA target, reactions including RNA (yeast) carrier performed better than those 
including DNA (salmon sperm) carrier. ERCC RNA sample measured at 50 
copies/reaction in DNA carrier generated amplification plots and quantification 
replicates with low precision (average ∆Cq 4.48, ∆Cq standard deviation 2.08, CV 
47.5%), while some replicates failed to demonstrate amplification at all (Figure 
3.5A). Quantification of the same target sample with RNA carrier remained highly 
consistent even down to 50 copies/reaction (Cq standard deviation was 0.35, at 50 
copies/reaction), (Figure 3.5B).  
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Figure 3.5 Carrier optimisation. ERCC-13 plasmid DNA and IVT RNA were serially diluted 
(1:10) to produce standard curves from 5E+06 to 5E+01 copies per one-step RT-qPCR 
reaction. Sample was analysed in the presence of 250 ng either total yeast RNA carrier or 
salmon sperm DNA carrier. (A) ERCC RNA, Salmon Sperm DNA Carrier, (B) ERCC RNA, Yeast 
Total RNA Carrier, (C) ERCC Plasmid DNA, Salmon Sperm DNA Carrier, and (D) ERCC Plasmid 
DNA, Yeast Total RNA Carrier.   
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To summarise the two carrier experiments, all carrier options tested, including no 
carrier, showed they were fit for purpose when analysing RNA samples between 
5E+08 and 5E+04 copies/reaction (i.e. linearity of measurement, as demonstrated 
by ∆Cq consistency across dilution series). However, in a separate experiment 
when analysing low sample copy numbers (50 copies, Figure 3.5) in reactions 
containing 250 ng of either RNA or DNA carrier, samples that contained DNA 
carrier experienced increased variability and lower discriminatory power between 
copy numbers, while those that contained RNA carrier continued to perform well. 
These data suggest that carrier chosen to match sample type (RNA versus DNA) is 
preferable for precise quantity estimates, particularly at low target levels. It has 
been shown previously for DNA measurements that while the inclusion of carrier 
had no effect on estimated quantity, it did improve measurement precision [103]. 
Furthermore, the addition of transfer RNA (tRNA) has been shown to significantly 
increase the sensitivity of quantitative PCR, in part by delaying the appearance of 
primer artifacts [255] and eliminating, or at least reducing, adsorption artifacts in 
the sample matrix [56]. tRNA loosely binds through hydrogen bonds to excess 
primer that is available during the early cycles of the amplification process and 
thus reduces the possibility of self-priming [255].  
The measurements obtained for these carrier experiments were highly precise 
with small variance, which is why there will always be some significant differences 
found. In reality, there are no real differences between carrier options. These 
differences translate to 6.4% difference in efficiency, which in our hands makes no 
difference. Reagents will most likely contain carrier material, which is one reason 
why experiments with no added carrier behave so well. By adding a carrier the 
amount of RNA included in the reaction is normalised, and it is known how much 
has been added. It is preferable to add RNA carrier because the template type is 
the same as the templates measured. Therefore, in order to match RNA template 
utilised throughout this study, yeast total RNA carrier was included in future 
experiments at 250 ng. 
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3.3.5 RNA Stability Analysis 
All replicate extracts (of the same cell type) over three months of analysis 
produced high total RNA yields at very good quality; RIN values ≥ 9.9 (Table 3.5). 
Experimental estimation of precision for quantity assessment by UV A260 was high, 
with CV = 3.67% (including replicate extracts over the three month time course). 
Analysis performed using two-factor ANOVA (month of extraction versus 
extraction replicates) indicated that there was no significant difference in 260/280 
ratios between extraction replicates, (p = 0.60), but that 260/230 ratios were 
significantly different between the same extraction replicates (p < 0.001). There 
was a significant difference observed for both ratios between months of extraction 
(p < 0.01). There was a significant interaction between month of extraction and 
extraction replicates for the 260/230 ratios (p < 0.001), whereas no interaction 
was observed between the same factors for the 260/280 ratios (p = 0.173). The 
260/230 ratios appear to decrease in a time-dependent manner. There was a 
significant difference in quantity between month of extraction and between 
replicate extracts (both p < 0.0001). There was also a significant interaction 
between the two terms (month of extraction and replicate extract) with p < 0.001. 
A 260/280 ratio of approximately 2.0 and a 260/230 ratio of approximately 1.8-
2.2 are generally accepted as pure for RNA [256-258]. However, a nucleic acid 
sample with 260/280 ratio of 1.8 can contain only 40% RNA, in the presence of 
other contaminants, such as protein [259-261]. This metric was originally 
developed for the detection of DNA contamination in protein samples, and it more 
sensitive when used for this purpose as it takes a relatively large amount of protein 
contamination to significantly affect the 260:280 ratio in a nucleic acid solution 
[260,262]. For these samples, 260/280 ratio range was 2.11-2.14 (average 2.13, 
standard deviation 0.01) and the 260/230 ratio range was 1.06-2.14 (average 1.64, 
standard deviation 0.33) (Table 3.5).  
Initial investigations of cell line-derived RNA variability and consistency associated 
with extraction and following storage, demonstrated that this source of RNA is   
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Table 3.5 RNA stability analysis. Average Hep-G2 RNA quantification and quality values for 
replicate cell lysates of the same cell type extracted over a period of three months.  
Samples 
Average 
ng/μL 
CV (%) 
Average 
260/280 
Average 
260/230 
Average 
RIN 
Month 1 
extracts 
A 256 0.32 2.14 1.87 10.0 
B 245 0.58 2.14 2.00 10.0 
C 256 0.76 2.13 1.93 9.9 
D 263 0.31 2.13 2.14 10.0 
Month 2 
extracts 
A 257 0.44 2.12 1.50 10.0 
B 260 3.72 2.12 1.85 10.0 
C 266 0.10 2.13 1.45 10.0 
D 257 0.97 2.11 1.70 10.0 
Month 3 
extracts 
A 240 0.47 2.13 1.33 10.0 
B 239 1.27 2.13 1.29 10.0 
C 250 1.05 2.13 1.53 10.0 
D 243 1.28 2.14 1.06 10.0 
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stable (according to A260 measurement) when these preparation, extraction and 
storage methods are adhered to. However, the ratio measurements are variable, 
which may mislead the initial quantity measurement. Other methods are needed to 
evaluate these findings (Chapter 5). While the 260/230 ratios were variable, this 
could be accounted for by the presence of co-extracted contaminants, which 
absorb at 230 nm, rather than sample degradation. Carbohydrates and phenol 
(TRIzol reagent is a phenolic solution) all have absorbance at or near 230 nm; 
TRIzol also absorbs UV at ~270 nm [263]. Presence of such contaminants may 
influence the concentration estimate as the quality and quantity estimates for this 
method are intrinsically linked.  
The 260/280 ratios were variable between months of extraction. However, this 
does not necessarily represent a decrease in sample integrity over time as the 
month 3 samples had higher 260/280 ratios with less variability than the month 2 
samples. Despite there being significant differences in 260/280 ratios across the 
month of extraction, all such ratios are between 2.1 and 2.2, which is indicative of 
good quality RNA. The significant differences observed may be as a result of the 
high precision in these data and in reality these differences do not impact the final 
result.  
Both the 260/280 and 260/230 ratios are used as a measure of nucleic acid purity 
[263]. In addition to affecting quantity estimates, co-purified contaminants may 
also exhibit inhibitory effects on subsequent enzymatic reactions, namely RT and 
qPCR [58]. Adjusting the pH and ionic strength of test solutions has been shown to 
significantly impact the variability of 260/280 ratios and change the ability to 
detect protein contamination [127]. For these reasons, 260/280 and 260/230 
absorbance ratios are not particularly reliable metrics. Despite the variability 
observed in this metric, 260/280 ratios and RIN values were highly consistent and 
close to the expected/desired values (~2.0 and > 8, respectively) for good quality 
RNA. RIN values below 7.0 have been shown to give high variation in Cq values 
[130,264].  
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qPCR data was also consistent with high quality RNA, showing good linearity 
(Figure 3.6). Using two-way ANOVA, there was no significant difference observed 
in RNA concentration between month of extraction (p = 0.341) or replicate 
extractions (p = 0.552). No interaction was detected between the two terms, 
month of extraction and replicate extracts (p = 0.724). These data suggest that the 
RNA remains stable when stored as unprocessed cell lysate over the time course. 
Furthermore, extractions were highly consistent between replicates (Figure 
3.6B); precision estimate (CV) between all extraction replicates (A-D) of all 
extraction time points, CV = 33.99%. RT replicates showed high precision, with the 
vast majority of replicates displaying ΔCq variance standard deviation of < 0.5. It is 
recommended that qPCR samples should not exceed a variation in between 
reaction replicates of > 0.5 Cq [252]. This equates to a fold change of 1.4, assuming 
100% efficiency (EfficiencyΔCq). 
The same evaluation was performed using month 1 RNA extracts stored post 
extraction and additionally analysed at T = 1 and T = 2. There was no significant 
effect of month of analysis (p = 0.725) or replicate extraction (p = 0.060) on stored 
RNA concentration. However both time and extraction replicates (p < 0.001 for 
both) significantly affected RNA concentrations derived from stored lysates. 
However, no interaction was measured between the two terms, month of analysis 
and extraction replicates (p = 0.780). This suggests that, while cell lysate remains 
stable, stored RNA maybe more stable than stored lysate and so extracted RNA 
should be stored in preference to unextracted lysates, when possible. Having said 
that, inspection of the data in Figure 3.6 intimates that the lysate data (Figure 
3.6A) have high precision and as such, is more likely to reveal significant 
differences between replicates than the RNA data (Figure 3.6B). In practical 
terms, there is no difference in the stability of stored lysates versus stored RNA 
and so storage at either process stage is equally valid. Overall these data are highly 
consistent (high precision) and confirm the stability of the extracted RNA when 
stored at -80ºC over this time course. Precision estimates (CV) between all   
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Figure 3.6 RNA Stability Analysis. Stability of Hep-G2 lysate preparations and extracted RNA 
over a three-month time course. (A) Replicate lysate aliquots from a single cell culture flask 
were stored for 1, 2 or 3 months before RNA was extracted in replicates (A-D). (B) RNA 
extracted in month 1 was stored and additionally analysed in month 2 and month 3. Average 
quantity in pg per qPCR (RNA equivalent), based on human Universal Reference RNA standard 
curve. n = 2 RT replicates. Error bars = standard deviation.   
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extraction replicates (A-D) for monthly analysis (n = 3) of month 1 extracts: CV = 
56.87%.  
These data demonstrated that the assayed mRNA target was not affected by 
degradation in stored RNA preparations over this time course. The reproducibility 
observed in terms of total RNA yield was precise (less than 5%, all but one CV < 
1.5%, month 2 extract B = 3.72, Table 3.5). Sellin Jeffries et al. [265] showed RNA 
kit extraction yield precision estimates (CV) > 6%. According to the user guide 
(ND-1000 Spectrophotometer v3.3), the reproducibility error (CV) associated with 
the Nanodrop ND-1000 instrument is 2%. The RNA extract precision estimates 
were within this range suggesting that in this experiment, extraction did not 
contribute significant variability to the measurement result. These preliminary 
experiments paved the way for further production of total RNA from the three 
chosen cell lines. All samples were extracted and stored as RNA for future 
experiments.  
It is worth considering how relevant cell culture extraction variability (a synthetic 
situation) is compared to clinical samples. The variability (or lack thereof) 
observed for these data may not be representative of a clinical sample scenario. 
Furthermore, different tissues are likely to contain different levels of RNases, and 
targets with differing susceptibilities to those RNases. Comparison of cell culture 
and clinical sample variability would be required to evaluate any differences 
effectively.  
3.3.6 RT Variability 
This experiment allowed evaluation of inhibition and variability attributable to RT 
and qPCR steps. In theory, RNA dilutions should minimise any reversible inhibition 
carried-over from extraction while cDNA dilutions of neat RT product should 
reduce any reversible inhibition ascribable to extraction carryover and RT reaction 
components. Furthermore, based on previous publications [47,48,55], qPCR 
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quantities derived from cDNA dilutions should exhibit greater precision as RT 
variability is excluded from this measurement and RT has been shown to 
contribute greater variability. These experiments aimed to test this hypothesis.  
The RNA and cDNA dilution series produced very similar standard curves (Figure 
3.7). An F-test confirmed that there was no significant difference between 
variances for the RNA versus the cDNA data sets (p = 0.9707). A two way ANOVA 
for dilution type (RNA versus cDNA) and dilution level (1-5) was performed to 
further analyse these data. There was a significant difference observed in Cq values 
between dilution types, p = 0.031. As values were not normalised for dilution, 
there was a significant difference detected between dilution levels (dilution 1-5), p 
< 0.0001. However, there was no significant interaction between the two factors 
(dilution type versus dilution level), p = 0.127.  
The RNA and cDNA dilutions generated standard curves with different slopes and 
as such would generate different measurement values for sample unknowns. In 
order to establish any differences between the two standard curves, a theoretical 
test sample with a nominal Cq value of 32 was used to calculate corresponding 
quantity estimates from the RNA and cDNA curves independently. Using arbitrary 
quantity values assigned to the standard dilutions, the test sample quantities 
generated were 6.50E+04, 3.87E+03 SEM (RNA curve) and 7.30E+04, 1.74E+03 
SEM (cDNA curve), with a difference between the two values of 7.97E+03, 
4.18E+03 SEM (arbitrary units). The value generated from the RNA standard curve 
was 90% of the value generated from the cDNA standard curve. While the 
difference in the curve gradients appears small, this can equate to a large 
difference in quantity estimates.  
When measuring small fold changes, the relative measurement difference derived 
from RNA and cDNA standard curves is negligible (for example, for a ΔCq of 2, both 
the RNA and cDNA curves yield a fold change measurement of 4). However, when 
larger differences need to be measured, the difference between the two standard   
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Figure 3.7 RNA versus cDNA Standard Curves. Dilution series generated pre-RT (RNA) and 
post-RT (cDNA) were compared by qPCR. Quantity values are in arbitrary units. n = 6 per 
dilution point/dilution type. Error bars: standard deviation.  
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curves becomes apparent, with ΔCq values > 7 generating observable differences in 
fold change measurements (for example, for a ΔCq of 12, the RNA curve yields a 
fold change measurement of 3873, while the cDNA curve yields a fold change 
measurement of 3718. Therefore the relative quantity estimation of samples 
becomes less comparable between standard curve types as fold change increases.  
As the two slopes are almost identical, it would suggest that discrepancies between 
the two curves are not dependent on the RT and PCR enzymes and that the 
variation observed between RNA and DNA standard curves is linked to aliquoting 
nucleic acid, and that no enzymatic variation is contributing. Using this particular 
experimental set-up, the RTase is both linear and precise and has no effect on the 
experimental outcome. This shows us the low variability that is possible when 
experiments are planned with variability contributions in mind and what analysts 
should be aiming for.  
It is clear that when measuring an RNA target, an RNA standard curve should be 
used to generate the most accurate measurement value. This is because it will 
include the variability associated with the RT reaction. An RNA standard curve 
when measuring an RNA target, and a DNA standard curve when measuring a DNA 
target, would offer the best approximation of the true value, with associated error. 
While RNA measurements are generally more variable than DNA measurements 
[56], this offers a true reflection of the variability inherent in the measurement. 
When performed correctly, both RNA and DNA standard curves may offer linear 
measurements over a defined range [47,48,55,56]. While a comprehensive 
assessment of RT variability contributions was not undertaken in this experiment, 
this is addressed fully in Chapter 4 Comparison of Different Reverse 
Transcriptases by Digital PCR.  
It is well established that the RT reaction may contribute greater variability to 
quantification than qPCR [47,48,55]. Without including variability measurements 
contributed by all components (including RTases), a true assessment of 
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measurement uncertainty cannot be performed. Purification procedures post-RT 
may be time consuming, expensive and more importantly, represent another stage 
whereby precious RNA yield may be reduced. For that reason, subsequent 
experimental protocols will include RNA-based dilutions to reflect the variability 
inherent to this step, which may be observed in the error of associated standard 
curves.  
3.3.7 Endogenous Target Selection 
Reference genes with least variable expression across the three different cell types 
(Hep-G2, SaOS-2 and Hs 683) were selected from 32 candidates for use as a 
reference target (Figure 3.8), as determined by the RefFinder programme [225]. 
(Table 2.1, 2.3.1 Endogenous Target Selection and 2.3.2 Assay Design). Further 
targets were subsequently assessed on the basis of GOI criteria: the expression of 
each gene was different between the cell lines. This enabled the generation of 
different TCM units with different GOI expression profiles.  
Initial endogenous target selection experiments were performed using assay-on-
demand, commercially bought assays (ABI). Accordingly, the endogenous targets 
selected were re-designed (based on the amplicon regions detailed by ABI). These 
assays were validated using optimisation of primer/probe concentrations and 
cross-reactivity tests with ERCC RNA standards (Chapter 2 Materials & 
Methods). The endogenous reference genes selected and validated were: CASC3, 
HPRT1 and UBC. GOI were: MMP1, NES and SLC1A3 (Table 3.6). GOI targets have 
previously been shown to be of interest in the selected cell lines, MMP1 in Hep-G2 
cells [266], SLC1A3 (GLAST1) in SaOS-2 cells [267] and NES in Hs 683 cells [268]. 
To complete ERCC assay validation, cross-reactivity with cell line-derived total 
RNA was assessed. All eight ERCC assays were tested against each of the three cell 
line-derived total RNA samples, with ERCC plasmid DNA positive controls and 
GAPDH assay-on-demand (ABI) analysis of cell line-derived RNA positive controls.  
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Figure 3.8 Comprehensive gene stability, generated from RefFinder output. Average expression stability values for assessed candidate reference 
genes measured in the three cell line-derived total RNA samples (Hep-G2, Hs 683 and SaOS-2. n = 3). Based on the rankings from each program 
(GeNorm [7], Normfinder [137], BestKeeper [226] and the comparative ΔCt (Cq) method [227]), individual genes are assigned an appropriate weight 
and the geometric mean of their weights is calculated for the overall final ranking. Starting from the most stable gene at the left, genes are ranked 
according to decreasing expression stability, ending with the least stable genes on the right.   
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Table 3.6 Endogenous reference genes and GOI selected and validated 
Target Name Function 
R
ef
er
en
ce
 CASC3 
Cancer susceptibility 
candidate 3 
Protein is involved in nonsense-mediated mRNA 
decay. Widely expressed. Overexpressed in breast 
cancers and metastasis, as well as in gastric 
cancers [269]. 
HPRT1 
Hypoxanthine 
phosphoribosyl-
transferase 1 
Enzyme plays a central role in the generation of 
purine nucleotides through the purine salvage 
pathway [270].  
UBC Ubiquitin C Encoded protein is a polyubiquitin precursor.  
G
O
I 
MMP1 
Matrix 
metallopeptidase 1 
Proteins of the MMP family are involved in the 
breakdown of extracellular matrix in normal 
physiological processes, such as embryonic 
development, reproduction, and tissue 
remodelling, as well as in disease processes, such 
as arthritis and metastasis.  
NES Nestin 
Gene encodes a member of the intermediate 
filament protein family. Expressed primarily in 
nerve cells.  
SLC1A3 
Solute carrier family 1 
(glial high affinity 
glutamate transporter) 
member 3 * 
Protein is involved in glutamate 
transport/signalling.  
* Also known as GLAST1 in rats 
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No PCR products were produced from ERCC assays on cell line derived cDNAs 
whereas all positive controls produced expected amplicons.  
3.3.8 Transcriptomic Calibration Material Homogeneity and Stability  
Following large batch production and aliquoting of described TCM (2.3 
Preparation of Transcriptomic Calibration Material (TCM)); the material was 
assessed for homogeneity and stability to confirm suitability as a pilot reference 
material for this study.  
RT-qPCR data were analysed by comparing both between and within replicate 
units (Figure 3.9). Several test runs show comparatively extreme outliers (Grubb’s 
test): Calibrant/ERCC-99 unit 1, Calibrant/HPRT1 unit 9, Unknown 1/ERCC-99 
unit 8 and Unknown 1/HPRT1 unit 5 (Figure 3.9A, B, D & E). Repeating analysis 
with and without outliers checked the effect of outliers on subsequent analysis; 
between-unit variance estimates with outliers removed were somewhat more 
conservative (larger) and values are accordingly reported on an outlier excluded 
basis. Between-unit variances were calculated by randomising units across the 
PCR thermocycling block (re-randomised for each replicate plate). Between-unit 
variation must be bigger than positional variance in order to not be lost in the 
noise. This approach removes systematic variation of the thermocycling block. A 
two-factor ANOVA (unit number versus randomised position on qPCR plate) was 
used to analyse these data. For ERCC-99, the between-unit CV was calculated to be 
6.1%, 6.8% and 4.4% for Calibrant, Unknown 1 and Unknown 2 units, respectively, 
which were found to be statistically significant (p < 0.05) for Calibrant and 
Unknown 1, in other words, these samples showed some signs of inhomogeneity. 
For HPRT1, the between-unit CV was calculated to be < 0.01%, < 0.01% and 2.8% 
for Calibrant, Unknown 1 and Unknown 2 units, respectively.  
The TCM homogeneity data are broadly consistent with the material origins 
(ERCC-99 showed greater variability between units than HPRT1); the ERCC   
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Figure 3.9 Results of Homogeneity study. RT-qPCR measurements (n = 8) of ERCC-99 (A-C) 
and HPRT1 (D-F) were performed on ten units (x-axis 1-10) of each study material (Calibrant, 
Unknown 1 and Unknown 2). Plots indicate median (bold line), interquartile range (box) and 
range (up to 1.5 interquartile range, whiskers) of Cq values for each unit 1-10. Values outside 
of the 1.5 interquartile range are plotted as individual points (circle).  
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material is synthetic and prepared by plasmid digestion, IVT, DNase-treatment, 
dilution and mixing; the endogenous material required less manipulation and 
there were fewer opportunities for introducing substantial heterogeneity [271]. 
The synthetic targets would therefore generate a larger uncertainty contribution 
to the uncertainty budget than endogenous targets and subsequently a more 
conservative estimate of target abundance. A synthetic reference material may be 
less variable than endogenous targets given that it is not influenced by dynamic 
transcriptomics. While this may be true for endogenous targets in other studies, 
this is not the case for the pre-prepared TCM as it is pre-prepared/aliquoted. In 
this case, the addition of synthetic targets generates a more complex background. 
Synthetic targets have the added benefit of being able to be value assigned before 
spiking into test material. Homogeneity studies are not generally performed within 
the wider research community. In the absence of a precedent, it was decided not to 
perform an assessment of all transcripts in all units (Calibrant, Unknown 1 and 
Unknown 2). ERCC-99 and HPRT1 targets were selected to be representative of the 
other ERCC and endogenous targets measured, for which homogeneity has not 
been individually assessed. In the absence of a homogeneity study that measures 
all targets therefore, the uncertainty associated with homogeneity was based on 
the largest between-unit relative standard deviation rounded to one significant 
figure: ERCC-99 = 0.07, for all ERCC targets in all unit types and HPRT1 = 0.03, for 
all endogenous targets in all unit types. As assigned values were not calculated for 
the endogenous gene targets, the HPRT1 results were interpreted as confirmation 
of acceptable between-unit homogeneity with respect to the endogenous gene 
targets.  
The short-term stability study showed no systematic effects up to and including 
4ºC (Figure 3.10, two-factor ANOVA, storage time versus temperature). Samples 
stored at 40ºC showed a significant (p = 0.0166) increase in Cq of 0.019 Cq 
units/day over all samples and both targets. The use of dry ice had no systematic 
effect on sample stability, despite the large variability observed in HPRT1, 
Unknown 1 at day 14 (Figure 3.10E). This variability may have been caused by   
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Figure 3.10 Results of Short-Term Stability study. For each Calibrant, Unknown 1 and 
Unknown 2 solution, three replicate units were isochronously tested after storage at -80 ºC, on 
dry ice, +4 ºC, and +40ºC at 0, 7 and 14 days. One-step RT-qPCR measurements of ERCC-99 (A-
C) and HPRT1 (D-F) were performed per unit. Calibrant (A & D), Unknown 1 (B & E) and 
Unknown 2 (C & F). Error bars standard deviation.    
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acidification of the material through penetration of CO2 through Eppendorf walls 
[272]. For all other samples there was no evidence of a significant impact on Cq 
from storage time or temperature (all p > 0.05). For potential shipping purposes 
therefore, there was no evidence of instability in the short-term at 4ºC or below.  
A longer-term stability study was also performed over six months (Figure 3.11, 
two way ANOVA for storage time versus temperature, applied separately to each 
transcript/unit combination). The results were checked for a significant 
time/temperature interaction (indicative of temperature-mediated instability) 
using two-factor ANOVA applied separately to each transcript and also to each 
transcript/sample combination. ANOVA demonstrated significant effect of time on 
copy number in all cases (p < 0.0001), however the differences are less than two 
fold and so are within the range of calibration; temperature was not significant (p 
> 0.05). There was no significant time/temperature interaction at the 95% 
confidence level (p > 0.05) for any of the groups studied.  
It is likely that the variability observed was due to an artefact of the analysis; 
possibly assay variation with time, as the experiments were performed six months 
apart. There was no evidence of temperature-mediated instability. Studies, 
including homogeneity and stability assessments, confirmed the suitability of the 
prepared TCM for the basis of future evaluation. Any variability associated with 
these materials has been included in the corresponding uncertainty budgets 
(Table 3.7. Discussed below in 3.3.9 Measurement Uncertainty). Both 
exogenous and endogenous transcripts will be employed for the identification and 
characterisation of variability contributors to the experimental measurement of 
mRNA levels. This is not done routinely, however is a fundamental basis of RM 
production (the TCM is a pilot RM). To our knowledge, this has never been done on 
a wholesale material for RNA.  
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Figure 3.11 Results of Long-Term Stability study. For each Calibrant, Unknown 1 and 
Unknown 2, three replicate units were incubated for one week on dry ice (to simulate a 
shipping period) before being transferred to either -80ºC or -20ºC (designated T = 0). One-step 
RT-qPCR measurements of (A) ERCC-99 (full data set) (B) ERCC-99 (adjusted scale for 
visualisation of lower concentration samples) and (C) HPRT1 were performed on each unit at 
T = 0 and 6 months. Error bars standard deviation.   
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Table 3.7 Assigned values and measurement uncertainty of ERCC standards. Uncertainty 
components common to both Unknown 1 and Unknown 2 are not included in corresponding 
uncertainty budgets as these contributions cancel out in measurement of combined standard 
uncertainty of assigned ratios. 
Calibrant 
ERCC 
Assigned 
value, 
(copies/µL) 
Combined 
Standard 
Uncertainty, uc 
Expanded 
Uncertainty, U 
(k=2) (±) 
Relative 
Expanded 
Uncertainty 
(%) 
ERCC-13 9.48E+05 101704 2.03E+05 21.46 
ERCC-25 1.00E+06 87498 1.75E+05 17.50 
ERCC-42 1.00E+06 87629 1.75E+05 17.52 
ERCC-99 9.86E+05 87160 1.74E+05 17.67 
ERCC-113 9.38E+05 87760 1.76E+05 18.70 
ERCC-171 9.39E+05 89207 1.78E+05 19.00 
 
Unknown 1 
ERCC 
Assigned 
value, 
(copies/µL) 
Combined 
Standard 
Uncertainty, uc 
Expanded 
Uncertainty, U 
(k=2) (±) 
Relative 
Expanded 
Uncertainty 
(%) 
ERCC-13 5.69E+04 4013 8027 14.11 
ERCC-25 5.00E+03 354 709 14.17 
ERCC-42 1.00E+03 71 143 14.29 
ERCC-99 6.90E+04 4870 9740 14.11 
ERCC-113 1.97E+04 1395 2790 14.16 
ERCC-171 9.39E+04 6633 13266 14.13 
 
Unknown 2 
ERCC 
Assigned 
value, 
(copies/µL) 
Combined 
Standard 
Uncertainty, uc 
Expanded 
Uncertainty, U 
(k=2) (±) 
Relative 
Expanded 
Uncertainty 
(%) 
ERCC-13 8.53E+04 6029 1.21E+04 14.14 
ERCC-25 5.00E+03 354 7.09E+02 14.17 
ERCC-42 7.00E+03 495 9.89E+02 14.13 
ERCC-99 6.90E+04 4870 9.74E+03 14.11 
ERCC-113 6.57E+03 464 9.28E+02 14.13 
ERCC-171 1.88E+04 1330 2.66E+03 14.17 
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ERCC Assigned Ratios (Unknown 1/Unknown 2) 
ERCC 
U1 Assigned 
value, 
(copies/µL) 
U2 Assigned 
value, 
(copies/µL) 
Assigned 
Ratio 
(U1/U2) 
Combined 
Standard 
Uncertainty, 
uc 
Expanded 
Uncertainty, 
U (k=2) (±) 
Relative 
Expanded 
Uncertainty 
ERCC-13 56867 85300 0.667 0.0999 0.200 29.965 
ERCC-25 5000 5000 1.000 0.1002 0.200 20.045 
ERCC-42 1000 7001 0.143 0.1005 0.201 140.684 
ERCC-99 69049 69049 1.000 0.0997 0.199 19.949 
ERCC-113 19706 6569 3.000 0.1000 0.200 6.668 
ERCC-171 93919 18784 5.000 0.1000 0.200 4.001 
The reported expanded uncertainty of measurement is stated as the standard uncertainty of 
measurement multiplied by the coverage factor k = 2, which for a normal distribution 
corresponds to a coverage probability of approximately 95%. The standard uncertainty of 
measurement has been determined in accordance with EAL Publication EAL-R2 [273].  
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3.3.9 Measurement Uncertainty 
Assigned target concentration values and uncertainty budgets were calculated for 
all six ERCC targets in all unit types (Calibrant, Unknown 1 and Unknown 2), 
according to EU recommendations [273]. Summaries of the assigned values and 
uncertainties (2.3.3 Measurement Uncertainty Budget) for each synthetic target 
and unit type are collated in Table 3.7. Comprehensive tables and figures 
describing measurement uncertainty contributing factors may be found in 9.3 
Appendix 3 – Measurement Uncertainty Budgets. Variability contributions to 
the assigned values were considered from several sources, which were 
subsequently included in the uncertainty budget. The factors included in the 
uncertainty calculation were; Nanodrop calibration, estimated purity 
(Bioanalyzer), homogeneity, stability and volumetric (error associated with 
pipetting steps). It should be noted that no extraction component is included in 
this calculation due to the nature of ERCC preparation. Assigned values for ERCC 
targets may be used to define variance, precision and accuracy of ERCC target 
measurements when spiked into test samples. Endogenous quantities could not be 
assigned by RT-qPCR due to transcript source. This could be achieved by RT-dPCR, 
but this was not undertaken for this study.  
3.4 Conclusions 
These preliminary studies were broadly undertaken for the purpose of developing 
the TCM for application to more in-depth investigations of measurement 
variability. In the process of this development, there have been several additional 
findings. The DNase reaction may not be 100% efficient but the effects of 
remaining gDNA contamination on RT and PCR may be alleviated by sample 
dilution. Furthermore, DNase efficiency may in part be influenced by sample 
source, for example, the cell line from which the RNA is derived from. In addition, 
appropriate assay design to target mRNA transcripts will limit gDNA cross-
reactivity.  
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The inclusion of carrier nucleic acid may be most valuable for trace detection of 
minority targets and is most beneficial in terms of increasing precision when 
carrier is chosen that matches sample type (i.e. RNA sample with RNA carrier as 
opposed to RNA sample with DNA carrier). Furthermore, the RNA used in this 
study may be stably stored at -80ºC as both unprocessed lysate and extracted RNA 
for at least two months. RT variability experiments revealed that RNA and cDNA 
generated standard curves may generate differences in quantity estimates due to 
differences in curve gradients. From these data it is recommended that sample 
type (RNA, cDNA etc.) should remain consistent between standard and test 
samples to ensure associated variabilities are captured appropriately.  
The uncertainty budgets assigned to the various synthetic transcripts in the TCM 
take into account the array of factors contributing to the variability in these 
measurements and define the level of precision achievable for these measurement 
spikes.  
Evaluation studies have successfully demonstrated that the TCM, including ERCC 
RNA spikes, is fit for purpose, i.e. it is appropriate to use for characterising 
variability contributions in mRNA analysis. All assays for selected endogenous and 
ERCC targets have been well optimised and will be employed to identify and define 
measurement variabilities associated with RNA measurement. The synthetic ERCC 
targets allow for an assessment of technical variability contributions at various 
stages of the experimental process and an opportunity to evaluate different fold 
change measurement challenges while the endogenous targets enable sample 
normalisation strategies to be applied to generated data sets and assessment of 
biological variability.  
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4 Comparison of Different Reverse Transcriptases by 
Digital PCR 
This chapter is adapted from the peer-reviewed publication: Evaluation of digital 
PCR for absolute RNA quantification. Sanders R, Mason DJ, Foy CA, Huggett JF. 
PLoS One. 2013 Sep 20;8(9):e75296. doi: 10.1371/ journal.pone.0075296. 
eCollection 2013. 
4.1 Introduction 
Measuring mRNA by RT-qPCR is an established approach for investigating gene 
expression and viral diagnostics. It is well known that the RT step, required to 
transcribe mRNA to complementary DNA (cDNA), is imprecise and that different 
reverse transcriptase enzymes (RTase) can work with considerably different 
efficiencies [82]. Many of the issues associated with differing RTase efficiencies 
may be sidestepped by taking advantage of the (assumed) linear nature of RT and 
performing relative quantification, with the results expressed as fold changes, or 
by comparing to a standard curve that is equally affected by the limitations of the 
RT.  
Digital (d)PCR is continuing to gain recognition in the field as a precise and 
reproducible method offering the potential for accurate, robust and highly 
sensitive measurement without the need for a standard curve [274]. Much work 
has already been done to meticulously evaluate this technique for DNA molecular 
measurement [103,104,223,275-277]. However, a comprehensive evaluation is yet 
to be established for applying this method to the measurement of RNA. RT-dPCR 
may offer the potential to maximise the accuracy, sensitivity and reproducibility of 
RNA measurements, for capabilities such as diagnostic mRNA profiling, biomarker 
analysis and monitoring of viral load.  
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While this may be true, many studies have demonstrated that the variability 
inherent in the RT component of the process far outweighs that observed from the 
PCR step when performing qPCR [47,48,55]. The RTase itself has been shown to 
confer reversible inhibitory effects to downstream PCR, demonstrating a need to 
limit these effects by, for example, heat inactivating the RTase or diluting the cDNA 
prior to PCR [71,72]. Improved quantification sensitivity reported for one-step 
versus two-step RT-qPCR for low copy targets or low concentration samples such 
as single cells may in part be attributed to gene-specific priming in one-step 
protocols (as opposed to random hexamers or oligo (dT) commonly used in two-
step protocols) [71,72,80,81].  
In addition to the sensitivity differences between one-step and two-step RT-qPCR, 
when performing RT-dPCR, one must consider sample partitioning. For two-step 
protocols, the cDNA is produced before sample partitioning for dPCR. This 
therefore must rely on the assumption that, even if not 100% efficient, the RT step 
is linear and so relatively speaking, the number of cDNA molecules accurately 
represents the actual proportions of target RNA molecules. If this is not the case 
and the RT is not linear or some target amplification occurs during the RT, 
significant bias may be introduced. For one-step protocols, the RNA population is 
partitioned into roughly single copies prior to RT and as such, even if one RNA 
target molecule is amplified during the RT step, these remain in one partition and 
so only one positive partition results. This would act to alleviate any bias 
unintentionally introduced by any amplification of target by the RT enzyme.  
This chapter details the investigation of how the RT might affect cDNA production 
and ultimately influence the dPCR measurement. It is hypothesised that RT 
variability affects the amount of cDNA and thus subsequent dPCR measurement 
capabilities. RNA analysis by RT-dPCR was evaluated and repeatability, linearity 
and sensitivity assessed. The aim was to determine the variability contributions of 
the RT step in RT-dPCR measurement using different RT enzymes. The 
Transcriptomic Calibration Material (TCM) documented in Chapter 3 was utilised 
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for both synthetic and endogenous target measurements, where RT-dPCR analysis 
was compared to UV A260, and the performance of different assays and 
commercially available one-step RT-qPCR kits was evaluated.  
4.2 Materials & Methods 
The techniques exploited in this chapter include one-step RT-dPCR (2.5.1 One-
Step RT-qPCR Kit Comparison by dPCR and 2.5.3 Linearity and Sensitivity of 
RT-dPCR) and UV A260 analysis (2.5.2 Comparison between dPCR and UV 
Measurement).  
Synthetic targets ERCC-25 and ERCC-99 and endogenous targets MMP1 and UBC 
were assessed in both uniplex (ERCCs only) and duplex format, utilising three 
different commercial one-step RT-qPCR kits. ERCC targets were used to establish 
quantification sensitivity. Subsequently, quantification of six ERCC targets by one-
step RT-dPCR was compared to UV A260 measurements.  
4.2.1 Statistical Methods  
All statistical analyses were performed using MS Excel 2007 and the R statistical 
programming environment (http://www.r-project.org/, ongoing access). 
Statistical analysis was performed in collaboration with Dr. Simon Cowen, 
Statistician, LGC, Teddington. Data were tested for normality and equal variance 
before analysis using ANOVA. Where necessary, data were transformed (square 
root or weighted regression, as appropriate) in order to obtain a data set in which 
the within group variances were sufficiently similar for an ANOVA to be 
performed. These transformed data were analysed using ANOVA.  
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4.3 Results & Discussion 
In this study we used a TCM containing synthetic RNA transcripts in a complex 
background made of mixtures of human cell line total RNA. This was used to both 
evaluate dPCR measurement and demonstrate the applicability of the TCM for 
supporting accurate RNA enumeration by RT-dPCR. 
4.3.1 One-Step RT-qPCR Kit & Format Comparison by dPCR using 
Synthetic RNA Targets 
Three commercially available kits were compared for quantitative performance by 
RT-dPCR. The three kits were initially assessed using both uniplex and duplex 
formats for quantification of two synthetic RNA targets: ERCC-25 and ERCC-99 
(Figure 4.1). The type of kit significantly affected RNA quantification (p < 0.0001) 
with the Ambion kit consistently yielding the highest signal. A significant 
difference in quantification was also observed (single-factor ANOVA) between 
uniplex and duplex formats for the Qiagen (ERCC-25 p = 0.045) and Invitrogen 
(ERCC-25 p = 0.025, ERCC-99 p = 0.019) kits but not the one supplied by Ambion 
(ERCC-25 p = 0.347, ERCC-99 p = 0.736), (Qiagen ERCC-99 p = 1.000); however the 
difference between uni/multi-plex formats was considerably smaller than the inter 
kit differences (Figure 4.1).  
Consistent ratios for ERCC-25:ERCC-99 between uniplex and duplex 
measurements were not maintained between kits suggesting an assay-dependent 
as well as a kit associated difference (Table 4.1). The ERCC-99 assay consistently 
resulted in lower estimated copies than that for ERCC-25 (with all kits), despite 
being added at the same concentration, as estimated by UV.  
The findings from the one-step kit comparison by dPCR indicate that there can be 
large numbers of RNA molecules present within the dPCR partitions that are not 
being detected with dPCR. This is because either they are not converted to cDNA or   
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Figure 4.1 One-step kit comparison. Three different one-step RT-qPCR kits were compared 
in both uniplex and duplex formats, by dPCR. Two synthetic targets, ERCC-25 and ERCC-99 
were analysed. Error bars: 95% confidence intervals. n=3 replicate panels. Equivalent UV 
estimates: ERCC-25 1185.41 copies/panel, 95% CI 17.34. ERCC-99 1185.41 copies/panel, 95% 
CI 26.19. 
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Table 4.1 Three one-step kit comparison with uniplex and duplex formats. Equivalent UV 
estimates: ERCC-25 1185.41 copies/panel, 95% CI 17.34. ERCC-99 1185.41 copies/panel, 95% 
CI 26.19. 
Method Format ERCC- 
Positive 
Partitions 
Copies per 
panel* 
Ratio† 
Standard 
Uncertainty 
Ambion 
Duplex 
25 627 1316 
1.37 0.051 
99 546 959 
Uniplex 
25 639 1383 
1.47 0.076 
99 541 944 
Invitrogen 
Duplex 
25 295 373 
3.31 0.223 
99 104 113 
Uniplex 
25 335 442 
5.18 0.262 
99 81 85 
Qiagen 
Duplex 
25 68 71 
4.22 0.588 
99 17 17 
Uniplex 
25 89 95 
5.57 0.906 
99 17 17 
*Copies per panel calculated from the number of positive partitions using the Poisson 
correction. †Ratio of ERCC-25/ERCC-99 dPCR values with standard uncertainties. Ratios 
calculated using copies per panel. Standard uncertainty calculated by dividing the standard 
deviation by the square root of n (number of replicate measurements).  
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are being converted to cDNA but not being amplified by the PCR. This diminished 
detection is kit and transcript dependent. However, this assumes that the UV 
measurement is accurate although in fact UV absorbance may potentially 
overestimate the initial valuation. This is explored in more detail below. 
4.3.2 Comparison Between dPCR and UV Measurement of Synthetic RNA 
Targets 
To investigate this disparity further, RT-dPCR measurements using the Ambion kit 
were compared when measuring a further four ERCC targets (all six present within 
the TCM) (Figure 4.2). dPCR estimates of ERCC transcript quantities were on 
average 40% lower than when measured by UV (p < 0.0001). Furthermore, despite 
all six ERCC targets being valued at the same concentration, as estimated by UV 
spectrophotometry, there was a significant difference between ERCC target 
concentrations estimated by dPCR (p = 0.0002). Bioanalyzer quantification for all 
six synthetic targets was comparable to nanodrop concentration estimates (p = 
0.660, with an average difference between the two approaches of 1.02 copies). The 
significant differences observed in absolute quantification between dPCR and UV 
were assay/target-specific (Figure 4.2). The number of dPCR estimated counts for 
ERCC-25 was closest to UV at 77.41% agreement, whereas ERCC-99 displayed the 
lowest agreement at 50.45%. Furthermore, there was no significant inter-plate 
difference observed despite 5-6 days between independent experiments. 
The analysis method was shown to significantly affect the RNA quantification 
result. There may be a number of reasons explaining the significant difference 
observed between dPCR and UV methodologies. While dPCR makes an absolute 
count of specific amplified cDNA target molecules, albeit a small part of a bigger 
molecule, UV cannot discriminate between nucleic acid species, non-target RNA 
and fragmented/degraded/non-amplifiable targets [12,47,103,125,126,128]. 
There is a concordance between UV and the 2100 Bioanalyzer (which utilises a 
fluorescent dye that interacts with nucleic acids); the Bioanalyser measurement   
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Figure 4.2 dPCR versus UV quantification. Six synthetic targets (ERCC-13, -25, -42, -99, -113 
and -171) were assessed by both one-step dPCR, utilising the Ambion one-step RT qPCR kit, 
and UV measurement. Error bars: 95% confidence intervals. n=3 replicate dPCR experiments 
or UV measurements.  
 
  
% Agreement 
ERCC-13 ERCC-25 ERCC-42 ERCC-99 ERCC-113 ERCC-171 
56.65 77.41 55.89 50.45 65.65 57.54 
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may also be influenced by contaminants and non-target species. This over 
estimation of RNA target concentration could contribute to the consistent 
increased RNA concentration estimated by UV. Another explanation for the 
discrepancy is that the RT-dPCR measurement value is underestimating the true 
concentration. Quantification of RNA reflects only the number of target cDNA 
molecules converted from the original RNA. This may or may not give an accurate 
estimate for the original concentration of the RNA molecules of interest [230]. 
Given the assumption that the RNA samples analysed are fairly pure in view of the 
high degree of gDNA removal (3.3.2 DNA Contamination Assessment), it is 
possible that the lower quantification by dPCR reflects the efficiency of the RT 
reaction. Not only is it shown here that RT sensitivity and variability will affect 
dPCR estimation, as previously reported when using RT-qPCR [56,82], but 
previous studies have shown similar disparity between dPCR and UV valuation 
when measuring DNA targets [103], suggesting the PCR step in the RT-dPCR may 
also contribute to the observed differences. The quantification divergence of these 
data demonstrates an assay/target specific bias attributable to the RT and/or 
dPCR step.  
4.3.3 Linearity and Sensitivity of RT-dPCR of Synthetic RNA Targets 
In order to identify RT-dPCR sensitivity and linearity of measurement for low copy 
targets the Ambion kit alone was used, due to its superior capabilities throughout 
the initial analyses. A dilution series of two synthetic RNA targets, ERCC-25 and 
ERCC-99, was analysed in duplex (Figure 4.3). Dilutions were performed based on 
UV evaluation, using dH2O 0.5% v/v Tween 20 as diluent, to generate samples 
equating to approximately 500, 250, 100, 50, 25, 10 or 5 copies/panel. 
There was a significant difference identified in RNA copy number estimates 
between dPCR and UV values, p < 0.0001 (Figure 4.3A & B), which concurred with 
previous observations (Figure 4.2). Both ERCC-25 and ERCC-99 displayed linear 
quantification capabilities, with good precision (CVs of less than 10%) achievable   
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Figure 4.3 dPCR sensitivity for RNA measurement. Assessment of RT-dPCR quantification 
sensitivity, using independent dilutions and quantifying ERCC-25 and ERCC-99 synthetic 
targets in a duplex format. n = 6 panels per dilution, in two replicate experiments. UV data 
based on initial UV quantification of stock and predicted target levels following volumetric 
dilutions. (A & B) dPCR sensitivity. (B) Focus on lowest level target dilutions. Error bars: 95% 
confidence intervals. (C) Precision of dPCR quantification compared to UV.  
  
C	
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down to 50 UV assigned copies (Figure 4.3C).  
The linearity and sensitivity data clearly show a pattern of increased variability 
with the increase of dilution factor below 50-100 estimated copies. We have 
previously demonstrated that when analysing DNA targets, dPCR is highly precise 
down to 16 copies/panel [103] suggesting RNA measurement is more variable. 
(RNA at 50 estimated copies, CV 12-20%. DNA at 16 estimated copies in carrier, CV 
24%). 
4.3.4 Evaluation of Reverse Transcriptase’s Targeting Endogenous 
mRNA Transcripts 
In order to investigate the applicability of these findings to real samples, the same 
three one-step RT-qPCR kits were tested to compare measurement of endogenous 
targets alongside synthetic controls in various duplex combinations in the TCM 
(Figure 4.4). Again for each target, there was a significant effect of kit on dPCR 
quantification (all p values < 0.0001). For endogenous targets, the Ambion kit 
yielded the highest quantification values, as previously observed with synthetic 
controls: although the variability observed for UBC (within the Ambion kit) was 
higher than for the synthetic targets (ERCC 95% CI all <38, UBC 95% CI 100-157). 
To establish whether duplex pairings influenced RT-dPCR results, duplex reactions 
were performed pairing different targets (Duplex A: ERCC-25 + ERCC-99. Duplex B: 
MMP1 + UBC. Duplex C: ERCC-25 + UBC). As observed above, there was a 
significant difference between the kits, but no significant difference observed in 
dPCR values between ERCC-25 or UBC when assessed in different duplex reactions 
using the Ambion reagents (ABC), p = 0.061 and 0.92, respectively. Therefore, for 
these targets, assays did not influence the quantification result of their duplex 
partners. Furthermore, measurement ratios between targets were not maintained 
owing to the inferior sensitivity of the Invitrogen and Qiagen kits (Ambion, 
Invitrogen and Qiagen ratios in duplex pairings for ERCC-25:ERCC-99 1.5, 3.26 and   
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Figure 4.4 Evaluation of Reverse Transcriptases. Three different one-step RT-qPCR kits 
were compared in different duplex formats, by dPCR. Quantification for synthetic (ERCC-25 
and ERCC-99) and endogenous (MMP1 and UBC) targets was evaluated. ERCC-25 with ERCC-
99 (duplex A), UBC with MMP1 (duplex B), and ERCC-25 with UBC (duplex C). In the 
key/tabulated values, the assay in brackets is the duplex partner for the assay whose positive 
partition values are being displayed. Error bars: 95% confidence intervals. n=3 replicate 
panels, plus two replicate experiments. Equivalent UV estimates: ERCC-25 1886.10 
copies/panel. ERCC-99 1860.30 copies/panel. 
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3.19, respectively. For ERCC-25:UBC 1.19, 3.61 and 2.16, respectively).  
The magnitude of the difference in mean quantification values between kits was 
not consistent between different targets, both synthetic and endogenous, 
suggesting an additional assay specific and kit associated bias. There was a greater 
difference between kits when measuring endogenous targets than for synthetic 
targets. Furthermore, both Invitrogen and Qiagen kits were unable to detect MMP1 
(0 positive partitions) despite being measured with six replicates totalling some 
4590 partitions. However, as the Ambion kit only measured on average 112 MMP1 
positive partitions, it would suggest that this transcript was below the limit of 
detection for the two former kits. Measurement, or specifically enzyme, 
efficiency/sensitivity is an important consideration when measuring low 
abundance RNA targets, in order to avoid false negative results and these data 
suggest that choice of kit is crucial for ensuring the most sensitive result when 
performing RT-dPCR. This also follows when performing RT-qPCR. One of the 
characterised applications of dPCR is for the detection of minority targets due to 
its increased sensitivity by increasing the signal to noise ratio (needle in a 
haystack). Therefore, when applying RT-qPCR for target detection, particularly 
minority targets, choice of kit is equally critical. It should also be noted that while 
MMP1 target was present at low abundance in the dilutions tested, evaluation of a 
more concentrated sample might circumvent the sensitivity issues associated with 
the two kits. Therefore, this must also be considered when validating protocols if 
low copy measurements are required. 
4.3.5 Causes of Differing RT-dPCR Results  
One of the most striking findings of this study is the large inter assay and inter kit 
difference in the estimated copies for a given target. There are a number of 
potential causes for these observations. It is clear from these data that some, if not 
all, of the kits analysed during this study were not measuring all the RNA 
molecules that were present. There may be a number of different reasons for this. 
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The assumption that DNA measurement by dPCR can be precise, reproducible, and 
absolute cannot be readily extrapolated to the measurement of RNA [230]. The RT 
step may introduce an additional source of variability and bias, with reaction 
efficiency being both assay and reagent dependent. It is a well-documented fact 
that RT does not convert all RNA to cDNA [57,278], which may explain these 
findings. RT inefficiency and variability may account for the majority of this 
measurement divergence, especially given that qPCR has been shown to be 
extremely sensitive and efficient [26,86]. In addition, several studies have shown 
that RT reaction components may have a reversible inhibitory effect on the 
subsequent qPCR, the magnitude of which depends on the RT system [47,62,69-
71]. While it would be hoped that in the one-step kits investigated in this study the 
RT components would have minimal effect on the PCR step, one cannot rule out the 
possibility that as well as RNA not being converted to cDNA, failed subsequent 
amplification of the cDNA may also explain the underestimation. If these biases are 
global, then the influence of these factors will be removed if data are normalised to 
validated, internal reference genes.  
A recent study documented a dPCR phenomenon termed molecular dropout [279]. 
This event is characterised as a failure to detect the presence of a target molecule 
during dPCR. In other words, the target molecule is present in the partition but is 
not amplified. Given this precedent, it is therefore plausible to assume that 
molecular dropout, either at the cDNA or RNA stage of the RT-dPCR process, on a 
much larger scale to that measured by dPCR alone, may explain why copy number 
detected by dPCR is lower than that predicted by UV. Moreover, it is possible that 
different enzymes may be affected to different degrees by this phenomenon. 
Indeed, given the findings of this study, it is possible that molecular dropout may 
occur on both an assay and kit-specific basis. Several factors may contribute to 
molecular dropout including reduced assay sensitivity attributable to complex 
template secondary structures [279], reagent inhomogeneity, whereby 
primers/probes/enzyme reaction components may not be evenly distributed and 
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thus not represented in all partitions, and PCR inhibitors that affect one assay 
more than another [74] (matrix effects).  
Template secondary structure and position of the assay along the target length is 
known to impact on the RT-qPCR [86] and may therefore contribute to this 
molecular dropout in RT-dPCR. Previous studies [279] have shown an increased 
prevalence of molecular dropout when analysing gDNA as opposed to linearised 
plasmid, and this variability was attributed to the increased structural complexity 
of the gDNA. The potential impact of template secondary structure was assessed 
[228,229] to evaluate whether this could be a cause for molecular dropout and 
determine positional influences contributing to assay performance. All templates 
displayed a degree of secondary structure within the amplicon region (Appendix 
2). When concentrating on the regions complementary to the reverse primer (used 
in the RT to prime cDNA synthesis), all templates exhibited some degree of stem-
loop structures. However, the 3’ ends of the reverse primer complementary region 
showed differing secondary structures. For example the 3’ end within ERCC-25 
was within an open (loop) structure while for ERCC-99, the final base was 
designed to bind to a closed (stem) region (Appendix 2, H & J). Given that the 
primers are extended from the 3’ end, this may explain why ERCC-25 consistently 
gave a higher value than ERCC-99 despite their being present at the same copy 
number. Furthermore, in addition to being a low abundance target, the structure of 
the MMP1 amplicon region is complex with the largest number of predicted stem-
loop structures within this location, which may in part account for the difficulty of 
some enzymes to detect it. MMP1 also has the longest amplicon size, at 133 bases, 
whereas ERCC-25 has the shortest, at 67 bases. The assay-specific bias observed 
between kits for different synthetic and endogenous targets maybe in part 
explained by predicted template secondary structures and this would also appear 
to be kit specific.  
The recommendation from the MIQE guidelines [86] that RT primers be designed 
to stem loops to improve qPCR maybe a particularly important consideration when 
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performing RT-dPCR to improve assay sensitivity; the data presented here 
suggests choice of reagent has a greater impact on the measurement result 
(detection of MMP1 transcript was dependent on the one-step kit used for 
analysis). For this data set, it was not possible to quantify the impact of reagent 
choice compared to target secondary structure for the detection of MMP1 due to 
the inability of both the Invitrogen and Qiagen kits to detect it. In order to evaluate 
which factor (reagent choice or target secondary structure) has the biggest 
influence on target quantification, a set of assays targeting different regions of the 
same transcript could be compared to test the influence of secondary structure 
when using the same template. Furthermore, these assays could be evaluated using 
the three different one-step kits. This would help discern where the greatest 
impact lies. This approach would be further aided by the utilisation of a high 
abundance target, as in the current set-up it cannot be determined whether the 
low abundance of MMP1 alone influences the detection sensitivity of the one-step 
kit or whether other factors, such as template secondary structure, precludes its 
identification when employing particular kits. Further work is required to test the 
hypothesis that RNA structure will effect RT-dPCR sensitivity, but these findings 
suggest reaction efficiency may in part reflect the ability of an enzyme to negotiate 
strong secondary structures and successfully progress the course of the reaction 
and that this is specific to different kits.  
The difference in the RTases themselves is likely to be the primary reason that the 
three kits performed differently. Both the Ambion (Multiscribe) and Invitrogen 
(Superscript III) RTases are derived from Moloney murine leukemia virus (MMLV) 
RTase. Alternatively, the Qiagen (Omniscript and Sensiscript) RTases are derived 
from a unique source (undisclosed). The Qiagen RTases maintain RNase H activity, 
while the Ambion and Invitrogen RTases are claimed to have reduced RNase H 
activity. If RTase pauses during synthesis (for example, when dealing with a 
complex secondary structure), its RNase H activity has been shown to cleave the 
template near the 3’ terminus of the growing DNA strand [63,64]. High levels of 
RNase H activity may therefore supress cDNA yield and restrict its length and thus 
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reduced RNase H activity may be better suited for RT-qPCR [65]. Its purported 
RNase H activity may be a factor in why the Qiagen kits’ performance was 
comparatively poor. Furthermore, the buffer has an influence on the efficiency of 
the reaction, and these proprietary components will differ between kits. In 
addition, the stability of the RT buffer may become compromised following several 
freeze/thaw cycles.  
There may be other factors contributing to RT yields. For example, the samples 
used were sourced from cell line lysates. Co-extracted inhibitors may affect 
different reverse transcriptases to different degrees. Furthermore, components of 
total RNA, such as rRNA and tRNA may additionally inhibit RTase efficiency [65], 
by competing for reagents and producing undesired products. However, the 
manufacturers claim that the RTase used in the Invitrogen kit is not significantly 
inhibited by such total RNA components although this was not specified for the 
other manufacturers. These considerations taken together may in part explain the 
disparity displayed between different one-step RT-qPCR kits.  
As may be seen from this comparison, despite the precision conferred by dPCR, 
analysis of RNA using RT-dPCR needs to be approached with caution. While for 
RNA measurement the precision of the RT-dPCR technique is high, it nonetheless 
introduces more variability into the measurement value than dPCR alone [103]. 
The significant differences observed between kit sensitivities, particularly for low 
abundance and/or structurally complex targets (MMP1), highlight the importance 
of reagent choice and protocol consistency as critical if data sets are to be 
meaningfully compared. Furthermore, the inability to detect certain targets may be 
due to the choice of RTase/kit and all experimental plans should therefore be 
validated appropriately before embarking upon studies analysing important 
samples.  
For accurate RNA analysis by RT-dPCR it is possible that unknown measurements 
should be properly correlated to an appropriate measurement standard, with a 
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well-defined value and uncertainty [1,6,7,230]. It may also be the case that while, 
unlike RT-qPCR, RT-dPCR may not need a calibration curve to assign a value, some 
kind of calibration molecule will be required to compensate for the assay/kit 
differences observed here. Using the data from Figure 4.4, normalisation to ERCC-
25 generated values with the closest concordance between the kits. Normalisation 
to: ERCC-25 (analysed with ERCC-99 in duplex A), average RQ (across all 
targets/kits) 0.650, SD 0.408; ERCC-25 (UBC, duplex C), average RQ 0.603, SD 
0.381; ERCC-99 (ERCC-25, duplex A), average RQ 1.607, SD 1.225. While 
normalisation of these data goes some way to aligning the values generated from 
different kits, it does not generate values in complete concordance. Normalisation 
does align Invitrogen and Qiagen kit data more closely, but these values are not in 
alignment with Ambion kit data. RQ range (across all targets/kits): ERCC-25 
(ERCC-99, duplex A) 0.02-1.26; ERCC-25 (UBC, duplex C) 0.02-1.00; ERCC-99 
(ERCC-25, duplex A) 0.06-4.11. Furthermore, relative standard deviation (RSD) 
estimates (standard deviation/mean) of RQ values lay within the RSD range of 
dPCR quantification estimates (RSD range: 0.628-0.763 for RQs, 0.03-1.57 for 
dPCR). In this case, normalisation using ERCC targets is limited and may not be fit 
for purpose for mitigating kit-to-kit differences. It is possible that because the 
ERCCs are synthetic targets, they do not behave in the same way as the 
endogenous targets, which is why their use as normalisers (at least in this 
experiment) is limited. Furthermore, the two ERCCs investigated for this particular 
comparison (ERCC-25 and ERCC-99) may not be representative of other ERCC 
synthetic targets in terms of, for example, their secondary structures, and it is 
therefore possible that other ERCC targets may behave in a more comparable way 
to endogenous targets. If indeed that were the case, other ERCC synthetic targets 
may be more appropriate for effective normalisation of endogenous targets.  
All samples may be normalised to a calibrator sample, also known as a reference 
sample, in a similar way as performed for relative quantification by RT-qPCR. It is 
possible that in some cases where assay bias is observed, only gene specific 
calibrators will be appropriate. For accurate absolute quantification these data 
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suggest use of a calibrator sample, with an accurate assigned value, will allow 
straightforward correction of dPCR data to account for differences in enzyme 
efficiencies, inhibitors and molecular dropout. Such dPCR-specific calibrator 
materials are yet to be developed and approaches combining validated synthetic 
and endogenous control materials, as described here, represent a possible 
strategy. The full power of this technique may only be realised on their 
experimental incorporation.  
4.4 Conclusions 
This study has shown that when compared with RT-qPCR, RT-dPCR is capable of 
making more precise measurements of synthetic and endogenous RNA molecules 
in a complex RNA background. RT-dPCR quantification of RNA targets was 
significantly lower than that derived from UV values suggesting a possible 
underestimation bias. Furthermore, absolute measurements differed between the 
three one-step kits assessed, with bias in detection sensitivity. Linearity and 
precision were sustained for duplex dPCR measurement of synthetic RNA using the 
Ambion kit, while sensitivities differed between RNA targets. dPCR is 
unencumbered by the restraints of calibration curve measurements, however, the 
employment of dPCR-specific calibrant materials (reference samples) would 
facilitate greater accuracy for absolute quantification. In fact, these data suggest 
that this is essential to achieve the best accuracy. Furthermore, use of the TCM 
shows the applicability of RT-dPCR for the target-dependent selection of suitable 
RT enzymes. This study is novel in demonstrating application of RT-dPCR for 
absolute quantification of RNA endogenous and synthetic targets. These findings 
give strong weight to the applicability of RT-dPCR to measurement fields including 
RNA diagnostics and RNA viral measurement, so that greater levels of accuracy 
and precision may be achieved.  
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5 Evaluation of the Impact of Extraction Protocol on 
Target Quantification  
5.1 Introduction 
The experimental starting point for the vast majority of nucleic acid molecular 
analyses after sample acquisition is nucleic acid extraction, separating RNA and/or 
DNA from other components constituting a sample. There are numerous methods 
available for nucleic acid extraction, including both commercial kits and well 
established, published protocols, utilising organic separation and/or silica 
membrane separation systems [201,203]. In addition, different sample types (cell 
culture, solid tissue biopsy, bone, bodily fluids, etc.), present different challenges 
for successful nucleic acid extraction. Methods may have different efficiencies 
when applied to different sample types and the samples themselves may present 
physical (bone) or chemical (matrix components) inhibition to the recovery yield 
of the chosen method.  
Following extraction, standard practices require assessment of RNA quality and 
quantity [86]. There are several methods available for this purpose, each of which 
may generate a different measure of such properties. Some methods rely on UV 
absorbance or fluorescence, such as the Nanodrop (Thermo Scientific) [280] or 
Qubit (Life Technologies) [281], respectively. Others employ gel electrophoresis 
for size separation (Bioanalyzer, Agilent) [282] or PCR-based detection, such as Alu 
PCR [283,284] or 3’:5’ ratio mRNA integrity assay [252]. Some of these methods 
conveniently offer both quality and quantity assessments in one (such as the 
Agilent Bioanalyzer), whereas others may only offer one metric and so multiple 
analyses must be performed in order to obtain both quality and quantity values.  
The aim of this chapter was to determine the variability in yield, quality and DNase 
treatment of RNA across different extraction procedures, and to determine if 
different approaches were more beneficial when evaluating different sample 
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sources and/or quantities. The overall intention of this study is to demonstrate 
how this kind of comparison should be approached. This strategy may be applied 
to any comparison of methods and is not restricted to the kits evaluated in this 
chapter. This work helps illustrate the wider problem within the field where 
comprehensive assessments of the methods/kits available may not be performed 
in preference of using habitual approaches.  
Three different extraction methods were evaluated for the extraction of total RNA 
from two different cell lines, SaOS-2 and Hs 683, using lysates from different cell 
densities. The RNA extraction step was evaluated in order to determine its impact 
on quantification. Furthermore, different quality metrics were applied for 
comparison; including the Nanodrop 1000, Qubit 2.0, 2100 Bioanalyzer and Alu 
PCR. The utility of these metrics were evaluated.  
5.2 Materials & Methods 
5.2.1 Lysate preparation  
All cell culture of Hs 683 and SaOS-2 cell lines, up to and including lysate collection, 
was performed by Dr Gary Morley, LGC, Teddington. Culture and further 
experimental details are described in 2.1.2 Cell Lines and 2.6 Experimental 
Details – Extraction Kit Comparison. Statistical analysis was performed in 
collaboration with Dr. Simon Cowen, Statistician, LGC, Teddington.  
Cell lysates of 17.5 mL were collected from T-175 flasks in aliquots for each cell 
line and lysate buffer. Four flasks per cell line were produced, one flask per each of 
three different lysis buffers plus a fourth for cell enumeration (Vi-Cell). The TRIzol 
experiment was repeated three times for an analysis of batch variability. Seven mL 
aliquots were prepared and stored at - 80ºC.  
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The ability of a method to extract high quality/yield RNA may be influenced by the 
concentration of starting material. It is unclear whether the concentration of input 
lysate versus RNA yield output remains linear at different input concentrations, 
and whether this influences the integrity of the recovered RNA. The linearity of 
extraction kits is seldom explored and it is generally assumed that kits perform 
equally efficiently across the given reference range provided by the manufacturer. 
It is also worth considering how outputs are affected when input amounts are 
outside this range (too much or too little). It may be the case that the extent of 
these differences may be different for different cell types and different extraction 
kits.  
To assess the linearity of each extraction method, lysates were extracted at 
different dilutions: neat, 1:2 and 1:5. Prior to total RNA extraction, the 7 mL lysate 
aliquots were thawed, mixed for 10 min on a spiromixer at 4ºC and dilutions 
prepared using the appropriate lysis buffer as diluent. Aliquots of total RNA were 
reserved for quantification and all extracted samples were stored at - 80ºC before 
DNase treatment.  
5.2.2 Total RNA Extraction using TRIzol  
Total RNA was extracted from cell lysates by following a standard TRIzol protocol 
(Invitrogen). One mL TRIzol lysates were incubated for 5 min at room temperature 
and harvested by centrifugation (12,000 × g for 10 min at 4ºC) to pellet DNA and 
cell debris. Chloroform (Sigma) was mixed with the supernatant (200 µL of 
chloroform for every 1 mL of TRIzol). Following phase separation using 
centrifugation (12,000 × g for 15 min at 4ºC), RNA was collected in the upper 
aqueous phase and precipitated at room temperature using 0.5 mL absolute 
isopropyl alcohol (Sigma) per 1 mL TRIzol. The RNA pellet was washed with 75% 
ethanol (Sigma) before resuspension in 50 µL nuclease-free water (Life 
Technologies).  
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5.2.3 Total RNA Extraction using RNeasy Mini Kit  
Total RNA was extracted from cell lysates by following the “Purification of Total 
RNA from Animal Cells” protocol in the kit handbook [285]. RLT buffer (containing 
1% beta-mercaptoethanol) was used to collect lysates, 600 µL aliquots of which 
were homogenized using a QIAshredder spin column. One volume of 70% ethanol 
was mixed with the eluate and transferred to an RNeasy spin column. After 
separation using centrifugation (8,000 × g for 15 s), the silica membrane-bound 
RNA was washed with 700 µL of RW1 buffer followed by 500 µL of buffer RPE 
(both at 8,000 × g for 15 s). A further 500 µL of buffer RPE was used to wash the 
membrane (30 s) and the membrane spun dry for 2 min at full speed. Total RNA 
was eluted in 50 µL nuclease-free water (Life Technologies).  
5.2.4 Total RNA Extraction using MasterPure RNA Purification Kit  
Total RNA was extracted from cell lysates by following the manufacturers’ protocol 
(Epicentre, CamBio). Fifty μg Proteinase K (Epicentre and Qiagen) was added to 
300 µL Tissue and Cell Lysis Solution lysates and incubated at 65ºC for 15 min with 
frequent vortexing, before placing samples on ice for 3-5 min. Addition of 175 μL 
MPC Protein Precipitation Reagent (a high concentration salt solution containing a 
precipitation carrier) preceded centrifugation (10,000 × g for 10 min at 4ºC). Total 
RNA was precipitated from the supernatant using 0.5 mL isopropyl alcohol 
(Sigma). The RNA pellet was washed with 70% ethanol (Sigma) before 
resuspension in 35 µL of TE Buffer. Samples were incubated at 26ºC for 15 min to 
aid resuspension of the pellet.  
RNA was eluted or resuspended in nuclease-free water or TE buffer and volume 
specified by individual kits.  
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5.2.5 Post-Extraction Treatment  
Following total RNA extraction, all samples were DNase treated, purified and 
subjected to the following quality metrics; Nanodrop, Qubit, 2100 Bioanalyzer and 
Alu PCR, as described in 2.6.6 RNA Quality Metrics.  
5.3 Results & Discussion 
Standard procedures require an assessment of RNA quality/integrity and quantity 
following extraction from test material. Typically, one metric is applied, such as UV 
absorbance, which will generate an estimate of both RNA yield and integrity. A 
nanodrop was used for an initial assessment of yield and quality for RNA derived 
from different extraction kits. Following this initial assessment, different quality 
metrics were compared.  
5.3.1 Effect of Extraction Protocol on RNA Yield 
Total RNA extracted from two different cell lines (Hs 683 and SaOS-2) were DNase 
treated and analysed by UV absorbance for an assessment of yield generated by 
three different extraction kits (Figure 5.1).  
Two-factor ANOVA (kit versus dilution) revealed a significant effect of extraction 
kit for both cell lines, both p <0.001. There was also a significant interaction 
between the two terms (dilution and kit) for Hs 683 (p = 0.012) and SaOS-2 (p = 
0.007), suggesting the yields of some kits (TRIzol) may be influenced by dilution 
level. Dilution did not significantly affect Hs 683 total RNA yields (p = 0.322), 
suggesting linear extraction efficiencies across this dilution range for these cells. 
Dilution significantly influenced SaOS-2 total RNA yields (p < 0.005); suggesting 
extraction efficiencies were not linear across this dilution range (two-factor 
ANOVA, kit versus dilution). However, on further analysis it was determined that 
the significant impact of dilution on total RNA yield for the SaOS-2 cell line was 
attributable to the TRIzol extraction kit alone (single-factor ANOVA, p = 0.023),   
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Figure 5.1 Average total RNA extracted by each extraction method. Post DNase RNA yields 
have been normalised for dilution (multiplied by respective dilution factor). Triplicate 
extractions were analysed with triplicate UV measurements. (A) Hs 683 cell-derived RNA. (B) 
SaOS-2 cell-derived RNA. Error bars SEM.  
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suggesting that the MasterPure and RNeasy kits did in fact maintain linearity in 
extraction across the dilution range.  
The error bars plotted in Figure 5.1 are SEM. Multiplying the SEM error by an 
appropriate coverage factor (to give 95% confidence intervals) gives largely 
overlapping error bars in keeping with statistical outcomes (no significant 
differences in RNA yields between dilutions for Hs 683). However, these error bars 
cross zero (y-axis) and so are theoretically not valid, which is why they have not 
been plotted here. This suggests that the statistical model is not powerful enough 
to detect true differences, as the extractions do appear to be quite variable. This 
may be improved in the future by increasing the number of samples analysed.  
These data demonstrate that different kits have varying efficiencies when 
extracting RNA and that not all kits extract RNA in a linear manner. The TRIzol 
method for example was variable in its RNA extraction yield linearity. Linearity 
was influenced by sample source (cell line), with Hs 683 cell extracts maintaining 
linearity throughout the dilution range, while SaOS-2 cell extracts did not. To 
provide relevant and reliable results, RNA needs to be effectively and reproducibly 
purified from various heterogeneous materials such as fresh or frozen tissues, cell 
lines, PCR products or long-term chemically preserved samples [258]. The 
efficiency of the extraction may be dependent on the concentration of input 
material, although additional factors such as sample matrix may further affect 
extraction efficiency [286]. While not all the kits specified a lower limit for sample 
input (RNeasy kit stated a minimum of 100 cells), all lysate dilutions contained 
≥1.0E+05 cells per lysate aliquot extracted. However, amount of input material 
appeared to be a limiting factor in terms of yield/extraction efficiency. Potential 
differences in kit yields need to be considered in any comparison studies. The 
differences between extraction kits are particularly important when limited source 
material is available (e.g. clinical biopsies), or extractions must be made from 
difficult material (e.g. bone, formaldehyde-fixed paraffin-embedded (FFPE) 
samples or compromised samples containing a lot of contaminating material). For 
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these samples and experiments, the TRIzol extraction yielded the most RNA for the 
neat extracts (> 14 µg), followed by RNeasy (> 10 µg) and MasterPure (< 4 µg), 
whereas for diluted samples the RNeasy extraction yielded the most RNA for both 
1:2 and 1:5 extracts (> 7 µg for both dilutions), followed by similar yields from 
TRIzol and MasterPure kits (< 7 µg for both kits and both dilutions).  
5.3.2 Effect of Extraction Protocol on RNA Quality 
In addition to an assessment of quantity, the same total RNA extracts underwent a 
quality assessment. This initial assessment was also performed using the UV 
absorbance measurement. The Nanodrop instrument gives a quality assessment 
based on UV absorbance ratios at 260/280 and 260/230 nm (Figure 5.2 and 
Table 5.1).  
There was a significant difference observed in Hs683 RNA 260/280 and 260/230 
ratios both between dilution levels and between extraction kits (260/280: p = 
0.036 and p < 0.001, respectively. 260/230: both p < 0.0001). For 260/280 ratios, 
there was also a significant interaction between the two terms (dilution level and 
extraction kit), p < 0.001. However, for 260/230 ratios there was no significant 
interaction between the two terms (dilution level and extraction kit), p 0.080.  
There was a significant difference observed in SaOS-2 RNA 260/280 and 260/230 
ratios both between dilution levels and between extraction kits (260/280: p = 
0.024 and p < 0.001, respectively. 260/230: both p < 0.0001). There was also a 
significant interaction between the two terms for both sets of ratios (dilution level 
and extraction kit), p < 0.032 and p < 0.015, 260/280 and 260/230 ratios 
respectively.  
A 260/280 ratio of approximately 2.0 and a 260/230 ratio of approximately 1.8-
2.2 are generally accepted as ideal for pure RNA [256-258]. Ratios (for either 
260/280 or 260/230) lower than expected maybe as a result of contamination by   
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Figure 5.2 RNA Nanodrop quality absorbance assessment. Absorbance ratios at 260/280 
and 260/230 nm were compared for RNA extracts performed at different lysate dilutions using 
different extraction kits. (A) Hs 683 cell-derived RNA. (B) SaOS-2 cell-derived RNA. Error bars 
95% CI. Triplicate measurements were performed on triplicate extracts.  
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Table 5.1 Nanodrop quality assessment based on UV absorbance ratios at 260/280 and 
260/230 nm. (A) Average values across all dilutions (neat, 1:2 and 1:5) for each of the 
extraction kits assessed. (B) Average values across all extraction kits (MasterPure, RNeasy and 
TRIzol) for each of the dilutions assessed. SEM = standard error of the mean. n = 27 for each 
comparison.  
A 
Cell line Ratio Kit Mean SEM 
Hs 683 
260/280 
MasterPure 2.01 0.02 
RNeasy 1.99 0.01 
TRIzol 1.86 0.03 
260/230 
MasterPure 1.18 0.10 
RNeasy 1.68 0.14 
TRIzol 1.87 0.07 
SaOS-2 
260/280 
MasterPure 1.93 0.10 
RNeasy 1.91 0.01 
TRIzol 2.91 0.35 
260/230 
MasterPure 0.98 0.09 
RNeasy 2.00 0.06 
TRIzol 1.52 0.18 
B 
Cell line Ratio Dilution Mean SEM 
Hs 683 
260/280 
Neat 1.99 0.01 
1:2 1.95 0.03 
1:5 1.92 0.03 
260/230 
Neat 1.90 0.11 
1:2 1.59 0.10 
1:5 1.24 0.12 
SaOS-2 
260/280 
Neat 1.94 0.02 
1:2 2.13 0.14 
1:5 2.68 0.35 
260/230 
Neat 1.85 0.13 
1:2 1.60 0.16 
1:5 1.05 0.10 
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residual phenol, guanidine, or other reagents carried over from the extraction 
protocol [12,125,126,256]. Such contamination might also result in an 
overestimation of the nucleic acid quantity. High 260/280 purity ratios are not 
necessarily indicative of a problem. However, a very high ratio can suggest a poor 
quality blank eliminating too much signal near the 280 nm wavelength [256]. At 
very low concentrations (less than 10 ng/µL) inaccuracies in the nanodrop 
measurement may also be encountered [256]. This will affect both the 
concentration estimate and the purity estimate based on absorbance ratios. Small 
changes in the pH of the solution are also known to cause variability in the 
260/280 absorbance ratio [127,258].  
The majority of 260/280 measurements are approximately 2.0 (excepting the 
TRIzol 1:5 dilution for SaOS-2). The majority of 260/230 estimates are below 1.8, 
which may indicate a degree of contamination or may reflect the low yields in 
some of these samples (low yields may hinder the accurate estimate of absorbance 
ratios). Hs 683 TRIzol and SaOS-2 RNeasy samples gave the best approximations to 
pure RNA [256-258].  
Although purity ratios can be indicators of sample quality, the best indicator of 
nucleic acid quality is functionality in the downstream application of interest. An 
RNA sample with an absorbance ratio outside the recommended values may still 
function well for RT-qPCR or other downstream applications [258], as for example, 
some fragmentation of target may actually open up previously inaccessible regions 
to PCR enzymes and primers. Likewise there are occasions when the purity ratios 
are within expected limits, yet there is a problem with sample performance in 
downstream applications [256]. Nevertheless, these metrics may still give an 
indication of sample quality and are often estimated concurrently with quantity 
estimates, required for downstream applications, and so no additional effort or 
sample is required for their estimation. However, UV absorbance ratio values are 
not necessarily a robust estimation of quality [130]; quantity alone may be 
sufficient for downstream applications. Unfortunately, this method of measuring 
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quantity is linked to the measurement of quality (UV absorbance) and so low 
quality estimates may influence quantity estimates, potential generating 
underestimated concentrations. Ideally, measurement of quantity would be 
independent of quality to prevent introduction of bias. Future studies to evaluate 
the effect of quality on abundance valuation would include the use of contaminants 
to adjust quality estimates and compare quantities with control samples. 
Furthermore, as discussed in the introduction to this chapter, UV absorbance and 
other methods such as capillary electrophoresis assess the quality of a total RNA 
population, rather than specifically the mRNA fraction. Methods such as 5’-3’ ΔCq 
that evaluate the integrity of the mRNA transcripts used as template for RT-qPCR 
analyses, may be more informative [130,252].  
5.3.2.1 Assessment of gDNA Contamination 
The Alu sequence is highly abundant throughout the genome (approximately 1 
million copies) [130] and as such offers an opportunity to measure residual gDNA 
contamination in total RNA extracts pre- and post-DNase treatment. Alu PCR 
analysis was performed on samples pre- and post-DNase treatment and post RT. 
Samples measured: Hs 683 post-DNase (all dilutions), SaOS-2 pre-DNase (neat 
only), SaOS-2 post-DNase (all dilutions), SaOS-2 post-RT (neat only).  
A significant difference in Alu signal was observed between extraction replicates at 
any dilution (all p < 0.05), different kits at any dilution (all p < 0.001) and different 
dilutions (all p < 0.001). Furthermore, an interaction was observed between 
different dilutions and different kits (all p < 0.05) (Figure 5.3). Samples appear to 
show non-linearity, with the 1:2 lysate dilution showing the highest values for 
genome equivalents in the SaOS-2 cell line (Figure 5.3B). The result for neat 
samples may be attributed to either inhibition or assay/sample saturation, which 
could be tested by performing a dilution series of the neat lysate preparations pre-
PCR [287]. Alternatively, the DNase treatment may be more   
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Figure 5.3 Alu PCR analysis of samples extracted using different methods. Alu PCR Post-
DNase. gDNA measured by qPCR was converted to genome equivalents. (A) Hs 683 cell-derived 
RNA. (B) SaOS-2 cell-derived RNA. Normalised for dilution (multiplied by respective dilution 
factor). Error bars 95% CI. 
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efficient in the neat SaOS-2 sample due to a greater availability of DNA substrate, 
and so have a greater impact on the removal of gDNA.  
Standard curves for linearity of Alu PCR were performed alongside unknown 
samples. All efficiencies were between 90 and 110%, although this was using a 
gDNA standard. The assay was linear over the 5 log range measured (all R2 > 0.990. 
All p > 0.994), suggesting neat samples were not assay saturating. Therefore, the 
differences between neat and 1:2 diluted lysates may be due to inhibition effects or 
greater efficiency of the DNase treatment in neat samples.  
It is observed from the Alu PCR data that the DNase treatment was more efficient 
in removing gDNA contamination in RNeasy and TRIzol extracts than in 
MasterPure extracts. The components of the extraction buffers and wash solutions 
used as part of the MasterPure protocol may have an inhibitory effect on DNase 
activity, resulting in a lower efficiency of gDNA removal. It is unlikely that 
extraction (or indeed DNase) components inhibited the Alu PCR as samples were 
purified post-DNase treatment.  
5.3.3 Effect of Quality Assessment Method on RNA Yield 
Total RNA yield estimations were compared between UV absorbance (Nanodrop), 
fluorescence (intercalating dye, Qubit) and capillary electrophoresis (Bioanalyzer) 
measurements.  
It is clear from these data that the different measurement approaches generated 
different yield estimates (Figure 5.4). There was a significant difference observed 
in RNA yield estimates for both cell lines and at all dilution levels between 
different extraction kits and different quantity estimation methods (metric) (p < 
0.05 for all), except for metric at the 1:5 dilution in Hs 683 cell-derived RNA (p = 
0.796) and metric at the neat dilution in SaOS-2 cell-derived RNA (p = 0.066). 
However, for Hs 683 neat and 1:2 lysate dilutions, there was no significant   
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Figure 5.4 RNA yields according to different metrics. (A) Hs 683 cells MasterPure. (B) Hs 
683 cells RNeasy. (C) Hs 683 cells TRIzol. (D) SaOS-2 cells MasterPure. (E) SaOS-2 cells 
RNeasy. (F) SaOS-2 cells TRIzol. Error bars SEM.   
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interaction between the two terms (extraction kit and metric), p = 0.094 and 0.262, 
respectively. There was a significant interaction between the two terms for the 1:5 
dilution only, p = 0.034. For SaOS-2 at all dilution levels, there was a significant 
interaction between the two terms (extraction kit and metric), p < 0.01 for all. All 
analysis performed using two-factor ANOVA.  
The Bioanalyzer estimates were generally lower than for the other two metrics 
(Nanodrop and Qubit), although these differences were also influenced by dilution 
level, with the RNA derived from diluted lysate being in better agreement with the 
Nanodrop and Qubit estimates. It is possible that this discrepancy is due to the 
calibration of ladder peaks required for the Bioanalyzer measurement. The 
additional differences between reagent batches have huge implications for the 
variability between measurements [47,90]. These data are of particular 
importance when such metrics are to be used for value assignment of a standard 
solution [12]. Reliance on a particular metric for value assignment may lead to bias 
in target quantification using a standard curve approach whereby the standard has 
been value assigned using one of these methods. Where qPCR absolute 
quantification against a standard curve has been utilised, disparity may become 
apparent when inter-laboratory comparisons are made where different metrics 
have been employed in the value assignment of a standard. These biases may not 
be recognised in originating from the different metric approaches and so 
differences between laboratories may be wrongly attributed to random variation. 
Using the yield data in the example above, neat sample quantity estimates were 
used to simulate a standard curve measurement by RT-qPCR (assuming 100% 
efficiency) and fold change in test sample quantity estimates based on these 
standard curves were compared. The biases introduced by the method used for 
RNA yield evaluation are shown in Table 5.2. These biases no longer have an 
influence if fold change/relative measurements are made instead (using 
endogenous reference genes).  
Nanodrop, Qubit and Bioanalyzer quality metrics are all positively correlated   
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Table 5.2 qPCR measurement bias introduced by standard curve value assignment. 
Theoretical fold change measurements of a test sample as a result of using a standard curve 
that has been value assigned using different RNA quantity metrics. Assuming 100% RT-qPCR 
efficiency. The Qubit gave the highest quantity measurement estimates for both cell lines and 
all extraction kits.  
Cell line Kit 
Fold change (from Qubit standard curve) 
Nanodrop Qubit Bioanalyzer 
Hs 683 
MasterPure 0.92 1.00 0.36 
RNeasy 0.92 1.00 0.55 
TRIzol 0.97 1.00 0.55 
SaOS-2 
MasterPure 0.92 1.00 0.95 
RNeasy 0.91 1.00 0.48 
TRIzol 0.95 1.00 0.63 
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(>0.9) (Figure 5.5), for both cell lines and all dilutions, except for the Bioanalyzer 
results with the MasterPure kit (no correlation observed with Nanodrop and 
Qubit). As the MasterPure extracted lysates are diluted, for Bioanalyzer 
measurements only the extracted concentration was no longer proportional to the 
number of cells extracted (the ratio was not maintained, Figure 5.5A, C, D & F). 
The Nanodrop and Qubit metrics show much lower yields for the MasterPure 
extracts. The fact that extraction kit has an effect on the performance of the quality 
metric may be influenced by extraction factors (such as efficiency) and matrix 
effects (co-purified contaminants). It may be the case that the Bioanalyzer metric 
was more sensitive to co-purified contaminants in the MasterPure extracted RNA 
than the Nanodrop and Qubit metrics, or alternatively, the Bioanalyzer may be less 
sensitive for measuring low concentrations. Furthermore, the MasterPure kit 
performed poorly in terms of yield when compared to TRIzol and RNeasy kit 
yields. This low yield and potential contaminant carryover combination may be 
particularly unfavourable to the effective application of the Bioanalyzer metric. If 
the ribosomal bands used for value assignment by the Bioanalyzer are weak, the 
instrument will struggle to quantify against the ladder. Furthermore, calibration of 
ladder peaks may explain Bioanalyzer yield discrepancies.  
When measuring Hs 683 neat lysate RNA extracts, precision estimates were 
smallest for Nanodrop and Qubit metrics, with CVs between 7 and 16% for the 
three extraction kits. Bioanalyzer CVs were highest, between 11 and 30%. The 
highest CV estimates (lowest precision) were attributable to the RNeasy extracts 
(13 to 30%). Measuring Hs 683 RNA for all extraction kits, precision in metric 
measurements decreased (increased CV) when diluted lysate RNA extracts were 
assessed (between 10 and 87%). Counter to the neat lysate RNA extract 
measurements, the highest precision (lowest CV) for the diluted lysate RNA 
extracts was observed for the 1:2 lysate dilution RNeasy extracts, between 10 and 
16%.  
For SaOS-2 RNA extracts (at all lysate dilutions), precision was lower than for Hs   
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Figure 5.5 Quality Metric Correlation Plots of Yield Estimates. All dilution levels are 
represented. (A-C) Hs 683 cell-derived RNA. (D-F) SaOS-2 cell-derived RNA. R2 values for 
MasterPure, RNeasy and TRIzol, respectively: (A) 0.0034, 0.9585, 0.8972 (B) 0.9777, 0.9977, 
0.9994 (C) 0.0268, 0.9451, 0.8859 (D) 0.0747, 0.9771, 0.9788 (E) 0.9744, 0.9971, 0.9987 (F) 
0.1007, 0.9809, 0.9823.   
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683 RNA extracts, with CVs between 5 and 89%. However, precision estimates 
were randomly distributed throughout the sample set, with no apparent trend 
relating to lysate dilution or extraction kit.  
The accuracy of the quantity assessment may be dependent on the composition 
(purity and integrity) of the extracted material. The different metric methods are 
estimating quantity by different means (Nanodrop: UV absorbance, Qubit: 
intercalating dye fluorescence and Bioanalyzer: capillary electrophoresis and 
intercalating dye fluorescence) and as such, may be affected to different extents by 
co-purified contaminants such as proteins, phenol and salts, as well as remaining 
gDNA (inefficient DNase treatment). It is well documented that A260 measurements 
are susceptible to extraction contaminants and changes in pH [12,47,103,125-
128]. It should be noted that RNA pellets were resuspended in TE buffer for the 
MasterPure kit, whereas the RNeasy and TRIzol kits used nuclease-free water. This 
was done according to manufacturer’s protocols and it is assumed these 
recommendations are for optimal results.  
Approaches using fluorescent dyes typically require a calibration curve where the 
calibrator has usually been assigned a value based on A260 measurement. In that 
case, the fluorescent dye approach may propagate the same errors inherent to the 
A260 measurement. As a result, while the Nanodrop and Qubit measurements are in 
good agreement, they may not be accurate as they may share equal bias. 
Furthermore, the Qubit may be considered to use an indirect measurement 
approach, as the bound fluorophore fraction is actually what is being measured. 
This gives rise to the possibility that not all RNA has fluorophore bound or that 
contaminants in the RNA sample may affect fluorophore binding or fluorescence.  
Gel electrophoresis is not commonly used for quantity estimates where other 
methods are available due to its subjective nature (based on band intensity). 
However, with automated capillary electrophoresis systems available, analyst 
subjectivity is removed in deference to autonomous digital data. The Bioanalyzer 
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has been shown not to be subject to influence by phenol contamination, but is 
influenced by low molecular weight DNA contamination [288]. Alu PCR analysis 
(Figure 5.3) revealed that removal of gDNA contamination by DNase treatment 
was more efficient in RNeasy and TRIzol extracts than in MasterPure extracts. This 
may account for why the Bioanalyzer yield estimates were low compared to 
Nanodrop and Qubit estimates for the MasterPure kit (residual gDNA may 
negatively impact of the RNA quantity estimation). While the electropherograms 
for measured samples looked clear in terms of degraded RNA/gDNA contaminants 
(Figure 5.6), 11 out of a total 18 MasterPure samples were too dilute to be 
measured by a Bioanalyzer nano chip (were measured by a pico chip). The low 
abundance of RNA in these samples may be more subject to the contaminating 
influences of gDNA.  
All samples measured (except one: SaOS-2 replicate TRIzol extract of the 1:5 
diluted lysate measured by the Qubit) were within the dynamic range of each 
respective metric. Nanodrop: 2-3000 ng/µL, Qubit: 1-1000 ng/µL, Bioanalyzer 
nano chip: 25-500 ng/µL, Bioanalyzer pico chip: 50-2000pg/µL (from 
manufacturer’s protocols). However, some samples measured were approaching 
the limit of the dynamic range of these metrics and as such may be subject to 
increased variability/error in their quantity estimates [289]. It can be assumed 
therefore, that for the majority of samples the different metrics were linear in their 
measurement of RNA quantity. Any non-linearity observed therefore, would likely 
be attributed to a lack of linearity in the RNA extraction itself.  
5.3.4 Effect of Quality Assessment Method on RNA Quality 
Quality assessment of the RNA extracts was made by 260/280 and 260/230 ratios 
from the Nanodrop measurement (evaluated in 5.3.2 Effect of Extraction 
Protocol on RNA Quality) and the RNA integrity number (RIN) from the 
Bioanalyzer measurement (evaluated below). The Qubit instrument gives no 
indication of RNA integrity.   
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Figure 5.6 Representative Bioanalyzer electropherogram. Measurement of Hs 683 cell-
derived RNA extracted from 1:2 diluted lysate using the MasterPure kit. RIN 9.5. 18S and 28S 
peaks are highlighted. Associated gel image shown alongside the plot. No gDNA or degraded 
RNA smearing observed.  
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Figure 5.7 shows the integrity of the various samples as determined by the 
Bioanalyzer RIN value. The RIN metric indicates the degree of RNA fragmentation, 
with increasing values representing more intact RNA [290]. Unfortunately, owing 
to the low concentration of several samples and subsequent analysis using the pico 
(rather than nano) Bioanalyzer chip, which does not provide an estimation of 
sample RNA integrity with a RIN value, there were too many data points missing to 
generate reliable statistical analyses. (Seven Hs 683 and 13 SaOS-2 samples were 
evaluated using a pico chip). However, on visual inspection of these data all except 
one sample (SaOS-2 RNA derived from one replicate extract of neat lysate using 
the MasterPure kit, RIN 4.6), had associated RIN values > 5, which is recognised as 
sufficient quality for RT-qPCR analysis [265,291]. Furthermore, all Hs 683 samples 
(20/20) and 79% (11/14) SaOS-2 samples with RIN estimates had values > 7. 
These data are in concordance with the 260/280 ratios provided by the Nanodrop 
assessment. However, as discussed above, such quality metrics are possibly 
misleading and it may be more appropriate to directly assess the quality of the 
mRNA fraction using for example, 5’-3’ ΔCq assessment [130,252].  
5.3.5 Influence of Different Cell Batches 
To further determine the variability associated with the extraction step, an 
assessment of cell batch (replicate cell cultures propagated in independent 
experiments) was undertaken. Different cryo vials of frozen cell pellets (both Hs 
683 and SaOS-2 cell lines) were thawed and propagated in culture before being 
collected for RNA extraction using TRIzol (neat lysates only). The extracted RNA 
was evaluated using three quality metrics, Bioanalyzer, Nanodrop and Qubit, 
which were compared for estimates of RNA yield and by Alu PCR for an assessment 
of gDNA contamination.  
There was a significant difference in Hs 683 RNA yield (normalised to cell count) 
between both analysis metric and cell batch, p < 0.02 for both (Figure 5.8). 
However, there was no significant difference observed in either factor for SaOS-2   
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Figure 5.7 RNA Bioanalyzer quality assessment. (A) Hs 683 cell-derived RNA. (B) SaOS-2 
cell-derived RNA. Post-DNase assessment. Error bars 95% CI. Missing values are due to low 
concentration. These samples were analysed on the pico chip (rather than the nano chip) and 
so no estimation of RNA quality was provided by the instrument. n = 3.  
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Figure 5.8 Batch Analysis. Different cell batches (1-3) for both Hs 683 and SaOS-2 cell lines 
were independently propagated before extraction of total RNA using TRIzol (only) and 
analysed post-DNase treatment for quantity by Bioanalyzer, Nanodrop and Qubit. Error bars 
SEM.  
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cell-derived RNA estimates, p > 0.5 for both. The lack of significance in the SaOS-2 
data may be attributable to the Qubit measurement for batch one, which is low, 
compared to the trend in measurements. This may be due to operator error when 
preparing this sample for Qubit measurement or inhomogeneity of the sample. As 
for previous assessments discussed above, Bioanalyzer quantity estimates were 
lower than for the other two metrics. Despite normalisation for cell count, different 
cell batches of Hs 683s generated different yields. This may be attributable to 
variability in the sample source (biological variability) as well as variability in the 
TRIzol extraction itself (technical variability) and should be taken into account in 
downstream measurements.  
There was a significant difference in Hs 683 RNA 260/280 ratios between cell 
batches (TRIzol and neat lysate volume analysed only), p = 0.027 (mean 1.97, SEM 
0.006). Alternatively, there was no significant difference in Hs 683 RNA 260/230 
ratios between cell batches, p = 0.153 (mean 2.02, SEM 0.056). There was also a 
significant difference in SaOS-2 RNA 260/280 and 260/230 ratios between cell 
batches (TRIzol and neat lysate volume analysed only), p = 0.004 (mean 1.99, SEM 
0.011) and p = 0.005 (mean 1.88, SEM 0.101), respectively. RNA purity and 
integrity was therefore not consistent between cell batches. 
The same samples (assessing variability between cell batches) were additionally 
analysed by Alu PCR (Figure 5.9). A significant difference was observed for both 
cell lines and all sample types (pre-DNase, post-DNase and post-RT) in Alu signal 
between both different cell batches and between extraction replicates (extracted 
neat with TRIzol only), all p < 0.001. A significant interaction was also seen 
between the two factors (cell batch and extraction replicate) for post-DNase 
samples (both cell lines) and post-RT samples (SaOS-2 measured only), all p < 
0.001. However, there was no significant interaction between the terms observed 
for the pre-DNase samples (SaOS-2 measured only), p = 0.618.  
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Figure 5.9 Alu PCR analysis of different cell batches. Different cell batches extracted using 
TRIzol. Total RNA was subjected to Alu PCR. (A) Hs683 cell-derived RNA, post-DNase 
treatment only. (B) SaOS-2 cell-derived RNA. Error bars SEM.  
0
5
10
15
20
25
Batch 1 Batch 2 Batch 3
A
ve
ra
ge
 C
q
0
5
10
15
20
25
Batch 1 Batch 2 Batch 3
A
ve
ra
ge
 C
q
A
B
Chapter 5 Evaluation of the Impact of Extraction Protocol on Target Quantification 
Page 180 
To further assess gDNA contamination, Alu PCR Cq data was converted to genome 
equivalents (assuming 1.0E+06 copies Alu/genome, weight of diploid genome 6.6 
pg and therefore 1.52E+09 copies Alu/10 ng), (Figure 5.10). Alu signal increased 
in post-RT samples as any Alu transcribed into RNA will be converted to cDNA 
(Figure 5.10B).  
For Hs 683 samples there was a significant difference in genome equivalents 
between cell batches, p = 0.0172 (single-factor ANOVA, Figure 5.10A). There was 
also a significant difference in genome equivalents for SaOS-2 samples between 
cell batches and stage of treatment (pre-DNase, post-DNase and post-RT), p < 
0.001 for both factors (two-factor ANOVA, Figure 5.10B). Additionally, there was a 
significant interaction between the two terms (batch and treatment stage), p < 
0.001. Post-DNase evaluation shows the degree of gDNA removal from the samples 
was substantial.  
These data suggest that the TRIzol extraction method is not consistent between 
replicates and that different cell batches contribute significant variability to RNA 
extraction yields, which may in turn contribute significant error to downstream 
applications.  
5.4 Conclusions 
These data clearly demonstrate differing yields between extraction methods for 
the recovery of total RNA. For neat lysates, TRIzol yielded more RNA than either 
RNeasy or MasterPure kits, while both TRIzol and RNeasy extracted the most pure 
RNA and had the most efficient removal of gDNA contamination. Dilution did not 
significantly impact RNA yields, suggesting that extraction efficiencies remained 
linear across this dilution range (except for the TRIzol kit when extracting SaOS-2 
cells). However, linearity was influenced by cell type. Nanodrop quality estimates 
were also influenced by dilution. Quantity estimates were linear for each of the 
different metrics and were higher from the Nanodrop and Qubit metrics than the   
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Figure 5.10 Alu PCR cell batch analysis: genome equivalents. Alu PCR analysis of different 
cell batches. gDNA measured by qPCR was converted to genome equivalents. (A) Hs683 cell-
derived RNA, post-DNase treatment only. (B) SaOS-2 cell-derived RNA. Error bars 95% CI.  
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Bioanalyzer. However, the Bioanalyzer quality assessments by RIN values were in 
concordance with the Nanodrop 260/280 ratios and generally good quality RNA 
was extracted. Precision estimates were dependent on cell line, with Hs 683 RNA 
measurements decreasing in precision (increasing CV), as lysates were diluted and 
SaOS-2 precision estimates appearing to be random across dilutions.  
The differences observed may be due to a number of factors including the potential 
of losing the RNA pellet (in relevant methods) and the ability of the extraction kit 
and/or quality metric to cope with sample contaminants. Furthermore, despite 
extracting samples with cell counts lower than the recommended maximum for 
each kit, it appears that some methodologies may be hindered by the extraction of 
neat lysates (MasterPure) and that they may benefit from a dilution of cell count 
within the lysate prior to extraction in order for that extraction to be more 
efficient. This may be due to matrix effects or simply the amount of cell debris. 
However, making such dilutions may hinder the measurement of rare, low 
abundance targets as it could adversely affect measurement sensitivity. This 
should be considered when choosing which extraction method to use for a 
particular sample type and downstream application. Furthermore, despite 
normalisation for cell count, different Hs 683 cell batches generated different RNA 
yields and variable RNA purity and integrity estimates, which may be attributable 
to both sample and extraction variability (TRIzol).  
The Alu PCR data suggests that DNase treatment efficiency is at least partly 
dependant on matrix effects derived from the extraction method used. Co-purified 
contaminants and extraction buffer compounds (notably used in the MasterPure 
kit) may have inhibitory contributions to the efficiency of gDNA removal. The same 
matrix inhibition may also affect the efficiency of the Alu PCR. The SPUD assay, 
utilising an artificial target spiked into the sample and designed to measure Cq 
differences can be used to determine the extent of inhibition [155] but it is unlikely 
to be representative of the Alu element.  
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Despite the differences observed between extraction kits, each one was capable of 
extracting sufficient RNA quantity of acceptable quality for downstream 
applications such as RT-qPCR, suggesting RNA yield and quality is unlikely to be a 
limiting factor for any of the extraction kits analysed. However, for downstream 
applications requiring higher amounts and/or quality RNA, such as NGS 
[265,290,291], careful consideration of extraction method must be made before 
proceeding to ensure optimal RNA is prepared. Propagation of the variability 
observed between kits and metrics should be accounted for in downstream 
analyses.  
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6 The Influence of Sample Type on Measurement 
Variability 
6.1 Introduction 
There is a plethora of studies detailing the variability in particular measurement 
parameters [74,76-78,88,90,112,183,278,292,293] (such as stress-inducing 
treatments in cell lines including hypoxia and drug administration). For an 
appreciation of the applicability of such studies to basic research, as well as the 
wider scope of potential biomarkers, preclinical studies and in some cases, 
successful translation of these findings to a clinical setting, the specific samples in 
question must be evaluated on an experimentally specific basis. That is to say, 
experimental findings cannot be inferred to a different experimental set-up 
without direct empirical evidence. This of course depends on what level of 
precision is required for a particular experiment, be it large fold-changes over 
several orders of magnitude (HIV viral load [108]), or small copy number 
variations (HER2 amplification in breast cancer [223]). The key point is that the 
correct variability must be captured in order to make clinically relevant and 
important assertions.  
Biologically relevant findings can be facilitated by the use of experimentally 
specific, validated reference genes. However, conclusions based on inappropriate 
(particularly single) reference genes that have not been validated for a particular 
sample set, may be erroneous. The continued use of GAPDH as a normaliser 
(without testing the assumption that it may be a suitable reference gene), despite 
years of evidence of its variable expression in a range of circumstances 
[47,131,142-146], is a clear example of where the utilisation of normalisation 
bestows confidence in a result that is fundamentally misplaced due to the 
inappropriate use of an otherwise powerful strategy. This is as damaging (if not 
more so) to data credibility as the application of no reference gene normalisation 
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strategy at all. A critical aspect therefore for relevant translation of data and 
methodologies, is the application of appropriate and effective normalisation.  
Findings from a given controlled experiment should be shown to reflect “real-life” 
scenarios before their applicability to such scenarios can be asserted. One of the 
principal sources of variability in molecular measurements is the sample itself. The 
application of experimentally specific and validated reference genes allows 
technical variability to be unpicked from biological variations. This permits an 
evaluation of the true biological impact of the experimental parameters (such as 
drug treatment or clinical intervention). However, use of inappropriate reference 
genes may introduce measurement bias and may influence the final outcome. 
Furthermore, what the sample is composed of and where and how it is sourced 
contributes often unpredictable variations to the final measurement result.  
Across disciplines, researchers analyse different sample types while employing the 
same types of measurements. The challenge is to highlight where the differences 
are introduced and how methods may be best used in a reproducible and robust 
manner so that despite analysing different sample types, the techniques are 
standardised to perform effectively within a study and between different studies. 
For RT-qPCR-based studies, gross variability in mRNA measurement may be 
standardised by controlling experimental details such as cell numbers, media, RNA 
quantity used for RT, rigorous experimental protocol, appropriate controls and 
standardised storage, handling and processing procedures. For smaller 
variabilities, appropriate normalisation strategies are needed. Material complexity 
ranges from a pure, single RNA target (from IVT), to a mixed mRNA population 
from a single primary cell line, cellular co-cultures or tissues in vivo. One might 
expect the level of error introduced increases from a pure, single RNA target, to a 
2D cell model, to a 3D cell model and finally to a clinical scenario, as the level of 
sample complexity increases. 3D cell models are used as they enable cells to be 
cultured in a manner more representative of their in vivo environment and as such, 
observed responses may be more biologically relevant [294]. Cell models are used 
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to inform on the clinical situation, and as such how representative they are in 
terms of error must be delineated. For bone there are multiple culture systems in 
use including cell lines [232,295-298], co-cultures [234,299-301], explants, 
isolation of primary cells from tissue – primary cells [294,301-303] and 3D cell 
scaffolds [304-307]. 
In this chapter, different sample types and sources were assessed to determine 
their influence on such variability in the final measurement result. The 
experimental approach used a series of simple (cell line) to complex (human 
tissue) samples of bone to investigate our normalisation strategy and the influence 
of changing different parameters, such as cell passage, addition of stimuli, or 
anatomical position, to determine the variability contributions of these factors. A 
2D cell model was used to evaluate the effect of cell passage and mineralisation on 
total RNA yields. A 3D co-culture model was used to evaluate the effect of cell 
batch, mechanical loading and RT on total RNA yields and specific mRNA levels. 
Bone cores from surgical total knee replacement (TKR) patients were used to 
evaluate the effect of patient, anatomical position and RT on total RNA yields and 
specific mRNA levels.  
This study makes use of osteoblasts and osteocytes. These cells, along with 
osteoclasts, are involved in bone formation and remodeling. Bone is a highly 
dynamic organ that is constantly undergoing remodeling and growth [308]. New 
bone is formed by osteoblasts (found near the bone surface) [308,309], which 
secrete osteoid, an unmineralised portion of immature bone matrix rich in collagen 
[308,310]. Osteoblasts then secrete alkaline phosphatase to create sites for calcium 
and phosphate deposition, allowing crystals of bone mineral to form [311]. 
Mineralisation of osteoid results in new bone formation. Osteoclasts are 
responsible for bone resorption. They travel to specific sites on the surface of bone 
and secrete acid phosphatase, which unfixes the calcium in mineralised bone to 
break it down [311]. Osteocytes are osteoblasts that have become trapped in the 
bone matrix and are no longer located at the bone surface. They are involved in 
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homeostasis [311] and act as mechanosensors and orchestrators of the bone 
remodeling process [308,312-315]. Mechanosensor activity, a capacity to detect 
mechanical pressures and loads, helps the adaptation of bone to daily mechanical 
forces [308,316-318]. Osteocyte cytoplasmic processes (up to 50 per cell) are 
connected to other neighboring osteocytes processes, as well as to cytoplasmic 
processes of osteoblasts, facilitating the intercellular transport of small signaling 
molecules among these cells [308]. The mechanosensitive function of osteocytes is 
possible due to this intricate network, which allows communication among bone 
cells [308].  
The aims of these experiments were to apportion variability contributions to 
different steps in the experimental process, to determine where the sources of 
error were largest and whether the error sources were different for different 
sample sources (2D cell culture, 3D co-culture and clinical samples) or transcripts 
(endogenous versus synthetic). Assessing three different systems enables 
determination of how the complexity of the sample source affects the variation. 
This will attribute weight to individual steps in terms of contribution to whole 
process variability and help inform future studies.  
6.1.1 2D Culture Model 
Firstly, SaoS-2 cell line was evaluated for differences in RNA yield and variability 
contributions introduced following mineralisation. This highly characterised, 
osteoblastic cell line has a mature osteoblast phenotype with high levels of alkaline 
phosphatase activity [204] and was selected because of its well-known ability to 
mineralise in culture, forming a calcified matrix typical of woven bone in vivo 
[204,205].  
Differentiation is a transforming event that can have a substantial impact on 
transcriptomic profiles [319-325]. Indeed, transcriptomic profiles also change in 
order to initiate differentiation [319,320]. It is a key-step in many fields of cell 
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profiling and as such investigations into the variabilities associated with this step 
are vital for meaningful comparisons to be made. In this study, bulk changes were 
evaluated rather than evaluating changes at a single cell level. The transcription 
factors released by individual cells may have an impact on the mass population 
and these are the variabilities we concentrated on. Utilisation of the osteoblastic 
cell line SaOS-2 alleviates the difficulties of RNA extraction from whole bone and 
offers the additional benefit of being able to mineralise in culture [204,205]. This 
2D mineralisation model also represents the simplest model of a bone-forming 
osteoblast employed in this chapter.  
6.1.2 3D Co-Culture Model 
A 3D co-culture model system for osteocyte/osteoblast interaction is more 
representative of physiological conditions than the 2D cell line. Within the body, 
cells grow in a 3D environment, which itself will have a known impact on their 
development and potential mRNA profiles [326-328]. Indeed osteocytes in vivo 
only exist embedded within the 3D bone matrix. Not only does the 3D-gel co-
culture model more closely mimic the in vivo environment than a conventional 2D 
culture system, but it also allowed an investigation of the impact of a different 
stimulation (mechanical loading) on mRNA levels and associated error. Osteocytes 
are the mechanosensitive component of the system and their response to loading 
direct the expression changes in osteoblasts and therefore the regulation of bone 
formation [308]. For this reason, a 3D co-culture model allows the interaction 
between the two cell types to play out in response to mechanical stimuli and 
informs on the equivalent situation in vivo [234]. Comparison of this model with 
clinical samples will help determine the applicability of the 3D co-culture model 
error propagation to accurately represent what happens in vivo.  
The aim was to measure mRNA level variabilities induced by mechanical loading 
forces on the 3D gel co-culture model system, similar to those experienced by load 
bearing bones in the body. Mechanical loading models are important for 
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understanding the mechanisms involved in various common musculoskeletal 
diseases including osteoarthritis and osteoporosis [233,234,329]. Appreciation of 
variability contributions in mRNA quantification using this model will allow 
utilisation of these data to their full potential in interpretation of biological 
mechanisms relevant to these important diseases.  
6.1.3 Clinical Samples 
The final stage in these investigations was to evaluate the most complex model 
employed in this chapter, human tissue in vivo, and applies the sTCM in their 
analysis. For this purpose, a clinical cohort of bone core samples were retrieved 
from the tibial plateau region of the knee joint that reflected altered mechanical 
loading from patients undergoing TKR surgery for osteoarthritis (2.7.3 Clinical 
Samples – Total Knee Replacement Bone Cores). These patients would have 
experienced prolonged unbalanced mechanical loading forces across this region. 
Cores were taken from four different biopsy positions in each patient (AM, PM, AL, 
PL) and assessed by dynamic array RT-qPCR. Samples were evaluated using the 
same markers as used for the 3D gel co-cultures. These clinical samples reflected 
the bone cells in their most complex, but most representative environment.  
Additional to mRNA analysis, 3D gel co-culture samples and clinical bone core 
samples underwent analysis by Alu PCR. RT-qPCR detection of the Alu element has 
been proposed as a new method for normalisation of gene expression data, as a 
measure for the total mRNA fraction [283]. The Alu element is present at more 
than one million copies interspersed throughout the human genome, with up to 
75% of all known genes containing Alu insertions within their introns and/or 
untranslated regions (UTRs) [330]. Therefore, the differential expression of a 
number of genes in the tissues or cells under investigation will not influence the 
abundance of expressed Alu repeats in the transcriptome [283]. Using this method 
may alleviate the time and expense associated with testing and validating a panel 
Chapter 6 The Influence of Sample Type on Measurement Variability 
  Page 191 
of suitable reference genes using an algorithm such as GeNorm [7], and limits use 
of precious, sometimes limiting, sample material.  
6.2 Materials & Methods 
6.2.1 2D Culture Model – SaOS-2 Mineralisation 
Cell culture of SaOS-2 cell line and mineralisation treatment (up to and including 
lysate collection) was performed by Dr Gary Morley, LGC, Teddington. Culture 
details are described in 2.1.2 Cell Lines and 2.7.1 2D Culture Model – SaOS-2 
Mineralisation.  
To assess variability contributions of mineralisation, SaOS-2 cells were analysed at 
two different passages (p33 and p36), cultured under suppliers’ recommended 
conditions (ATCC), and treated with mineralising media (98.8 mL propagation 
media, 1 mL of 0.2 M β-Glycerophosphate (Sigma), 100 mL of 50 mg/mL Ascorbic 
acid (Sigma) and 100 mL of 10-3 M Dexamethasone (Sigma)). Control media 
consisted of propagation media and 1:1000 ethanol. For full details see 2.7.1 2D 
Culture Model – SaOS-2 Mineralisation. Following lysate collection 24 hrs or 1-
week post initiation of mineralisation, total RNA was extracted using TRIzol 
reagent and DNase treated (Chapter 2). All samples were quantified by UV 
spectrophotometry.  
6.2.2 3D Co-Culture Model 
Dr Cleo Bonnet (Cardiff University) performed all 3D co-culture work preceding 
total RNA extraction (2.7.2 3D Co-Culture Model). A mouse osteocyte cell line 
(MLO-Y4 cells) was grown in 3D collagen gels before being layered with human 
osteoblasts (SaOS-2 cells). These 3D co-cultures were prepared in silicone plates 
designed specifically for mechanical loading experiments (2.7.2.3 Mechanical 
Loading of 3D Co-cultures) [234].  
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Three independent experiments were performed using different cell batches 
(three different cryo-banked vials of frozen cell pellets) with three replicate gels 
each for loaded and control treatments in each experiment. Total RNA extraction 
(TRIzol) and DNase treatment were performed as described in 2.7.2.4 TRIzol 
Treatment of 3D Co-cultures.  
6.2.3 Clinical Samples 
Human samples were used, in collaboration with Dr Mason (Arthritis Research UK 
Biomechanics and Bioengineering Centre) at Cardiff University, to gain insight into 
the clinical relevance and power of the TCM for accurate quantification. A 100 
mix of synthetic Unknown 1 ERCC RNA (sTCM) was used as a spike for all samples 
pre-RNA extraction. This enabled an assessment of all stages in the measurement 
process post cell lysis.  
Clinical samples were collected by the Arthritis Research UK Biomechanics and 
Bioengineering Centre (Andrea Longman, Helen Roberts, Deborah Mason, Cleo 
Bonnet) and surgeons (Rhys Williams, Chris Wilson and Sanjeev Argawal) under 
their ethical approval (Research Ethics Committee for Wales, reference number 
10/MRE09/28). There were five patients; one patient had a bilateral TKR and so 
there were six ‘patient’ sample sets in total. All patients were female aged between 
44 and 75 years. Bone cores were extracted in theatre using bone biopsy needles 
and put into cryo-vials containing RNAlater on dry ice. Samples were transported 
frozen (in a nitrogen carrier) and stored at -80ºC until processing.  
Patient and biopsy positional variability contributions were assessed through 
analysis of TKR patient bone cores, taken from anterior medial (AM), posterior 
medial (PM), anterior lateral (AL) and posterior lateral (PL) positions (2.7.3 
Clinical Samples – Total Knee Replacement Bone Cores). Total RNA was 
extracted (TRIzol) and DNase treatment completed.  
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6.2.4 RT-qPCR: Dynamic Array 
For both 3D gel co-culture and clinical bone core sample sets, triplicate RTs from 
each sample were performed and the cDNA was preamplified (2.7.5.1 
Preamplification) before being analysed in duplicate on individual dynamic 
arrays. Preamplification is part of the Fluidigm Biomark dynamic array protocol. 
An assessment of preamplification linearity (evaluating preamplified versus non-
preamplified samples) was performed for each of the assays used, as described in 
2.7.5.2 Dynamic Array Analysis. A six-point, 10-fold RNA dilution series was 
performed, with each undergoing RT. Each cDNA was preamplified and 
subsequently measured (n = 8) by dynamic array qPCR.  
The dynamic array output is a Cq value. The efficiency corrected delta Cq method 
[93] was used to calculate relative quantity values, which were normalised using 
three validated reference genes. Validation of reference genes is described in 
2.3.1.1 Reference Genes. As described previously (2.3 Preparation of 
Transcriptomic Calibration Material (TCM)), sTCM was spiked into all lysates 
pre-extraction, enabling measurement of ERCC synthetic transcripts, providing an 
opportunity to assess the validity of using this synthetic reference gene panel for 
normalisation of mRNA data. In addition to RT-qPCR analysis of reference genes 
and GOI, Alu PCR was performed on post-DNase samples as an additional quality 
metric.  
6.3 Results & Discussion 
6.3.1 Comparison of RNA Yield and Quality from Different Sample 
Sources 
Samples derived from three different sources (2D cell culture with mineralisation 
treatment, 3D gel co-culture with mechanical loading treatment and clinical TKR 
bone core samples from different anatomical positions and different patients) 
underwent extraction of total RNA and yields determined. 2D cell culture samples 
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were evaluated for process precision factors to define the error contributions of 
this phase of the analysis. 3D gel co-culture and clinical bone core samples were 
also analysed by Alu PCR before undergoing assessment by RT-qPCR.  
6.3.1.1 RNA Yield and Precision 
Samples from all sources were first evaluated for total RNA yield and quality 
following extraction, using the Nanodrop.  
6.3.1.1.1 2D Culture Model 
Using two-factor ANOVA (time point versus mineralisation treatment), there was a 
significant difference in total RNA yield between time points for both cell passages 
(both p < 0.02) (Figure 6.1A). For p38 there was a significant difference observed 
in RNA yield between conditions (treatment and control, p = 0.018), as well as a 
significant interaction between the two factors (time point versus condition, p < 
0.0001). For p35 there was no significant difference (p = 0.06) or interaction (p = 
0.349) in RNA yield observed between conditions.  
When considering the condition groups separately (two-factor ANOVA, passage 
versus time point, performed independently for control and treatment samples), 
both the control and treatment groups showed a significant difference between 
both passage and time points, p < 0.0001 for all, meaning that both the passage of 
the cell population and the time post-treatment had a significant impact on the 
RNA yield; yield increased with time post treatment and decreased between p35 
and p38. For the control samples only, there is also a significant interaction 
between the two factors (passage and time point), p < 0.0001, whereas for the 
treatment samples, there is no significant interaction observed, p = 0.127. The 
variability in these measurements was greater for the later passage (older) cells 
(Figure 6.1D): p35 CV range 6.34-40.62%, p38 CV range 35.87-91.99%.   
Chapter 6 The Influence of Sample Type on Measurement Variability 
  Page 195 
 
B
A
C
0	
10	
20	
30	
40	
50	
60	
70	
80	
90	
100	
24	hr	 1	week	 24	hr	 1	week	
p35	 p38	
C
o
ef
fi
ci
e
n
t	
o
f	
V
ar
ia
n
ce
	(
%
)	
Control	 Treatment	
0
20
40
60
80
100
120
1 2 3 4 5 6
A
ve
ra
ge
 Q
u
an
ti
ty
 (
n
g/
µ
L)
0
200
400
600
800
1000
1200
1400
1600
1800
24 hr 1 week 24 hr 1 week
p35 p38
A
ve
ra
ge
 Q
u
an
ti
ty
 (
n
g/
µ
L)
0
20
40
60
80
100
120
Exp 1 Exp 2 Exp 3
A
ve
ra
ge
 Q
u
an
ti
ty
 (
n
g/
µ
L)
Chapter 6 The Influence of Sample Type on Measurement Variability 
  Page 196 
 
Figure 6.1 Total RNA yields. Post-DNase UV quantification, not corrected for cell count or 
tissue weight. (A) 2D culture. Average quantity yields 24 hrs and 1-week post initiation of 
mineralisation for passage 35 and 38. (B) 3D co-cultures. Average quantity yields per 
experiment for loaded versus control samples. (C) Clinical bone cores. Average quantity yields 
per patient. (D) Coefficient of variation (multiple extraction and flask replicates) for 2D culture 
quantity estimates. (E) Coefficient of variation (multiple gels) for 3D co-culture quantity 
estimates. (F) Coefficient of variation (multiple anatomical positions) for clinical bone core 
sample quantity estimates. Error bars SEM (A-C). n = 18 (A&D), n = 9 (B&E), n = 12 (C&F).   
E
D
F
0	
10	
20	
30	
40	
50	
60	
70	
80	
90	
100	
24	hr	 1	week	 24	hr	 1	week	
p35	 p38	
C
o
ef
fi
ci
e
n
t	
o
f	
V
ar
ia
n
ce
	(
%
)	
Control	 Treatment	
0
20
40
60
80
100
120
1 2 3 4 5 6
C
o
ef
fi
ci
en
t 
o
f 
V
ar
ia
n
ce
 (
%
)
0
10
20
30
40
50
60
70
80
90
100
24 hr 1 week 24 hr 1 week
p35 p38
C
o
ef
fi
ci
en
t 
o
f 
V
ar
ia
n
ce
 (
%
)
0
10
20
30
40
50
60
70
Exp 1 Exp 2 Exp 3
C
o
ef
fi
ci
en
t 
o
f 
V
ar
ia
n
ce
 (
%
)
Chapter 6 The Influence of Sample Type on Measurement Variability 
  Page 197 
Variability (CV) in the measurement of 2D culture samples was high, with all but 
two groups being greater than 20%. The variance was significantly different 
between control and treatment groups for p35 at both time points and p38 at 24 
hrs only (all p < 0.001, Ftest). In all three instances, treatment group variability 
was far greater than control group variability, ranging between 2.5 and 5-fold 
higher. There was no significant difference observed between control and 
treatment groups for p38 at 1 week (p = 0.798, Ftest). Increased variability 
attributed to the treatment groups may be as a result of mRNA level changes 
resulting from the treatment itself.  
SaOS-2 cells have been characterised as osteoblastic due to the expression of 
phenotypic markers [331-333] such as alkaline phosphatase (ALP) activity 
(enzyme involved in mineralisation) [332-334], parathyroid hormone-linked 
adenylate cyclase [335], osteonectin production [336], specific receptors for 1,25-
dihydroxyvitamin D 3 [337], and osteogenic potential as assessed in diffusion 
chambers [205]. SaOS-2 cells have also demonstrated an ability to deposit an 
extensive collagenous matrix comprised largely of type I and V collagen, which can 
mineralise with hydroxyapatite-like crystal formation [338,339]. Mineralisation 
will cause a reduction in the number of active osteoblasts via osteocyte formation, 
and a reduction in substrate available for mineralisation as more osteoid becomes 
mineralised.  
The components of the extracellular matrix synthesised by SaOS-2 cells are 
consistent with a normal osteoblastic phenotype. These include collagen types I 
and V, the proteoglycans decorin (a small chondroitin sulfate proteoglycan) and a 
large chondroitin sulfate proteoglycan (CSPG), as well as mRNA encoding bone 
sialoprotein (BSP) and osteonectin [339]. Osteoblasts become embedded in the 
extracellular matrix consisting mainly of type I collagen (ColI), and matrix 
mineralisation begins as mineral deposits extend along and within collagen fibrils 
[338,340]. Once matrix synthesis begins, cells differentiate as genes encoding 
osteoblastic markers such as alkaline phosphatase (ALP, differentiation middle-
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stage marker) [341], osteocalcin (OCN, differentiation late-stage marker) 
[340,341] and osteopontin (OPN, the last in a chronological sequence of markers of 
osteoblastic differentiation) [338,342], are expressed. Factors important for 
osteoblastic differentiation and modulating osteoblast-specific mRNA levels 
include bone morphogenic proteins (BMPs), transforming growth factor (TGF), 
insulin-like growth factor I (IGF-I), vascular endothelial growth factor (VEGF), and 
glucocorticoids [338,343-348].  
Hausser and Brenner [349] previously evaluated phenotypic stability of SaOS-2 
cells over 100 passages. Their study demonstrated that higher passage cells 
exhibited higher proliferation rates and lower specific alkaline phosphatase 
activities with mineralisation significantly more pronounced in cultures of late 
passage cells. They also observed differential expression of some targets between 
early and late passage cells; for example, expression of decorin, a regulator of 
proliferation and mineralisation was strongly decreased in late passage cells. They 
concluded that special care is required when results obtained with SaOS-2 cells 
with different culture history are to be compared [349]. These cells may behave 
differently in certain experimental situations, depending on their culture history. 
Such differences in culture history occur, for example, when the cells are 
propagated in different laboratories [349]. Total RNA yields were not compared 
between different passages.  
The supplier (ATCC) suggested that passaging should not affect RNA yield and 
purity (personal correspondence). However, no citation can be found to support 
this claim. It is possible that this question may not have been directly addressed, as 
most studies focus on target-specific expression levels rather than total RNA 
abundance. It would therefore be a valid approach to assess this parameter in 
future experiments. It has been shown that MSC populations become more 
homogeneous with serial passaging; however, this leads to senescent cell behavior 
and an impaired capacity for multipotent differentiation [350,351].  
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While there was no significant difference observed for p35 cells between control 
and treatment groups in total RNA yield, treatment had a significant impact on 
RNA yield for p38 cells. It is therefore important to capture this variability (and not 
just use the mean quantity value) in order to reflect true error propagation and 
experimental influences. Further work would be required to determine if these 
findings are reproducible and to elucidate whether cell passage (age) has a 
consistent impact on the effect of treatment on RNA yield. While RNA yields were 
not significantly affected by treatment for the earlier passage, p35, this does not 
necessarily reflect expression profiles of mRNA targets and any changes resulting 
from such treatment.  
6.3.1.1.2 3D Co-Culture Model 
Using a two-factor ANOVA (experiment versus gel replicate) there was a significant 
difference observed in RNA quantity between independent experiments and gel 
replicates for both treatment conditions (loaded and control), all p < 0.001 (Figure 
6.1B). Furthermore, there was a significant interaction between the two terms 
(experiment and gel) for both treatment conditions (p < 0.001). These data suggest 
that both cell batch (different experiments) and gel replicates have a significant 
impact on the total RNA quantity variability for these samples. There was no 
significant difference observed in RNA quantity between loaded and control 
sample sets (p = 0.243, control sample mean 55.17 ng/µL, standard deviation 
20.06 ng/µL, loaded sample mean 44.59 ng/µL, standard deviation 42.08 ng/µL), 
suggesting that treatment had no impact on total RNA yield (single-factor ANOVA).  
The 3D co-culture model was assessed according to experiment and treatment 
(Figure 6.1E). The variability (CV) for these sample groups was high, with all but 
one (experiment 3, control) being greater than 35%. The variability was highest 
for experiment 1 groups (loaded and control). This was due to large differences in 
total RNA yield between different gels. In addition, experiment 2, loaded samples 
displayed a low average quantity, mainly attributable to a low total RNA 
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concentration from gel 1. Low concentrations are known to exhibit increased 
variability on measurement (NanoDrop 1000 Spectrophotometer V3.8 User’s 
Manual).  
Total RNA yields varied between samples. This may be explained, as these data 
cannot be normalised to cell count. The top layer, SaOS-2 cells, of the co-culture 
was collected directly in TRIzol reagent and as such, a cell count was not possible. 
However, based on previous studies of this model system, it would be expected 
that the SaOS-2 osteoblastic cells formed a monolayer over the surface of the 
collagen gel [234], and therefore the cell counts might expect to be similar.  
6.3.1.1.3 Clinical Samples  
Two-factor ANOVA (anatomical position versus patient) showed there was a 
significant difference observed in RNA quantity between anatomical position and 
between patients, both p < 0.001. There was also a significant interaction between 
the two terms (position and patient), p < 0.001. This suggests that both anatomical 
position and patient introduce significant variability to total RNA yield 
measurements. However it should be noted that, as for the 3D gel data, a 
normalisation for cell count or tissue weight was not undertaken due to this 
information not being available and so at least part of the variability in these 
measurement values may be due to differing amount of material processed.  
Assessing variability per patient (Figure 6.1F), all sample groups except one 
(patient 6) showed variabilities (CV) greater than 35%. Patient 4 showed the 
greatest variability in total RNA yields, which was attributable to an RNA yield for 
anatomical position AM being almost twice that of any other anatomical position 
for the same patient.  
There was a degree of variability in total RNA yields not only between patients, but 
also between biopsy positions within the same patient. In osteoarthritis 
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development, subchondral bone undergoes an increase in bone turnover 
(remodelling) and an increased thickness and volume, but is weaker and less 
mineralised than normal bone (hypomineralisation due to abnormal bone 
remodeling, reducing its stiffness) [352-359]. These changes result in altered 
apparent and material density of bone that may adversely affect the joint’s 
biomechanical environment [356,358]. Bone attrition, a depression or flattening of 
the bony surface, represents remodelling of the subchondral bone envelope, 
leading to a consequential change in bone shape and/or bone loss [356]. With 
alterations in its properties, subchondral bone may be less able to absorb and 
dissipate energy, thereby increasing forces transmitted through the joint and 
predisposing the articular surface to deformation [356]. As a result, it is likely that 
the amount of bone (density/cellularity) retrieved from these osteoarthritis 
patients varied within the same biopsy volumes, which may go some way to 
explaining the variability in total RNA yields.  
Clinical bone core samples were stored at -80ºC in RNAlater immediately following 
collection during surgery and required thawing to remove excess RNAlater before 
being frozen on dry ice and subjected to the standard dismembration protocol 
(2.7.3.1 Dismembrator). As a result, the yield data could not be normalised 
according to the weight of the cores collected. This was unavoidable due to the 
constraints of collecting during surgery and efforts to preserve RNA. In the future, 
procedures could be put in place to make such weight measurements viable on 
collection. This is important because a portion of any observed variability may be 
due to differing amounts of starting material.  
It is difficult to compare total RNA yield between sample sources as not all sources 
can be normalised for cell count and different factors are contributing to the 
variability in each. However, it is clear from all three sources that RNA extraction 
yields show a degree of variability, which increases as yields diminish.  
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In order to assess how sample complexity affects variability, total RNA quantities 
were pooled (all data at all replication levels; therefore process variability 
included) for all samples per data set (2D cell culture, 3D gel co-culture and clinical 
bone cores). Measurement variabilities (CV) were estimated as 78.88%, 66.33% 
and 64.03%, respectively. These data suggest that the least complex model, the 2D 
cell culture, has the greatest variability between samples, while the 3D co-culture 
model and clinical bone core samples have similar variability. However, the 2D cell 
culture experiment included twice as many samples as either of the other two 
models (48 samples, n = 144 due to triplicate A260 measurements per sample. 3D 
gel co-culture: 18 samples, n = 54. clinical bone cores: 24 samples, n = 72). When 
evaluating the two cell passages included in the 2D cell culture experiment 
independently (24 samples, n = 72), measurement variabilities (CV) were 
estimated at 57.63% and 98.00% for p35 and p38, respectively. This agrees with 
the findings above that the older cells (p38) display greater variability in RNA 
yields. This needs further investigation to determine whether it is an anomaly in 
these data or is in fact reproducible, and that cell passage has an impact on RNA 
yield precision. Considering p35 variability alone, these data suggest that 2D cell 
culture variability is lowest and sample complexity is positively correlated with 
RNA yield variability; as sample complexity increases, so does measurement 
variability of extracted total RNA. The total RNA yields were greatest for the 2D 
model samples; followed by the clinical bone cores, with the 3D co-culture model 
returning the lowest total RNA yields (average yields 76.84 ng/µL, 10.86 ng/µL 
and 9.98 ng/µL, respectively, with associated standard errors 5.05, 0.82 and 0.90 
ng/µL, respectively).  
6.3.1.2 RNA Extraction Process Precision Factors 
2D cell culture samples were assessed for variability contributions from sample to 
extraction (Figure 6.2).  
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Figure 6.2 SaOS-2 mineralisation process precision contributed by different factors. 
Nanodrop quantification variability contributions were apportioned to experimental factors in 
the measurement process, displayed as control versus treatment for two different cell 
passages (p35 and p38).  
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Average variability contributions to nanodrop RNA quantification were highest for 
flask replicates (65.1%), followed by time point (34.3%), with the lowest 
contribution from extraction replicates (0.56%).  
These data suggest that the TRIzol extraction replicates in this experimental set-up 
were highly robust and reproducible, adding little variability to the final RNA 
quantity measurement. Flask replication contributed the greatest variability to the 
final measurement followed by time point and as such these factors should be 
considered as points of replication in similar experimental set-ups. This will 
ensure variability contributions are taken into account when interpreting 
measurable changes and results are therefore less likely to become biased. The 
next step in the analysis of these samples would be to measure specific mRNA 
changes of suitable GOI targets to discern whether the magnitude of these 
variability contributions are maintained in the RT-qPCR data and if there are 
target-specific influences.  
6.3.1.3 Alu PCR 
All 3D gel co-culture and clinical bone core RNA samples were evaluated post 
DNase treatment using Alu PCR as an additional metric for sample quality and 
measure of gDNA contamination.  
6.3.1.3.1 3D Co-Culture Model  
Using two-factor ANOVA (condition versus gel replicate, for each independent 
experiment), a significant difference was observed in Alu signal between replicate 
gels and between treatment conditions for all cell batch replicate experiments (all 
p < 0.0001), except for between treatment conditions for experiment 1 only (p = 
0.085) (Figure 6.3A). There was also a significant interaction observed between 
the factors (condition and gel replicate) for all cell batch replicate experiments (all 
p < 0.006).   
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Figure 6.3 Alu PCR expression. The extracted total RNA was analysed for Alu element 
expression post-DNase treatment. (A) 3D gel cell batch variability, gel replicate variability 
captured within condition, n = 9. (B) Clinical bone core patient variability, n = 18. (C) Clinical 
bone core anatomical position variability, n = 12. Error SEM.   
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6.3.1.3.2 Clinical Samples  
A two-factor ANOVA (anatomical position versus patient) showed a significant 
difference in Alu signal between different positions and between individual 
patients (all p < 0.0001), Figure 6.3B & C. Similarly, a significant interaction was 
measured between the two factors (position and patient), p < 0.0001.  
6.3.2 Comparison of mRNA Expression Variability from Different Sample 
Sources 
6.3.2.1 Preamplification 
In order to show the applicability of using a preamplification step in the dynamic 
array protocol, a dilution series of samples with and without preamplification were 
evaluated on an additional dynamic array. This allowed assessment of the linearity 
of preamplification across the dilution range for each of the assays used. The 
accuracy and precision of qPCR detection for each target was assessed by linear 
regression, comparing the slope and R2 of the data to the starting concentration of 
RNA (Table 6.1). Using single-factor ANOVA (non-preamplified slopes versus 
preamplified slopes for all assays), there was a significant improvement in the 
slope of the linear regression of Cq versus quantity value (p = 0.032), with the 
mean slope of preamplified targets within 5% of the ideal slope of 1.  
The Pearson’s correlation for Cq of preamplification versus no preamplification 
subsets (per assay) was calculated. Sixteen (of 17) assays had data for more than 
two of the non-preamplified standard dilutions, allowing this comparison to be 
made. Eight out of the 16 assays had coefficients ≥ 0.94 (Table 6.1). There were 
four assays that were poorly correlated, HPRT1, MMP1, PPIA and RPLPO. It may be 
expected that both MMP1 and RPLPO would perform poorly in this assessment as 
both were expressed at low levels and so an accurate evaluation of expression 
levels in the non-preamplified samples was difficult to obtain. PPIA has been used 
as an endogenous reference gene for normalisation of both 3D gel co-culture and   
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Table 6.1 Accuracy and Precision between PreAmplified and Non-PreAmplified cDNA. A 
six-point RNA standard curve was generated using 10-fold serial dilutions of Calibrant. Each 
dilution point underwent RT. Of the cDNA produced, a proportion was reserved (non-
preamplified), while the rest was subject to preamplification using all target assays. All 
samples for each preamplified and non-preamplified standard curve were analysed by 
dynamic array qPCR (n = 8). Linear regression was performed with Cq values versus 
log2(quantity) for each target. Pearson’s correlation was performed between preamplified and 
non-preamplified Cq data.  
Assay 
Slope R2 
Correlation No 
PreAmp 
PreAmp 
No 
PreAmp 
PreAmp 
B2M -0.66 -1.31 -0.99 -0.95 0.99 
CASC3  -0.54  -0.91 1.00 
GAPDH -0.66 -0.98 -0.95 -1.00 0.95 
HPRT1  -0.92  -1.00 -0.15 
MMP1  -1.13  -1.00 -0.79 
PPIA  -1.04  -1.00 -0.30 
RPLPO  -1.15  -1.00 -0.19 
SLC1A3  -0.79  -1.00  
TBP  -1.03  -0.99 1.00 
UBC -0.43 -0.90 -0.87 -0.99 0.83 
YWHAZ -0.41 -0.96 -0.82 -0.99 0.81 
ERCC-13 -0.84 -0.94 -1.00 -1.00 0.94 
ERCC-25 -1.02 -0.97 -1.00 -1.00 1.00 
ERCC-42 -1.00 -0.93 -1.00 -0.99 1.00 
ERCC-99 -0.40 -0.70 -0.80 -0.83 0.78 
ERCC-113 -1.28 -0.93 -0.98 -1.00 0.70 
ERCC-171 -0.77 -0.95 -1.00 -1.00 1.00 
Average -0.75 -0.95 -0.94 -0.98 0.92 
PreAmp = preamplification 
  
Chapter 6 The Influence of Sample Type on Measurement Variability 
  Page 208 
clinical bone core data sets. It is unclear why PPIA and HPRT1 assays performed 
poorly in this assessment. The Cq values generated for the non-preamplified 
samples were not linear. It may be that the stability of the cDNA was compromised 
during storage (having a greater impact on low abundance targets as a proportion 
of the total number of low copy molecules) and so did not provide an ideal target 
for qPCR amplification of the non-preamplified samples. This was not observed for 
the preamplified samples suggesting the amplicons generated in the 
preamplification may have provided a more stable and more easily amplifiable 
template for the qPCR. In addition, the low variability observed for the 
preamplified samples highlights the variability between samples. Inhibition may 
also be a factor in the observed difference. It is not known to what extent inhibition 
may have affected the amplification of these targets and whether or not the 
preamplified and non-preamplified targets were affected to the same degree. 
Inhibition evaluation was not performed as part of this study, however, future 
studies may address this concern by evaluating different target concentrations and 
measuring a dilution series to determine the influence of reversible inhibition and 
matrix components [155].  
6.3.2.2 Reference Gene Determination 
As detailed in the introduction to this thesis (Chapter 1), for accurate 
normalisation of mRNA data, reference genes should be validated experimentally 
for specific sample sets [132].  
6.3.2.2.1 3D Co-Culture Model 
Using the RefFinder program, dynamic array Cq data was evaluated for the 
selection of endogenous reference genes appropriate for the 3D gel co-culture 
sample set (Figure 6.4A). PPIA, GAPDH and YWHAZ were selected with geometric 
mean of ranking values of 1.57, 3.13 and 3.25, respectively. This ranking value in 
and of itself does not give an indication of how stable a reference gene is, just a 
ranking of stability relative to the other potential reference genes analysed.   
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Figure 6.4 Comprehensive gene stability, generated from RefFinder output. Average 
expression stability values for assessed candidate reference genes. Targets showing 
expression in all samples (3D gel or bone core) were included (from dynamic array RT-qPCR 
data set). (A) 3D gel co-culture sample assessment. (B) Clinical bone core sample assessment. 
Based on the rankings from each program (GeNorm [7], Normfinder [137], BestKeeper [226] 
and the comparative ΔCt (Cq) method [227]), individual genes are assigned an appropriate 
weight and the geometric mean of their weights is calculated for the overall final ranking. 
Starting from the most stable gene at the left, genes are ranked according to decreasing 
expression stability, ending with the least stable genes on the right.   
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However, the RefFinder program does provide a summary of the analysis from 
each of the programs utilised in the evaluation (GeNorm [7], Normfinder [137], 
BestKeeper [226] and the comparative ΔCt (Cq) method [227]). The GeNorm 
program evaluates the stability of the applied reference genes (and hence the 
reliability of the normalisation) by calculating the GeNorm stability M-value for 
each of the potential reference genes analysed [360]. The lower the M-value, the 
more stably the reference genes are expressed in the tested samples. M-values 
lower than 0.5 are typically observed for stably expressed reference genes in 
relatively homogeneous sample panels. For more heterogeneous panels, M-values 
can increase to 1 [360]. M-values greater than 1.5 are considered as unacceptable 
levels of expression variability [7]. For the reference genes selected for the 3D gel 
co-culture sample set, the M-values were 0.079 (PPIA), 0.068 (GAPDH) and 0.084 
(YWHAZ). This suggests that all three selected reference genes were stable and 
therefore suitable for normalisation.  
As discussed in 1.3.1.6.2 Internal Reference Genes, GAPDH may be used as an 
appropriate normaliser under validated conditions.  
6.3.2.2.2 Clinical Samples 
As for the 3D gel co-culture sample set, appropriate reference genes were selected 
for the clinical bone core samples using dynamic array Cq data input to the 
RefFinder program (Figure 6.4B). On this occasion, PPIA, YWHAZ, and UBC were 
selected as suitable reference genes with geometric mean of ranking values 1.86, 
2.34 and 2.91, respectively. The selected reference gene M-values for the clinical 
bone core sample set were 0.012 (PPIA), 0.012 (YWHAZ) and 0.022 (UBC). These 
M-values suggest that all three selected reference genes were stable and therefore 
suitable for normalisation.  
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6.3.2.3 mRNA Quantification Process Precision Factors  
3D gel co-culture and clinical bone core samples were individually assessed for 
variability contributions from sample to mRNA target quantification. This analysis 
was performed using Cq values without any normalisation in order to determine 
the magnitude of variance contributions at the different stages of analysis. As the 
role of normalisation is to remove much of this variability these differences cannot 
be easily determined once normalisation has been applied. This approach allows 
an assessment of where the most benefit would be obtained from replication, i.e. 
steps contributing the most variability would benefit most from increased 
replication. This provides a better estimation of the variability of the whole 
experiment. Once variance contributions have been determined, the impact of 
normalisation can be assessed.  
6.3.2.3.1 3D Co-Culture Model 
For the 3D gel samples (Figure 6.5), the average variance (as a percentage of the 
total) across all targets was greatest in both the control and loaded samples for the 
Gel factor (49.1% and 41.2%, respectively) and lowest for the Experiment factor 
(25.4% and 28.5%, respectively). When considering the ERCC (synthetic) targets 
only (Figure 6.5L-P), the average variance was greatest in both the control and 
loaded samples for the Gel factor (50.6% and 54.9%, respectively) and lowest for 
the RT factor (11.9% and 13.3%, respectively). However, when considering the 
average variance of only the endogenous targets (Figure 6.5A-K), the greatest 
contributing factor for control samples was again Gel replicate (48.4%), but for 
loaded samples it was RT (37.7%). The lowest variability-contributing factor was 
Experiment for both control and loaded samples (19.9% and 27.4%, respectively).  
6.3.2.3.2 Clinical Samples 
For the clinical bone core samples (Figure 6.6), the average variance (as a 
percentage of the total) across all targets was greatest for the patient factor   
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Figure 6.5 3D Gel co-culture process precision contributed by different factors. Cq 
variability contributions for different transcript targets were apportioned to experimental 
factors in the measurement process for 3D Gel co-culture samples, displayed as loaded versus 
control treatments. (A) B2M (B) CASC3 (C) GAPDH (D) HPRT1 (E) NES (F) PPIA (G) RPLPO (H) 
SLC1A3 (I) TBP (J) UBC (K) YWHAZ (L) ERCC-13 (M) ERCC-25 (N) ERCC-99 (O) ERCC-113 and 
(P) ERCC-171.   
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Figure 6.6 Clinical bone core process precision contributed by different factors. Cq variability contributions for different transcript targets were 
apportioned to experimental factors in the measurement process for 3D clinical bone core samples. (A) Endogenous targets (B) Synthetic targets.  
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(43.3%) and lowest for the RT factor (28.1%). When only synthetic ERCC targets 
were compared (Figure 6.6B), again the lowest variance attributed was to the RT 
factor (14.5%) and the greatest variance was attributed to the patient factor 
(45.6%). However, when only endogenous targets were considered (Figure 6.6A), 
the patient factor contributed the most variability (42.3%), while anatomical 
position contributed the least (23.5%). 
6.3.2.4 Comparison of Factor Variability  
Following assessment of process precision factors and validation of reference 
genes appropriate for normalisation of each sample set, dynamic array RT-qPCR 
data was normalised and RQ values (relative to sTCM calibrant) compared to 
determine experimental differences. In this context, ERCCs are not being used as 
normalisers. By normalising them to the validated endogenous reference genes, we 
can assess if they remain stable and therefore whether they would be suitable as 
normalisers.  
6.3.2.4.1 3D Co-Culture Model 
3D co-culture samples were normalised to the geometric mean of three reference 
genes: PPIA, GAPDH and YWHAZ (as determined above, 6.3.2.2 Reference Gene 
Determination).  
There was a significant difference observed in normalised RQ values between 
loaded and control samples for all synthetic targets (all p < 0.02, single-factor 
ANOVA). There was an average 42-fold difference between control and loaded 
normalised RQ values for the ERCC targets, with control values being lowest. The 
levels of these synthetic targets should remain constant, as they were spiked into 
samples post-stimulation and it is therefore not possible to alter their regulation in 
response to mechanical loading. Alternative hypotheses for the deviation in 
synthetic target normalised RQ values post-treatment may include the influence of 
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changes to the extracellular matrix in response to mechanical loading [361]. The 
observed effect may be due to factors specifically pertaining to the synthetic origin 
of the ERCC targets, which are not shared by the endogenous targets. It is also 
possible that endogenous targets may be protected by cellular mechanisms, not 
available to the synthetic targets. It therefore brings into question the suitability of 
the ERCC transcripts for normalisation purposes in such an experiment.  
Single-factor ANOVA was used to compare loaded versus control sample data 
individually for each target (Figure 6.7). There was no significant difference in 
normalised RQ values between loaded and control samples for all but three of the 
endogenous targets analysed (all p > 0.08). For three endogenous targets, GAPDH, 
PPIA and SLC1A3, there was a significant difference observed between loaded and 
control data sets (p = 0.027, 0.003 and 0.0003, respectively). SLC1A3, the only GOI 
detected with sufficient expression, was therefore shown to be influenced by 
mechanical loading in this experiment. There was a 33-fold difference between 
loaded and control normalised RQ values for SLC1A3, with loaded values being 
lowest. This finding is in concordance with previous studies demonstrating the 
down-regulation of SLC1A3 (also known as EAAT1 and GLAST) in response to 
mechanical loading [210,362].  
Data was analysed further using two-factor ANOVA of gel versus RT for all targets 
individually and each condition (loaded and control) separately. For all targets and 
both conditions (except B2M loaded p = 0.074 and RPLPO control p = 0.066) there 
was a significant difference in normalised RQ values between gel replicates (all p < 
0.04). All targets under both conditions showed a significant difference in 
normalised RQ values between RT replicates (all p < 0.035), except for TBP, both 
loaded and control samples (p = 0.134 and 0.178, respectively) and ERCC-25 and -
99, for loaded samples only (p = 0.156 and 0.086, respectively). There was no 
significant interaction observed for any target between the two factors (gel and RT 
replicates) for either condition (loaded or control), all p > 0.06, except for CASC3,   
Chapter 6 The Influence of Sample Type on Measurement Variability 
  Page 217 
 
Figure 6.7 3D co-culture treatment variability. Normalised RQ distributions for control 
versus mechanically loaded 3D gel co-cultures. (A) B2M, representative of no significant 
difference between conditions (B-D) display a significant difference between loaded and 
control treatment samples (B) GAPDH (C) PPIA (D) SLC1A3. Error bars SEM, n = 54. Single-
factor ANOVA (loaded versus control) p-values: (A) B2M = 0.702, (B) GAPDH = 0.027, (C) PPIA 
= 0.003 and (D) SLC1A3 = 0.0003.  
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TBP and UBC control samples only and YWHAZ loaded samples only (p = 0.003, 
0.045, 0.008 and 0.017, respectively).  
Gel was determined to be the greatest contributor to whole process variability and 
so it is not surprising that significant differences were observed between gel 
replicates. Such large variabilities in sample measurements are not conducive to 
measurements of small fold changes.  
Data were analysed using two-factor ANOVA of experiment versus RT for all 
targets individually (Figure 6.8). For all targets except one (RPLPO, p = 0.101, 
Figure 6.8A versus B) there was a significant difference in normalised RQ values 
between experiments (all p < 0.002). All synthetic targets (ERCCs, Figure 6.8F 
versus E) and one endogenous target (TBP, Figure 6.8D versus C) showed no 
significant difference in normalised RQ values between RT replicates (all p > 0.1). 
All other endogenous targets (B2M, CASC3, GAPDH, HPRT1, PPIA, RPLPO, SLC1A3, 
UBC and YWHAZ) showed a significant difference in normalised RQ values 
between RT replicates (all p < 0.001). There was no significant interaction 
observed for all but one target (B2M, p = 0.001) between the two factors (gel and 
RT replicates), all p > 0.09.  
The larger contribution of RT to whole process variation compared to experiment, 
which had the lowest contribution, is represented in Figure 6.8A & B for target 
RPLPO. From the plot presented according to replicate experiments (Figure 6.8A), 
it is clear that there was no observable difference across the data set. All 
experimental replicates appeared to have similar normalised RQ values (for this 
particular target). However, when the same data is presented according to RT 
replicate, differences between RT replicates are clear. The trend is matched in the 
loaded and controlled samples for this target data set (RPLPO). These plots nicely 
demonstrate the influence of the RT on whole process variability.  Alternatively, 
the TBP target data displays the opposite scenario, that is, there was a discernible 
trend in normalised RQ values across both loaded and controlled samples   
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Figure 6.8 3D Gel co-culture variability distributions. Normalised RQ variability for 
different transcript targets are displayed as loaded versus control treatments according to 
experimental factors, experiment or RT replicates. (A) RPLPO by experimental replicates (B) 
RPLPO by RT replicates (C) TBP by experimental replicates (D) TBP by RT replicates (E) ERCC-
13 by experimental replicates (F) ERCC-13 by RT replicates. Error bars SEM, n = 18. (A, C & E) 
RT replicates (from the same RNA sample) and gel replicates are pooled and individual 
experimental data is plotted. (B, D & F) RT data combines the gel and experimental replicates 
data. Each of three replicate RTs (from the same RNA sample) is plotted individually.  
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according to experimental replicates (Figure 6.8C), whereas RT replicates 
appeared to remain consistent, with no significant differences measured (Figure 
6.8D).  
The ERCC targets displayed increased variability for the loaded RT replicates 
compared with control samples and experimental replicates (Figure 6.8E & F, 
represents ERCC-13). This may have contributed to the lack of a significant 
difference in normalised RQ values between RT replicates (where significance is 
found in all but one endogenous target, TBP). ERCC-13 data, displayed in Figure 
6.8E & F is representative of all the ERCC targets. It is important to note this 
increase in RT variability for loaded (treated) samples when measuring synthetic 
targets. No increase in RT variability is observed for loaded (treated) samples 
when measuring endogenous targets. Since the synthetic targets were spiked into 
samples after the cells were lysed in TRIzol, their absolute levels should remain 
constant. It is possible therefore, that the treatment of samples (mechanical 
loading) stimulated a change in the sample matrix (change in endogenous mRNA 
and/or protein expression profile), which subsequently affected measurement 
sensitivity when evaluating ERCC targets. It is possible that all extracts were 
affected by sample matrix but that this was hidden in the noisier, endogenous data. 
It is not possible to distinguish between variability contributions from the 
extraction and RT steps using these protocols. However, the ERCC targets could be 
utilised for this purpose in future experiments. Suitable reference genes should 
maintain stable levels, regardless of treatment or matrix effects [47]. It appears 
that for this particular experimental set-up the ERCC synthetic targets are not 
suitable reference genes for normalisation of these data.  
These data suggest that replicate gels are a major contributory factor to whole 
process variance, more so than replicate experiments (within experiment is more 
variable than between experiment). Furthermore, the synthetic ERCC targets do 
not behave in the same way as the endogenous targets, with experiment 
contributing more variability to the measurement of synthetic targets than RT; 
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whereas the opposite is true for endogenous targets (RT is more variable than 
experiment). However, it must be remembered that the synthetic ERCC targets 
were spiked into samples pre-extraction and so cannot accurately represent 
variability contributions in steps prior to this point. Therefore, for the analysis of 
endogenous targets, RT (three RT reactions from each RNA extraction) contributed 
more variability to the measurement than experiment. This is an important finding 
as many cell culture-based studies may replicate an experiment without also 
replicating the RT step. However, it is extremely difficult to ascertain quite how 
significant this problem is due to the poor standards of reporting of RT-qPCR 
technical details [59]. This could lead to an underestimation of the experimental 
error; possibly biased results and potentially measurement claims of fold changes 
smaller than actual capability.  
6.3.2.4.2 Clinical Samples 
Clinical bone core samples were normalised to the geometric mean of three 
reference genes: PPIA, YWHAZ, and UBC (as determined above, 6.3.2.2 Reference 
Gene Determination).  
There was a significant difference observed in normalised RQ values between 
anatomical positions and between patients for all assays (all p < 0.0001, two-factor 
ANOVA per assay), except for between anatomical positions for B2M (p = 0.0758) 
and SLC1A3 (p = 0.2274) only (Figure 6.9 Figure 6.10). There was a significant 
interaction between the two terms (patient and anatomical position) for all assays 
(all p < 0.00001). There were similar trends across the patient panel for all the 
synthetic ERCC assays evaluated (Figure 6.9), with patient 4 samples generating 
higher normalised RQ estimates with increased variability in the measurement. To 
define these differences, patient 4 samples analysed using ERCC-13 and -99 were 
plotted to reveal their contributing variance components (Figure 6.9E & F). These 
plots clearly show that the majority of the variability in the patient 4 samples was 
attributable to the posterior locations, especially the PL anatomical position.   
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Figure 6.9 Clinical bone core patient variability. Normalised RQ distributions for different 
patients. (A) B2M (B) UBC (C) ERCC-13 (D) ERCC-99. Error bars SEM, n = 24 (A & B), n = 12 (C 
& D). Patient 4 for assays ERCC-13 and ERCC-99 are also shown displaying their contributing 
factors (RT replicate and anatomical position) to display variance contributions attributable to 
this patient for these targets (E) ERCC-13 (F) ERCC-99. Anatomical Position: Anterior Lateral 
(AL), Anterior Medial (AM), Posterior Lateral (PL), Posterior Medial (PM).  
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Figure 6.10 Clinical bone core anatomical position variability. Normalised RQ 
distributions for different biopsy positions of the tibial plateau during TKR surgery. (A) GAPDH 
(B) NES (C) SLC1A3 (D) ERCC-13. (A & B) Significant difference in normalised RQ between 
anatomical positions. (C & D) No significant difference in normalised RQ between anatomical 
positions. Error bars SEM, n = 36 (A-C), n = 18 (D). Anatomical position PM for assay NES is 
also shown displaying its contributing factors (qPCR replicate, RT replicate and patient) to 
show variance contributions attributable to this anatomical position for this target (E). The 
same evaluation for ERCC-13 is shown in Figure 6.9E (attributable to patient 4).   
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There was no significant differences observed in normalised RQ values between 
anatomical positions for all of the assays (all p > 0.05, single-factor ANOVA per 
assay), except GAPDH and NES (all p < 0.04), (Figure 6.10). The large variability 
observed for anatomical position PM when analysing samples using NES, was 
further assessed by plotting contributing variance components (Figure 6.10E). 
This plot suggests that the majority of the variability in the PM position samples 
was attributable to patients 1 and 6, in particular, RT replicates 1 and 2.  
It may be possible that GOI targets would be affected by an uneven gait (and 
consequently an uneven mechanical load) on osteo-arthritic joints due to 
varus/valgus deformity (bone or joint is twisted inward/outward from the centre 
of the body), formation of osteophytes (bony projections that form along the joint 
margins) and subchondal sclerosis (causes joint pain and numbness due to 
increased bone density and mass, producing a thin layer of bone beneath the 
cartilage in the joints in the affected area) [363,364]. Further data, assessing a 
greater number of patients and several more GOI targets, would be needed to test 
this hypothesis.  
Endogenous targets highlight the variability distribution across all factors 
considered. In which case, anatomical positional variance was lower than both RT 
and patient variabilities. Biological variability between patients was the largest 
contributory factor for overall process variance in this study [365,366].  
Given the differential expression observed between loaded and control samples in 
the 3D co-culture model, and its mechanical regulation as reported in the literature 
[210,362], GOI SLC1A3 was evaluated for expression differences between 
anatomical positions for each of the patients (Figure 6.11). Comparing the 
normalised RQ values across anatomical positions for each patient, 44.44% of the 
lowest normalised RQ values were attributable to the AL position, 30.56% to PM, 
13.89% to AM and 11.11% to PL. Alternatively, 27.78% of the highest normalised 
RQ values was attributed to each AL and PL, and 22.22% each to AM and PM   
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Figure 6.11 Clinical bone core SLC1A3 anatomical position expression variability. 
Normalised RQ distributions for GOI SLC1A3 between anatomical positions for different 
patients. Error bars SEM, n = 8. Anatomical Position: Anterior Lateral (AL), Anterior Medial 
(AM), Posterior Lateral (PL), Posterior Medial (PM). RQ values were calculated relative to 
sTCM calibrant.  
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positions. However, replicate RT and preamplification/qPCR samples did not 
always agree. Therefore, there does not appear to be a pattern between anatomical 
position and difference in RQ values between individual patients. However, this 
experiment utilised a small patient cohort, by increasing patient numbers, 
positional differences may become apparent.  
Anatomical positional variance may be low if in fact it does not have much or any 
influence on mRNA levels. Indeed, the ANOVA evaluation suggested that neither 
patient nor anatomical position significantly impacted these data. However, there 
are a couple of points that should be considered. Firstly, anatomical position was 
assigned solely at the discretion of the surgeon. There was no grid or template for 
location of a particular position and so locations did not remain uniform across 
collections. For that reason, the boundaries may be blurred. Secondly, the vast 
majority of endogenous targets measured were candidate reference genes, and as 
such, would be hypothesised to remain fairly stable, regardless of anatomical 
position. Of the targets that were detected with sufficient expression, SLC1A3 was 
the only one that could be described as a GOI. For this target, the anatomical 
position factor was more variable than the patient factor (35.4% and 22.4%, 
respectively). Furthermore, the RT factor was actually the largest contributor to 
whole process variability (42.3%). Based on this finding, it is possible that mRNA 
levels are influenced by anatomical position and by extrapolation; this may be due 
to different mechanical loading pressures at different positions of the joint. In 
order to test this hypothesis further, a larger cohort of patients could be analysed, 
considering additional patient factors such as sex, age and medical treatment. A 
new selection of GOI targets should be assessed to determine if they are affected by 
mechanical loading in these patients. Mechanical load has been shown to regulate 
glutamate signalling in bone [210,362,367], and glutamate concentrations are 
greatly increased in osteoarthritis and rheumatoid arthritis [368], where major 
disruption in bone remodelling occurs [369]. Additional targets within the 
glutamate-signalling pathway would therefore be worth investigating in these 
samples. Such targets may include: AMPA1-3, KA1-2, mGluR1, mGluR5, GluR5, 
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VGlut1 and NR1 [208-210,362,369,370]. In addition, some effort should be made 
to maintain consistency between positional collections.  
In terms of attributing variability contributions across the whole process, it may be 
argued that reference genes only should be assessed as they are less biased by 
biological variations. This would be true if one wanted to assess the contribution of 
technical factors alone (such as extraction, RT and qPCR), but in order to get the 
full picture biological variability must also be accounted for. In terms of 
streamlining a process to reduce as much as possible the technical variability and 
to assess where best to replicate in order to reflect those variabilities accurately, 
an assessment of variability contributions may be best made using only multiple 
validated reference genes. However, in order to fully characterise the true 
sensitivity to which measurement claims can be made, an assessment of all factors 
in the process by the analysis of multiple GOIs should be made.  
The Cardiff Research team applies a ‘molecule to man’ approach to investigate 
normal joint biomechanics and determine how this is influenced by pathology to 
inform clinical intervention and rehabilitation in musculoskeletal disorders. The 
work presented here aids in the attainment of the project goals by measuring 
mRNA profiles in patient bone core samples and defining variability associated 
with key parameters including inter-patient and positional disparity. This work 
will act to outline best practice for experimental approaches and highlight key 
sources of variability that should be considered in order to generate meaningful 
results reflecting true biological variability. These include patient and RT 
variability, where replication should be focussed.  
6.3.2.5 Assay Troubleshooting 
Dynamic array analysis of preamplified clinical bone cores, 3D gel and calibrant 
(standard curve) samples showed no amplification in seven of the assays chosen 
for their applicability to bone samples (AMPA1, AMPA2, AMPA3, EAAT1, EAAT3, 
Chapter 6 The Influence of Sample Type on Measurement Variability 
  Page 228 
KA1 and KA2 – all involved in glutamate signalling). As this result was unexpected, 
a subset was analysed by qPCR for comparison.  
SLC1A3 (which was detected on the dynamic array) and EAAT1 assays actually 
target the same transcript (accession NM_004172.4). The assays were designed to 
different regions of the target molecule and were named differently (with 
recognised synonyms) to avoid confusion. Given that the SLC1A3 assay generated 
a positive amplification result, EAAT1 would be expected to do the same, as they 
are linked targets (on the same transcript). EAAT1/SLC1A3 is known to be present 
at reasonable abundance in the SaOS-2 cell line [267]. It was therefore chosen, 
alongside GAPDH, which performed consistently well in the dynamic array 
experiments, to be analysed further by qPCR to test assay performance. Triplicate 
samples of preamplified calibrant units were analysed alongside non-preamplified 
human whole bone total RNA (following RT).  
These data show presence of both GAPDH (in agreement with the dynamic array 
data) and EAAT1 (not observed in the dynamic array data, despite positive 
amplification of the SLC1A3 target) (Figure 6.12). This proves that the EAAT1 
assay is performing sufficiently, despite the negative result on the dynamic array. 
Furthermore, the preamplification process is not a cause for concern as the results 
reflected those expected, i.e. preamplified targets have a lower Cq than non-
preamplified targets; the assay is shown to be working. It may be the case that 
some or all of the seven mRNA targets that failed to demonstrate positive 
amplification in the dynamic array format may in fact be present, but for some 
reason, failed in this format. This may be due to assays not being sufficiently 
optimised, sensitivity problems related to the dynamic array, or other factors yet 
untested. It is possible that these targets were low abundance and the dynamic 
array was not sensitive enough to detect them, despite the application of 
preamplification. This is certainly possible as due to the low reaction volumes 
utilised by this platform (9 nL), targets are required to be present at 
concentrations exceeding 1E+04 to 1E+05 copies/5 µL reaction per inlet (1E+02 to   
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Figure 6.12 RT-qPCR test for abundance. Amplification plots are shown. GAPDH and EAAT1 
were analysed for mRNA level in both Calibrant (preamp, preamplified) and human whole 
bone total RNA (No preamp, non-preamplified) materials.  
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1E+03 copies/9 nL reaction chamber) in order to be reliably detected [45].  
The fact that target was successfully identified using the SLC1A3 assay, but not 
using the EAAT1 assay (same transcript, different regions targeted) may be 
explained by the different amplicon positions within the structure of the template. 
On investigation into the predicted secondary structures (mFold [228]), it appears 
that the SLC1A3 amplicon region contains more stem-loop structures than the 
EAAT1 amplicon region (Figure 6.13), thus does not explain the difference in 
assay sensitivity. However, further folding of the transcript may occur in solution, 
obscuring the primer target sites for the EAAT1 assay, making amplification of the 
SLC1A3 amplicon more efficient. Furthermore, decreased sensitivity of low copy 
number targets may arise due to decreased efficiency of the RT (and potentially 
preamplification), and increased stochastic variation of the qPCR [45,48]. The 
sequence used for designing the assays was transcript variant 1, which is the 
longest transcript variant. The SLC1A3 assay crosses exon 2-3. The EAAT1 assay 
crosses exon 7-8. SLC1A3 transcript variant (GLAST-1a), which is an exon 3 skip 
transcript, has previously been shown to be expressed in bone [267,371]. It is 
possible that this transcript variant decreases RT-qPCR detection using the 
SLC1A3 assay, as this crosses the exon 2-3 boundary and so expression of the 
variant would not be detected by the SLC1A3 assay (although it would be detected 
by the EAAT1 assay). However, the SLC1A3 amplicon is amplified whereas the 
EAAT1 amplicon is not detected and so it is not possible from these data to detect 
the abundance of the full-length transcript versus the exon 3 skip transcript 
variant.  
Further work required to resolve these issues include analysis of these samples by 
qPCR. The assays in question were optimised using Human whole bone total RNA 
(DV Biologics P/N pM007r-107, used at 200 ng/reaction), by qPCR prior to 
dynamic array analysis. However, these assays were not tested with the clinical 
samples by RT-qPCR, only on the dynamic array (where observation of 
amplification failed). The clinical samples should be tested both with and without   
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Figure 6.13 EAAT1/SLC1A3 RNA Secondary Structure Prediction from mFold. Green 
highlighted regions indicate amplicon. Folding predictions were performed at 45ºC 
(temperature of RT step).   
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preamplification, with relevant positive controls, to fully discern the mRNA level of 
the targets in question. Furthermore, low abundance targets may benefit from RT-
dPCR analysis, which has been shown to be more sensitive than RT-qPCR for 
detection of minority targets [111,372]. 
6.4 Conclusions 
The 2D cell culture experiment indicated that there was a disparity between 
different cell passages regarding the impact of treatment on RNA yield, with only 
older cells showing a significant difference from control populations after 
treatment. Furthermore, cell passage (age) had an impact on RNA yield precision, 
with older cell populations displaying greater variability in total RNA 
measurement. However, this study analysed two different passages and so the 
variability observed may not be linear. Additional passages (and additional cell 
lines) would need to be assessed in order to determine whether these cell passage-
induced biases are real (cell passage impacts RNA yield precision). Variability 
contributions suggest that replication efforts should be concentrated at the level of 
flask repeats followed by time point. Extraction replicates contributed little 
variability to the total error. If the variability observed for older cells is confirmed 
through reproducibility experiments, then cell passage should also be taken into 
account and replicates focused at this level. For the 3D co-culture experiment, 
treatment appeared to have no impact on total RNA yield, while both cell batch 
(different experiments) and gel replicates impacted RNA quantity variability. The 
clinical bone core experiment suggested that both anatomical position and patient 
introduce significant variability to total RNA yield measurements. Considering 
earlier cell passage variability alone (2D cell culture), these data suggest that 2D 
cell culture variability is lowest of the three models tested and sample complexity 
is positively correlated with RNA yield variability; as sample complexity increases, 
so does measurement variability of extracted total RNA.  
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The RT-qPCR experiment analysing 3D co-culture samples revealed that for 
endogenous targets, the greatest factor contributing to variability for control 
samples was Gel replicate and for loaded samples was RT, with the lowest 
variability-contributing factor for both control and loaded samples being 
Experiment. In similar experimental set-ups, efforts should therefore be made to 
replicate the gel and RT steps, an important finding as similar cell culture-based 
studies may replicate an experiment without also replicating the RT step. GOI 
SLC1A3 was shown to be influenced by mechanical loading, and warrants further 
investigation into the mechanism of this regulation [208-210,369,373]. The RT-
qPCR analysis of clinical bone core samples illustrated that for endogenous targets, 
biological variability between patients was the largest contributory factor for 
overall process variance, while anatomical position contributed the least. 
Replicates should therefore be focussed on the patient and RT level in future 
studies of similar design. It should be noted that there are several factors relating 
to the patient variability that have not been taken into account in this study. These 
include patient age, sex, disease status/progression, medical interventions (drug 
treatments), etc. These biological variabilities add a layer of complexity beyond 
that modelled by the 3D co-culture system. A comprehensive assessment of such 
factors would require a much larger cohort of patient samples. These data 
combined also suggest that the ERCCs are not suitable for normalisation of values 
in these experiments as their levels are variable between treatment conditions.  
The variability observed in the ERCC targets suggests that these transcripts may be 
more susceptible to matrix effects/inhibitors than the endogenous reference 
genes. Furthermore, there may be some influence in terms of enzyme efficiency 
when dealing with these synthetic targets. Although the ERCC consortium 
produced them with a mind to generate materials as close to endogenous targets 
as possible, it is inevitable that differences will be inherent in these synthetic 
molecules and as a result, their very nature may render them unsuitable (at least 
as a gold standard) for sample normalisation and comparison by these means.  
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There were some experimental factors that were not highly controlled, such as 
surgically obtained samples, which could stand to be regulated. This may include 
standardisation of biopsy sites for bone core sample collection (although the 
surgeons involved have extensive experience in these collections), weighing bone 
cores for normalisation of RNA quantity to tissue weight and standardising storage 
procedures (such as time to snap freezing, thawing for removal of RNAlater, etc.). 
These measures would aid analysis by improving error measurements and 
allowing true biological differences to be realised. A key finding of these data has 
shown very little error between technical replicates. It should be noted that these 
experimental studies have been well controlled (where possible) and performed 
very carefully due to the concern for variability. As a result, these investigations 
may not reflect common study protocols and therefore may not be representative 
of variabilities typically observed, particularly for cell line and patient replicates, 
where reported variances are often high [374-377]. These synthetic scenarios have 
demonstrated good intermediate precision. However, if researchers routinely 
follow such rigorous methodologies and achieve the same levels of high precision, 
then data capabilities will be improved. Standardising all aspects of laboratory 
procedure may not be necessitated if individual studies can maintain consistency 
in variability measurement and understand the sources of bias and error intrinsic 
to a particular approach. Ultimately, different methods, whether it be RT-qPCR or 
RT-dPCR using various different platforms (ABI 7900, Roche Light Cycler, Qiagen 
Rotor Gene, Fluidigm Biomark, BioRad QX200, Life Sciences Quant Studio 3D, etc.) 
or other approaches such as RNA-Seq, may be followed and still maintain their 
relevance through the use of appropriate standardisation and calibration.  
The question becomes, if repeatability (experimental replicates under the same 
conditions with the same operator) can generate very low/negligible error 
components to a measurement result, even when analysing complex clinical 
samples from different sources, what is lacking from the normalisation strategy 
that prevents intermediate precision (different operators) and reproducibility 
(inter-laboratory) from masking biological variabilities [19,378-385], in other 
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words, why are multiple validated reference genes not rectifying the situation? 
Reproducibility attempts will be made easier by choosing to replicate at stages 
where most variability is introduced, rather than say the qPCR step, which is 
frequently replicated in preference to other stages. By replicating stages further 
back in the process, more of the experimental noise will be captured allowing a 
more comprehensive evaluation of measurement uncertainty. Replication at 
appropriate stages will remove technical variability, with biological variability 
remaining. In addition, rather than pursuing external reference gene strategies 
(given our findings for ERCC target variabilities), it may indeed be prudent to focus 
efforts on internal target standardisation approaches, whether that is using 
multiple reference genes, expressed repetitive elements (such as Alu repeats), an 
alternative approach or a combination of such methods. The “Catch 22” in regards 
to qPCR is that when done correctly, it can be extremely reproducible with low 
variances. While this is obviously desirable and one of its major selling points, this 
tight precision may generate a source of bias, whereby the precision that makes it 
such a successful technique also opens up the variability in measurements 
between laboratories; the repeatability within a laboratory does not translate to 
reproducibility between laboratories. In addition to applying replication to 
appropriate stages of the experimental process, one way to address these biases 
would be to employ validated internal standards that are used for expression fold 
change (relative) measurement claims, as differences in absolute quantification 
values are less relevant if fold change values are maintained.  
One aspect that has not been investigated here is the difference between relative 
and absolute quantification for RT-qPCR approaches and whether or not 
normalisation strategy influences one approach differently to another. Future 
work would include evaluating these possibilities for the best approach. For 
example, if relative changes are maintained regardless of normalisation strategy, 
differences in absolute values may not be meaningful (dependent on the 
measurement need).  
Chapter 6 The Influence of Sample Type on Measurement Variability 
  Page 236 
The process precision factors detailed in the variability plots evaluated in this 
chapter (Figure 6.2, Figure 6.5 and Figure 6.6) demonstrate which steps in the 
experimental process would benefit most from additional replication. This work 
can be used to guide readers in the approach required to make relevant decisions 
on process variability contributions and in so doing, make valid improvements to 
experimental workflow and impact of generated data.   
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7. Final Discussion & Overall Conclusions 
Measurement standardisation is a crucial step in maintaining the integrity of 
scientific studies and is a key feature of robust investigation. Currently, the field of 
molecular biology is lacking behind other disciplines such as chemistry and 
physics in terms of the development of measurement standards that can be used 
for this purpose. However, there have been several standardisation efforts within 
the field including the International Organization for Standardization (ISO) who 
develop and publish International Standards [87], Minimum Information About a 
Microarray Experiment (MIAME) standard guidelines for reporting microarray 
experiments [386], the Minimum Information for Publication of Quantitative Real-
Time PCR Experiments (MIQE) standard guidelines for reporting qPCR 
experiments [86], the Minimum Information for Publication of Quantitative Digital 
PCR Experiments (dMIQE) standard guidelines for reporting dPCR experiments 
[230], Standards, Guidelines and Best Practices for RNA-Seq published by the 
ENCODE (Encyclopedia of DNA Elements) Consortium to establish best practices 
for RNA-seq measurements [387] and the Genetic European Variation in Disease 
(GEUVADIS) Consortium who aim to develop standards on medical genome 
sequencing, using both RNA (RNA-seq) and DNA (exonSeq) sequencing [388]. 
Since the publication of these guidelines there has been a concerted effort to 
increase standardisation within the associated literature [133-135,141,150-152]. 
This includes both standardised laboratory practices and reporting of methods 
used as well as appropriate investigation and validation of relevant reference 
standards within individual studies.  
Our recent review of the literature [59] has shown that the qPCR data underlying 
the vast majority of publications reporting use of this technique are, at the very 
least, inadequately reported and that the peer review process allows the 
publication of incomplete experimental protocols, yielding results that are difficult 
to evaluate independently. When some such studies are reassessed, it may lead to 
publication retractions [389-392]. This may have contributed to untold quantities 
Chapter 7 Final Discussion & Overall Conclusions 
239 
of wasted time and money invested in dead ends by researchers following on from 
these data. Such errors may be particularly difficult to spot when applying findings 
from one model system to another. For example, findings from cell line based 
studies or animal models being applied to clinical samples. Disparity in clinical 
findings compared to a model system may be put down to the inapplicability of the 
model system, when in fact; the study procedures may be at fault.  
Retractions, however, are rare and evidence suggests that this can be due to poor 
data analysis [59] suggesting that the original data has not been questioned/re-
evaluated rather than because such mistakes are infrequent. When standardised 
practices, both in the laboratory and during data reporting, are not followed, it 
becomes difficult not only for such results to be successfully reproduced, but also 
to determine where the causes of erroneous findings lie when they arise. Studies 
reporting conflicting findings are of concern for this very reason; it may be the case 
that the second, conflicting study has difficulty getting published at all. Authors of 
such investigations should endeavor to collaborate in order to resolve such 
conflicts in data reporting. However, the majority of conflicting reports may be 
avoided if all laboratories and researchers were to follow standardised and 
validated procedures within their own laboratories and remain compliant with 
accepted guidelines (such as MIQE [86]) when reporting data. Of course, it is also 
possible that some conflicting reports represent the normal reproducibility range.  
During the tenure of this thesis, investigations of variability contributions at each 
stage in the experimental process from RNA sample source to RNA target 
quantification have been performed with the use of both internal and synthetic 
experimental standards for normalisation. Possible sources of variability have 
been scrutinised including, sample source and type, RNA extraction, sample 
quantification, RT, qPCR and/or dPCR and use of different standards for 
normalisation. The findings presented here are significant in terms of real-life 
impact whereby the sources and degree of variability contributions have been 
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examined and shown to be reduced effectively when validated normalisation and 
standardisation procedures are in place.  
The scope of this study has generated many statistically significant findings. dPCR 
is capable of making precise measurements of synthetic and endogenous RNA 
molecules in a complex RNA background. A possible underestimation bias exists 
for RNA measurements; RT-dPCR quantification was significantly lower than that 
derived from UV values. RT-dPCR has been shown to be more precise than 
previous methods. However, RT-dPCR was able to highlight the diverse 
quantification and sensitivity capabilities of different one-step RT-qPCR kits; 
leading to the conclusion that cDNA prepared using different RT enzymes cannot 
be meaningfully compared. Not every enzyme is equal in its capabilities and such 
kits should be validated, particularly when attempting to measure low abundance 
targets and difficult sample types that may contain inhibitors (such as clinical 
samples). This study suggests that dPCR may be used to inform and improve 
practices for qPCR. For example, using dPCR (instead of UV) to value assign 
standards that will be used for qPCR analysis.  
It has been clearly demonstrated that different extraction methods recover RNA 
with differing efficiencies. Matrix effects, cell debris and/or the quantity of input 
material, such as the number of cells, may influence this. Extraction efficiencies 
remained linear across the dilution range; however, linearity was influenced by 
cell type. This is particularly relevant when evaluating transcripts of low 
abundance and so experimental-specific validation is important. Furthermore, 
DNase treatment efficiency may also partly be affected by kit-dependent co-
purified contaminants and extraction buffer compounds, as DNase efficiency 
varied between kits. The ERCC transcripts may be more susceptible to matrix 
effects/inhibitors than the endogenous reference genes. Both extraction 
kit/chemistry and yield determination must be maintained in a method specific-
manner for sample sets to remain equally valid. 
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The studies evaluating the effect of sample type on process variabilities suggested 
an impact of cell passage (age) on RNA yield precision, with cell age positively 
correlating with variability in total RNA measurement. However, with only two 
passages evaluated, the link between cell passage and RNA yield precision should 
be further investigated with a range of cell types and passage levels. Furthermore, 
it was shown that an increase in sample complexity concomitantly increases 
measurement variability. 
A key finding of these data has been the low error between technical replicates. 
Therefore, concentrating replication on sources determined to contribute greater 
variability will best capture experimental error and provide accurate estimates of 
measurement uncertainty. It is worth considering how relevant cell culture 
extraction variability (a synthetic situation) is compared to clinical samples. The 
variability (or lack thereof) observed for these data may not be representative of a 
clinical sample scenario. However, it could explain the very discrepancies 
mentioned above, i.e. everyone is using precise but varyingly biased methods. The 
very fact that this study was designed to measure variability contributions 
necessitates an attention to experimental detail most likely resulting in a 
consequential decrease in variability. So by ‘observing the variability’, the 
measurement result is fundamentally changed, in what might be biology’s version 
of Heisenberg’s uncertainty principal.  
Overall, this work has shown the level of precision that can be achieved when all 
sources of error are monitored. When there is maintenance of experimental 
consistency and an understanding of sources of bias and error, theoretically any 
methods may be used and be expected to generate the same result. This work 
could be developed in future to generate power calculations to inform future 
experimental design. Furthermore, this work provides a guide for the assessment 
of variability contributions and the translation to reducing experimental error.  
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Based on the findings in this thesis, the author makes the following 
recommendations:  
General best practice guidelines:  
• When handling RNA samples at any stage prior to qPCR, experimental 
procedures should include routine treatment of surfaces/racks/pipettes etc. with a 
solution to remove RNases (such as RNaseZap, Ambion).  
• RNase-free plasticware and water should be used.  
• Laboratory space must be separated into at the least two areas comprising 
PCR set-up (no PCR product handling) and PCR product analysis areas with 
separate reagents and pipettes.  
 
mRNA measurement by RT-qPCR 
• Replication should be performed at all stages of the process (at a minimum 
n = 3), except at the PCR level only.  
• If replication can only be performed at limited stages due to cost/resources, 
it should be focussed at earlier steps in the protocol, i.e. subject/independent 
experiment replicates should hold the highest priority.  
• Samples may be stored at -80ºC as either lysate or extracted total RNA.  
• For total RNA extraction, organic and silica membrane-based extraction 
methods are preferable to salt precipitation methods.  
• Total RNA extracts should have an aliquot prepared for initial 
quantification and the rest stored at -80ºC. There is no preferred method for this 
as quantity is not as important as quality (integrity and purity) assessment. 
Relative levels are sufficient to ensure equal RNA quantities are processed.  
• Total RNA should be diluted in a stabilising agent such as RNA storage 
solution (Ambion), or equivalent.  
• Total RNA should always be DNase treated, and preferably assessed for 
DNase efficiency, for example by using Alu PCR or equivalent (samples pre and 
post DNase treatment).  
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• Total RNA should be tested for integrity, preferably using a 5’-3’ assay, for a 
highly abundant target [252].  
• Total RNA purity, in terms of co-extracted inhibitors, should be tested using 
the SPUD assay [155,157], or equivalent.  
• RT may be performed using either one-step or two-step processes. When 
measuring low abundance targets, oligo d(T)16 or gene specific RT priming is 
recommended (as opposed to random primers), based on specificity for mRNA or 
specified targets, respectively.  
• Carrier RNA (such as Yeast total RNA) should be added to the RT reaction 
(both one-step and two-step processes) to ensure linear performance of the RTase.  
• The validity of the RTase should be tested for each experimental purpose, 
particularly when evaluating low abundance targets. Furthermore, when 
measuring such minority mRNA species, one-step RT-qPCR and RTases lacking 
RNase H activity should be considered (and validated).  
• If a standard curve will be used for quantification of a target, standard 
dilutions should be performed at the RNA (not cDNA) stage (at a minimum n = 3).  
• External controls should be spiked into matrix-matched samples.  
• qPCR is highly robust and precise and does not necessarily need to be 
replicated.  
 
qPCR Assay design:  
• If DNase treatment is performed (and validated by Alu PCR), assays do not 
necessarily need to be designed to cross an exon-exon boundary. RT negative 
controls should be employed as standard.  
• Where possible when performing qPCR, probes such as hydrolysis probes, 
molecular beacons and scorpion probes, can be used to ensure additional 
specificity. Where intercalating dyes are used, melt curve analysis should always 
be performed to evaluate specificity.  
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Additional considerations:  
• Passage number of cells should be considered and where possible, matched 
throughout a study.  
• All possible aspects of an experimental set-up should be controlled, e.g. 
consistency in sample source/type, reagent batches, instrument calibration etc.  
• Meaningful comparisons can only be made where the same experimental 
set-up, reagents and methods are used.  
• Published data must include all sample and experimental details to 
facilitate data reproduction and comparison.  
• All sources of variability should be considered and accounted for before 
conclusions can be made (particularly discriminatory power of the particular 
experimental process).  
7.1. Future Work 
Projects following on from this work may include an inter-laboratory study 
evaluating the reproducibility of RNA measurement from the point of RNA 
extraction from cell lysates. This would test inter-laboratory capabilities and 
consistency in RNA extraction as well as all processes downstream. It would also 
allow for evaluation of normalisation techniques and their ability to control for 
more variable steps in the process (i.e. the RNA extraction rather than just the RT 
or qPCR). The next step would be to evaluate RNA measurement reproducibility 
when starting from tissue samples; an increase in sample complexity. These 
studies would test the resilience of method standardisation and normalisation 
techniques to the pressures of increased sample complexity and variability, testing 
the limits of technical variability and what may be overcome.  
The development of a universally applicable RT-qPCR standard for accurate and 
comprehensive data normalisation could be considered a Holy Grail in the 
transcriptomics field. Such a material would aim to rectify reproducibility 
problems and systematic biases, improving the robustness, reliability and 
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applicability of such studies. However, in practical terms, such a material maybe 
some way off coming to fruition. In the meantime, recognised and accredited 
standards should be used to improve reproducibility between laboratories, 
comparisons between which should only be made when the same standards are 
utilised. This includes calibration materials that have been accurately value 
assigned using dPCR or a higher order method. dPCR may also be utilised, as 
shown in this thesis (Chapter 4), to determine RT enzyme performance and to 
ensure that the RT enzyme generates the same result as the PCR enzyme, i.e. 
counting RNA molecules per cell (without the introduction of bias). The higher 
precision possible with dPCR methodologies will allow a determination of when an 
RT enzyme or RNA extraction method is not working efficiently; biases which 
cannot always be defined using qPCR. Such scrutiny of measurement processes 
will enable identification of biases allowing improvements to the experimental 
protocol to be made. Application of dPCR in this way, as a kind of process 
evaluator, helps to keep those processes faithful to the measurement. It will allow 
an improvement of all process steps and aid harmonisation of protocols and 
ultimately improve inter-laboratory reproducibility.  
Important continued efforts in this field include the education and uptake of 
standardised laboratory and reporting practices. When scientists, and people in 
general, have been doing things a particular way for years it can be tremendously 
difficult to convince them why they should be doing it differently. Seasoned 
researchers may be resistant to change, especially with funding pressures and 
demands to publish. Nevertheless, this may be helped remarkably by requirement 
of such standards in manuscripts by publishing journals. Furthermore, capturing 
training and newly qualified young scientists, and ensuring they are schooled in 
the importance of such standardisation approaches, will go a long way to 
safeguarding the integrity of future scientific endeavor.  
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7.2. Overall Impact 
The findings reported in this thesis give strong weight to the applicability of RT-
dPCR to measurement fields requiring high precision and determination of small 
changes such as transcriptomic biomarkers, as well as to the development and 
validation of new material standards for biological measurement. This work 
further highlights the need for standardisation in all aspects of methodology. This 
thesis may be used to guide development of studies investigating sources of 
variability. The employment of dPCR value assigned calibrant materials (reference 
samples) would facilitate greater accuracy for absolute quantification by qPCR. 
Efforts should focus on internal target standardisation approaches, whether that is 
using multiple reference genes, expressed repetitive elements (such as Alu 
repeats), an alternative approach or a combination of such methods, and be used 
to investigate the extent of variability contributions. Moreover, in-depth validation 
and analysis of external synthetic ERCC standards has been completed as a 
potential augmentation to internal controls for normalisation of data in validated 
circumstances; while these standards were variable under some experimental 
conditions, their applicability may still be confirmed in certain experimental 
approaches.  
This thesis contributes to the field by outlining processes that should be followed 
in order to produce scientifically sound and valid results. Furthermore, it 
highlights areas where harmonisation of methodologies should be maintained.  
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 Appendices 9
9.1 Appendix 1 – Assay Information 
Table 9.1 Primer and probe sequences 
Target DNA 
Gene Accession 
Number 
Primer/Probe Sequence 
(5’ to 3’) 
Exogenous/synthetic targets: 
ERCC-13 EF011062 (F) CGGACATGGTGTTGGTCAAG 
(R) TTGTTGGGCGGACCGTAA 
(P) FAM-TGCATGAGGACCCGCAAATTCCTC-BHQ1 
ERCC-25 DQ883689 (F) CGGTCGTGAACTGCTATAGGA 
(R) GGTAGTTTCGCTGGTTCGTT 
(P) FAM-AGCCTGATACGAGCGCACAACA-BHQ1 
ERCC-42 DQ516783 (F) AGAGAGCTTTTGGCAATCCT 
(R) TCATTTGCTAAGGCAGTTAAAGA 
(P) FAM-TCACCAGTTCCCATGAATGTTCCAC-BHQ1 
ERCC-84 DQ883682 (F) TGGATAAGCGAGGTCAGTCAAG 
(R) ATGCAGGCAAACGATCTACGT 
(P) FAM-ATTCGTTGCCTCCGGGTCC-BHQ1 
ERCC-95 DQ516759 (F) GAGCGTTTTTATGCAGTTCATCTTT 
(R) GGATAAGATTGTTGAGTGGGCTTT 
(P) FAM-ACCTCATCCCACAAAGCCGCTTTCTT-BHQ1 
ERCC-99 DQ875387 (F) TCGTCCATCCCTCAAGAGAGA 
(R) CGCAATCGCGTGTGAATG 
(P) FAM-CATGGAAAGAGCTCGACAAAATTTACTC-BHQ1 
ERCC-113 DQ883663 (F) GCGACACCAACATCGTTACG 
(R) CCGCGCGTGAGCACTT 
(P) FAM-ACACACCGGACGCTTGGATCAGTG-BHQ1 
ERCC-171 DQ854994 (F) TTAGTTTCGTGGCGGGATTT 
(R) CACGAATCGCACGGATGTT 
(P) FAM-AGGAAAACTGCGACTGTTCTTTAACC-BHQ1 
Endogenous Targets:  
Alu [130]  (F) CATGGTGAAACCCCGTCTCTA 
(R) GCCTCAGCCTCCCGAGTAG 
CASC3 NM_007359.4 (F) AGCCTTCTTTCCTGCAACCA 
(R) CATATACACATGGGAGCAGGACC 
(P) FAM-ACTTCGAGGTATGCCC-MGB 
HPRT1 NM_000194.2 (F) CCTTGGTCAGGCAGTATAATCCA 
(R) AGCTTGCTGGTGAAAAGGACC 
(P) FAM-AGATGGTCAAGGTCG-MGB 
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MMP1 NM_001145938.1 (F) GGCCCACAAACCCCAAA 
(R) TCTACCCGGAAGTTGAGCTCA 
(P) FAM-AAGACAGATTCTACATGCGCA-MGB 
NES NM_006617.1 (F) CCCAAGACTGCCCTGGAAA 
(R) GAAGAGTCTGACCCTGTTTCCTTG 
(P) FAM-AGTGCTGAGCCTTCT-MGB 
SLC1A3 NM_004172.4 (F) AGTGCAGAACATTACAAAGGAGGAT 
(R) GATTTACCCTCCGACCATACAGA 
(P) FAM-TTAAAAGTTACCTGTTTCG-MGB 
UBC NM_021009.5 (F) TTGTGGATCGCTGTGATCGT 
(R) AGACTCTGACTGGTAAGACCATCACC 
(P) FAM-ACTTGACAATGCAGATCT-MGB 
AMPA1 NM_000827.3 (F) CCTTCTTCTGCACCGGTTTC 
(R) GAAATAATCCCCCGATCTGGAT 
(P) FAM-TAGGCGCGGTAGTAGG-BHQ1 
AMPA2 NM_000826.3 (F) GAGCTCTCCTTAGCTTGATTGAATACTA 
(R) TTGATAAGCCTCTGTCACTGTCATAGA 
(P) FAM-CAATGGGACAAGTTTGCATA-BHQ1 
EAAT1 NM_004172.4 (F) TTTATTGGAGGGTTGCTGCAA 
(R) GTAGGGTGGCAGAACTTGAAGAG 
(P) FAM-ACTCATCACCGCTCTG-BHQ1 
EAAT3 NM_004170.5 (F) GCGATCCAGAGATGAACATGAC 
(R) TCCTTTGTTTTGTTCTTGGAAATTG 
(P) FAM-AAGAGTCCTTCACAGCTGT-BHQ1 
KA1 NM_014619.2 (F) GAGCTGATCGCTAGGAAAGCA 
(R) TCAATCACCTTCTCCCGTTCA 
(P) FAM-AGGCCTCACCATTACA-BHQ1 
KA2 NM_002088.4 (F) TTCCAGAATTCACGGTACCAAA 
(R) TCTTCTGTGCTCTTGACGAACAC 
(P) FAM-TGGAACTACATGCAGTCGA-BHQ1 
NRI NM_007327.3 (F) CATAGGCATGCGCAAAGACA 
(R) CGTGGGACTTGAGGATGGA 
(P) FAM-AGCAGAACGTCTCCCT-BHQ1 
Assay-on-demand* (ABI): 
TBP  Hs00920497_m1 
(F) forward primer, (R) reverse primer, (P) probe, BHQ1: black hole quencher 1, MGB: minor 
groove binder. ERCC assays previously described by Devonshire et al. (2011) [45]. *Assays on 
demand, all FAM-MGB probes. All ERCC assays: (F) 900 nM, (R) 900 nM, (P) 180 nM. Alu assay: 
(F) 250 nM, (R) 250 nM. All other in-house endogenous targets: (F) 900 nM, (R) 900 nM, (P) 
250 nM. 
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Assays used for dynamic array experiments (Chapter 6): ERCC-13, -25, -42, -99, -113, -171, 
CASC3, HPRT1, MMP1, NES, SLC1A3, UBC, AMPA1, AMPA2, EAAT1, EAAT3, KA1, KA2, NR1, 
TBP, PSMC4, PGK1, B2M, GAPDH, PPIA, RPLPO AND YWHAZ. Details covered in Tables 9.1 and 
9.2.  
 
Table 9.2 Human endogenous control assays, TaqMan Array Plate. 
Assay ID Gene Symbol Assay ID Gene Symbol 
Hs99999901_s1 18S Hs00201226_m1 CASC3 
Hs99999905_m1 GAPDH Hs00355782_m1 CDKN1A 
Hs99999909_m1 HPRT1 Hs00153277_m1 CDKN1B 
Hs99999908_m1 GUSB Hs00169255_m1 GADD45A 
Hs99999903_m1 ACTB Hs00206469_m1 PUM1 
Hs99999907_m1 B2M Hs00197826_m1 PSMC4 
Hs00609297_m1 HMBS Hs00426752_m1 EIF2B1 
Hs00183533_m1 IPO8 Hs00362795_g1 PES1 
Hs99999906_m1 PGK1 Hs00245445_m1 ABL1 
Hs99999902_m1 RPLP0 Hs00152844_m1 ELF1 
Hs99999910_m1 TBP Hs02596862_g1 MT-ATP6,LOC100133315 
Hs99999911_m1 TFRC Hs00608519_m1 MRPL19 
Hs00824723_m1 UBC Hs00198357_m1 POP4 
Hs00237047_m1 YWHAZ Hs01102345_m1 RPL37A 
Hs99999904_m1 PPIA Hs00265497_m1 RPL30 
Hs00172187_m1 POLR2A Hs00734303_g1 RPS17 
Assay ID prefix indicates species: Hs = human. Assay ID suffix indicates assay placement: _m = 
an assay whose probe spans an exon junction and does not detect genomic DNA; _s = an assay 
whose primers and probes are designed within a single exon. Such assays, by definition, detect 
genomic DNA; _g = an assay that may detect genomic DNA. The assay primers and probe may 
also be within a single exon. (3.2.6 Endogenous Target Selection). 
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Table 9.3 Human endogenous GOI assays 
Assay ID Gene Symbol Assay ID Gene Symbol 
Hs00180269_m1 BAX Hs01075667_m1 IL6-R 
Hs00153120_m1 CYP1A1 Hs00158148_m1 ITGA2 
Hs00366488_m1 SLCO1A2 Hs00233958_m1 MMP1 
Hs00234219_m1 SULT2A1 Hs00365167_m1 COL6A2 
Hs00358656_m1 ABCC3 Hs00705137_s1 IFITM1 
Hs00166123_m1 ABCC2 Hs01110251_m1 HO-1 
Hs99999141_s1 JUN Hs00155249_m1 GCLC 
Hs00992441_m1 IL32 Hs00998421_m1 M6PRBP1 
Hs00234415_m1 IL11RA Hs00171993_m1 TNFRSF12A 
 Hs01556193_m1  BRCA1 Hs00242448_m1 COL6A1 
Hs00707120_s1 NES Hs00174360_m1 IL6ST 
Hs00221623_m1 CLDN1* Hs00934682_m1 GATA6 
Hs00415716_m1 SOX2OT   
In-house designed assays 
Target DNA 
Gene Accession 
Number 
Primer/Probe Sequence 
(5’ to 3’) 
GFAP NM_001131019.1 (F) GAGATGGCCCGCCACTTGCA 
  (R) TGGTGATCCGGTTCTCCTCGCC 
  (P) FAM-CAAGCTGGCCCTGGACATCGA-TAMRA 
PDGFRA NM_006206.4 (F) CGTTCCTGGTCTTAGGCTGTCT 
  (R) GGAAGGATAGAGGGTAATGAAAGCT 
  (P) TCACAGGGCTGAGCCTAATCCTCTGC 
PDGFRB NM_002609.3 (F) ATGAGCGGAAACGGCTCTAC 
  (R) GAATAGTTCCTCGGCATCATTAGG 
  (P) CTTTGTGCCAGATCCCACCGT 
SLC1A3 As Table 9.1   
Assays highlighted in BLUE were used to test the applicability of the mocked up mixed ratio 
model units (2.3.1.2 Genes of Interest). GFAP assay: (F) 900 nM, (R) 900 nM, (P) 250 nM. 
PDGFRA assay: (F) 300 nM, (R) 900 nM, (P) 200 nM. PDGFRB assay: (F) 900 nM, (R) 900 nM, 
(P) 200 nM. 
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Table 9.4 Assay Positions 
Target 
Transcript Length 
(bases)* 
Base position in transcript (5’ to 3’) 
Forward 
Primer 
Probe Reverse Primer 
CASC3 4198 1734-1753 1759-1774 1778-1800 
HPRT1 1435 610-632 634-648 651-671 
MMP1 1903 802-818 884-904 914-934 
NES 5591 4574-4592 4607-4621 4631-4654 
SLC1A3 4188 572-596 598-616 670-692 
UBC 2594 430-449 451-468 475-500 
ERCC-13 808 540-559 563-586 588-605 
ERCC-25 1994 1772-1792 1795-1816 1819-1838 
ERCC-42 1023 680-699 703-727 730-752 
ERCC-99 1350 732-752 756-783 785-802 
ERCC-113 843 80-99 103-126 129-144 
ERCC-171 505 237-256 258-283 285-303 
*Length of transcript including poly(A) tail.  
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Table 9.5 Sample dilutions analysed during study. Concentrations initially estimated using UV spectrophotometry. Calibrant (C), Unknown 1 (U1), 
Unknown 2 (U2). 
Experiment Assay 
RT-qPCR 
(steps) 
Copies or concentration 
DNA* target per reaction 
Replicates 
(RT or qPCR) 
Concentration carrier 
Plasmid Contamination 
Assessment 
 
gDNA Contamination 
Assessment 
All eight ERCC 
assays 
 
Alu 
qPCR 
 
 
qPCR 
~5E+08 to 5E+03  
(copies) 
 
1 to 1E-05 ng Human 
gDNA (positive control), 
20 ng cell line RNA 
1 per dilution, per assay 
 
 
3 per cell line/positive control. 
6 NTC 
None 
 
 
None 
Human Cross-Reactivity All eight ERCC 
assays 
qPCR - 1 per assay 250 ng human gDNA 
Carrier Optimisation 1 
 
 
 
Carrier Optimisation 2 
 
ERCC-13 
 
 
 
ERCC-13 
RT-qPCR  
(one-step) 
 
 
RT-qPCR  
(one-step) 
~5E+08 to 5E+04  
(copies) 
 
 
~5E+06 to 5E+01  
(copies) 
3 per dilution, per carrier 
 
 
 
3 per dilution, per carrier 
50 or 250 ng salmon sperm 
DNA or yeast total RNA, or 50 
ng Hep-G2 total RNA 
 
250 ng salmon sperm DNA or 
yeast total RNA 
RNA Stability Analysis 
 
GAPDH RT-qPCR  
(two-step) 
20, 2 or 0.2 (ng)  
RNA equivalent 
2 (RT), 3 (qPCR, via dilution) None  
(total RNA) 
RT Variability 
 
GAPDH RT-qPCR 
(two-step) 
20, 2 or 0.2 (ng)  
RNA equivalent 
2 (RT and qPCR) per sample 
extraction (4) & dilution (3) 
None 
(total RNA) 
Endogenous Target Selection: 
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Reference Genes 
 
 
 
Genes of Interest 
32 control 
genes 
(Appendix 1) 
 
31 potential 
GOI 
(Appendix 1) 
RT-qPCR 
(two-step) 
 
 
RT-qPCR  
(one-step) 
10 ng total cDNA 
 
 
 
10 ng total RNA 
Triplicates per assay, per cell 
line 
 
 
1 per assay, per cell line 
Mocked up mixed ratio model 
units U1 & U2 analysed in 
triplicate 
None 
(total RNA) 
 
 
None 
(total RNA) 
TCM Homogeneity 
 
 
TCM Short Term 
Stability 
 
TCM Long Term 
Stability 
ERCC-99 & 
HPRT1 
 
ERCC-99 & 
HPRT1 
 
ERCC-99 & 
HPRT1 
RT-qPCR  
(one-step) 
 
RT-qPCR  
(one-step) 
 
RT-qPCR  
(one-step) 
C, U1 & U2 
 
 
C, U1 & U2 
 
 
C, U1 & U2 
Ten aliquots each of C, U1 and 
U2, with replicates of 8  
 
Three aliquots each of C, U1 
and U2, per temperature and 
time point 
Three aliquots each of C, U1 
and U2, per temperature and 
time point 
250 ng yeast total RNA 
 
 
250 ng yeast total RNA 
 
 
250 ng yeast total RNA 
One-Step RT-qPCR Kit 
Comparison by dPCR 
ERCC-25 & 
ERCC-99 
RT-qPCR  
(one-step) 
~1896 (copies/panel) 1 panel/assay, 3 replicate 
chips 
250 ng yeast total RNA 
Comparison between 
dPCR and UV  
All six ERCCs RT-qPCR  
(one-step) 
~200-400 (copies/panel) 3 panels/assay 250 ng yeast total RNA 
Linearity and Sensitivity 
of RT-dPCR  
ERCC-25 & 
ERCC-99 
RT-qPCR  
(one-step) 
~500, 250 100, 50, 25, 10 
or 5 (copies/panel) 
6 panels/ dilution/assay, 2 
replicate chips 
250 ng yeast total RNA 
Further Evaluation of 
Reverse Transcriptase’s  
ERCC-25, -99, 
UBC & MMP1 
RT-qPCR  
(one-step) 
~1886 (copies/panel) 3 panels/assay duplex, 2 
replicate chips 
250 ng yeast total RNA 
Impact of Extraction 
Protocol 
Alu qPCR and 
RT-qPCR 
(two-step) 
20 ng total RNA (or cDNA 
equivalent) 
Triplicates per sample None 
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3D Gel Co-cultures Alu 
 
Appendix 1 
qPCR 
 
RT-qPCR 
(two-step) 
with 
§PreAmp 
20 ng total RNA 
 
10 ng/µL cDNA per 
§PreAmp 
Triplicates per sample 
 
Triplicate RTs measured per 
sample 
None 
 
None 
Clinical Samples Alu 
 
Appendix 1 
qPCR 
 
RT-qPCR 
(two-step) 
with 
§PreAmp 
20 ng total RNA 
 
10 ng/µL cDNA per 
§PreAmp 
Triplicates per sample 
 
Triplicate RTs measured per 
sample 
None 
 
None 
*Dilutions are quoted based on RNA copies or concentration (total RNA equivalent) per qPCR well of a standard 96 well plate, or RNA copies per dPCR 
panel (where specified). No template controls (NTCs) for every experiment resulted in no amplified signal observed (except for Alu assessment, as 
described, 3.2.1 DNA Contamination Assessment). RNA concentrations were estimated by UV and converted to copy number using published 
methods [224]. §PreAmp: Preamplification 
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Table 9.6 ERCC RNA concentration and copy number estimates 
ERCC- 
Concentration 
(ng/µL)* 
Molecular weight with 
poly(A) tail (g/mol)† 
Estimated copy 
number/µL 
Estimated 
copies/ng 
13 442 261410 1.02E+12 2.30E+09 
25 428 640925 4.02E+11 9.40E+08 
42 395 325739 7.30E+11 1.85E+09 
99 401 434398 5.56E+11 1.39E+09 
113 815 271727 1.81E+12 2.22E+09 
171 385 163019 1.42E+12 3.69E+09 
*As estimated by UV, n = 3.  
†The inverse of the molecular weight (Mw) is the number of moles of template present in one 
gram of material. By multiplying the moles/gram by Avogadro's number, 6.023E+23 
molecules/mole, the number of template molecules per gram can be calculated. The number of 
template molecules in the sample can be estimated by multiplying copies/gram by 1.0E+09 to 
convert to ng and multiplying by the amount of template (ng) [393].  
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9.2 Appendix 2 –Endogenous and ERCC Transcript Predicted 
Secondary Structures 
 
A 
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Figure 9.1 RNA Secondary Structure Predictions from mFold. (A) CASC3, (B) HPRT1, (C) 
MMP1, (D) NES, (E) SLC1A3, (F) UBC, (G) ERCC-13, (H) ERCC-25, (I) ERCC-42, (J) ERCC-99, (K) 
ERCC-113 and (L) ERCC-171. Green highlighted regions indicate amplicon. Folding predictions 
were performed at 45ºC (temperature of RT step). Structures discussed in 4.3.5 Causes of 
Differing RT-dPCR Results.   
L 
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9.3 Appendix 3 – Measurement Uncertainty Budgets 
Table 9.7 Calculation of Calibrant assigned value and measurement uncertainty. u = 
standard uncertainty, u'=(u/x) = relative standard uncertainty. *Relative to assigned value for 
additive contributions. **Volumetric Identifiers (equipment:nearest specified volume). 25k 
denotes 25  1000 µL.  
ERCC-13 
` Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 1.018E+12 2.37E+10 0.023 
Nanodrop. u based on observed precision 
with allowance for between-day effect 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 3.94E+04 0.042 
Effect modelled as additive correction to 
final value: Estimated uncertainty based 
on observed Nanodrop relative bias [394]; 
Uncertainty (u) calculated as Relative 
standard uncertainty (RSSu) [395] 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
0.948 0.05961 0.063 
Taken from purity assessment. Note that 
for some ERCC targets purity is taken as 
100% with nominal 1% u 
Homogeneity Homogeneity (cp) 0 6.6E+04 0.070 Max observed s[bb] 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.1 0.012 P10:10 
Diluted with (µL) RSS 45.91 0.2 0.005 P100:50 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.1 0.012 P10:10 
Diluted with (µL) RSS 495 2.4 0.005 P1000:500 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 100 
ERCC 
solution 
Aliquot (µL) 150 0.9 0.006 P200:200 
Diluted with (µL) RSS 600 2.4 0.004 P1000:500 
Diluted with (µL) ERCC-25 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-42 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-99 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-
113 
150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-
171 
150 0.9 0.006 P200:200 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 5000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 549.25 2.4 0.004 P1000:500 
Diluted with (µL) SaOS-2 735.00 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 1000 4.7 0.005 P1000:1000 
Diluted with (µL) Hs683 506.75 2.4 0.005 P1000:500 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 9.48E+05 1.0E+05 1.07E-01 
 
 
Expanded uncertainty 
 
2.0E+05 2.15E-01 
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ERCC-25 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 4.020E+11 9.72E+09 0.024 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 4.15E+04 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
1.000 0.00999 0.010 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 7.0E+04 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.1 0.012 P10:10 
Diluted with (µL) RSS 15.1 0.1 0.004 P20:10 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.1 0.012 P10:10 
Diluted with (µL) RSS 495 2.4 0.005 P1000:500 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 100 
ERCC 
solution 
Aliquot (µL) 150 0.9 0.006 P200:200 
Diluted with (µL) RSS 600 2.4 0.004 P1000:500 
Diluted with (µL) ERCC-13 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-42 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-99 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-
113 
150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-
171 
150 0.9 0.006 P200:200 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 5000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 549.25 2.4 0.004 P1000:500 
Diluted with (µL) SaOS-2 735.00 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 1000 4.7 0.005 P1000:1000 
Diluted with (µL) Hs683 506.75 2.4 0.005 P1000:500 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 1.00E+06 8.7E+04 8.75E-02 
 
 
Expanded uncertainty 
 
1.7E+05 1.75E-01 
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ERCC-42 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 7.305E+11 1.71E+10 0.023 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 4.15E+04 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
1.000 0.00999 0.010 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 7.0E+04 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.1 0.012 P10:10 
Diluted with (µL) RSS 31.52 0.2 0.008 P100:50 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.1 0.012 P10:10 
Diluted with (µL) RSS 495 2.4 0.005 P1000:500 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 100 
ERCC 
solution 
Aliquot (µL) 150 0.9 0.006 P200:200 
Diluted with (µL) RSS 600 2.4 0.004 P1000:500 
Diluted with (µL) ERCC-13 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-25 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-99 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-
113 
150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-
171 
150 0.9 0.006 P200:200 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 5000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 549.25 2.4 0.004 P1000:500 
Diluted with (µL) SaOS-2 735.00 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 1000 4.7 0.005 P1000:1000 
Diluted with (µL) Hs683 506.75 2.4 0.005 P1000:500 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 1.00E+06 8.8E+04 8.76E-02 
 
 
Expanded uncertainty 
 
1.8E+05 1.75E-01 
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ERCC-99 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 5.559E+11 1.42E+10 0.026 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 4.10E+04 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
0.986 0.00999 0.010 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 6.9E+04 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.1 0.012 P10:10 
Diluted with (µL) RSS 22.79 0.2 0.010 P100:50 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.1 0.012 P10:10 
Diluted with (µL) RSS 495 2.4 0.005 P1000:500 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 100 
ERCC 
solution 
Aliquot (µL) 150 0.9 0.006 P200:200 
Diluted with (µL) RSS 600 2.4 0.004 P1000:500 
Diluted with (µL) ERCC-13 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-25 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-42 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-
113 
150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-
171 
150 0.9 0.006 P200:200 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 5000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 549.25 2.4 0.004 P1000:500 
Diluted with (µL) SaOS-2 735.00 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 1000 4.7 0.005 P1000:1000 
Diluted with (µL) Hs683 506.75 2.4 0.005 P1000:500 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 9.86E+05 8.7E+04 8.84E-02 
 
 
Expanded uncertainty 
 
1.7E+05 1.77E-01 
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ERCC-113 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 1.807E+12 4.16E+10 0.023 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 3.90E+04 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
0.938 0.03225 0.034 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 6.6E+04 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.1 0.012 P10:10 
Diluted with (µL) RSS 85.34 0.5 0.005 P100:100 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.1 0.012 P10:10 
Diluted with (µL) RSS 495 2.4 0.005 P1000:500 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 100 
ERCC 
solution 
Aliquot (µL) 150 0.9 0.006 P200:200 
Diluted with (µL) RSS 600 2.4 0.004 P1000:500 
Diluted with (µL) ERCC-13 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-25 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-42 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-99 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-
171 
150 0.9 0.006 P200:200 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 5000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 549.25 2.4 0.004 P1000:500 
Diluted with (µL) SaOS-2 735.00 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 1000 4.7 0.005 P1000:1000 
Diluted with (µL) Hs683 506.75 2.4 0.005 P1000:500 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 9.38E+05 8.8E+04 9.35E-02 
 
 
Expanded uncertainty 
 
1.8E+05 1.87E-01 
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ERCC-171 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 1.421E+12 3.27E+10 0.023 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 3.90E+04 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
0.939 0.03607 0.038 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 6.6E+04 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.1 0.012 P10:10 
Diluted with (µL) RSS 66.05 0.2 0.004 P100:50 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.1 0.012 P10:10 
Diluted with (µL) RSS 495 2.4 0.005 P1000:500 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 100 
ERCC 
solution 
Aliquot (µL) 150 0.9 0.006 P200:200 
Diluted with (µL) RSS 600 2.4 0.004 P1000:500 
Diluted with (µL) ERCC-13 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-25 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-42 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-99 150 0.9 0.006 P200:200 
Diluted with (µL) ERCC-
113 
150 0.9 0.006 P200:200 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 5000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 549.25 2.4 0.004 P1000:500 
Diluted with (µL) SaOS-2 735.00 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 1000 4.7 0.005 P1000:1000 
Diluted with (µL) Hs683 506.75 2.4 0.005 P1000:500 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 9.39E+05 8.9E+04 9.50E-02 
 
 
Expanded uncertainty 
 
1.8E+05 1.90E-01 
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Figure 9.2 Calibrant Unit Measurement Uncertainty Contributing Factors. Purity 
assessment based on multiple banding (Bioanalyzer).   
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Table 9.8 Calculation of Unknown 1 assigned value and measurement uncertainty. 
Measurement uncertainty components common to both Unknown 1 and Unknown 2 are not 
included in corresponding uncertainty budgets as these contributions cancel out in 
measurement of combined standard uncertainty of assigned ratios. 
ERCC-13 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 1.018E+12 0.00E+00 0.000 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 0.00E+00 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
0.948 0.00000 0.000 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 4.0E+03 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 45.91 0.0 0.000 P100:50 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 495 0.0 0.000 P1000:500 
Step 3: 
Dilution to 
1E+8 c/µL 
Aliquot (µL) 20 0.0 0.000 P20:10 
Diluted with (µL) RSS 180 0.0 0.000 P200:200 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 
100 ERCC 
solution 
Aliquot (µL) 90 0.5 0.005 P100:100 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 114.5 0.9 0.008 P200:200 
Diluted with (µL) ERCC-25 7.5 0.1 0.008 P10:10 
Diluted with (µL) ERCC-42 1.5 0.02 0.012 P2:2 
Diluted with (µL) ERCC-99 105 0.5 0.005 P200:100 
Diluted with (µL) ERCC-
113 
31.5 0.2 0.008 P100:50 
Diluted with (µL) ERCC-
171 
150 0.9 0.006 P200:200 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 4000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 116 0.5 0.004 P200:100 
Diluted with (µL) SaOS-2 735.00 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 2000 4.7 0.002 P1000:1000 
Diluted with (µL) Hs683 940 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 5.69E+04 4.0E+03 7.06E-02 
 
 
Expanded uncertainty 
 
8.0E+03 1.41E-01 
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ERCC-25 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 4.020E+11 0.00E+00 0.000 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 0.00E+00 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
1.000 0.00000 0.000 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 3.5E+02 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 15.1 0.0 0.000 P20:10 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 495 0.0 0.000 P1000:500 
Step 3: 
Dilution to 
1E+8 c/µL 
Aliquot (µL) 20 0.0 0.000 P20:10 
Diluted with (µL) RSS 180 0.0 0.000 P200:200 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 
100 ERCC 
solution 
Aliquot (µL) 7.5 0.1 0.008 P10:10 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 114.5 0.9 0.008 P200:200 
Diluted with (µL) ERCC-13 90 0.5 0.005 P100:100 
Diluted with (µL) ERCC-42 1.5 0.02 0.012 P2:2 
Diluted with (µL) ERCC-99 105 0.5 0.005 P200:100 
Diluted with (µL) ERCC-
113 
31.5 0.2 0.008 P100:50 
Diluted with (µL) ERCC-
171 
150 0.9 0.006 P200:200 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 4000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 116 0.5 0.004 P200:100 
Diluted with (µL) SaOS-2 735.00 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 2000 4.7 0.002 P1000:1000 
Diluted with (µL) Hs683 940 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 5.00E+03 3.5E+02 7.09E-02 
 
 
Expanded uncertainty 
 
7.1E+02 1.42E-01 
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ERCC-42 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 7.305E+11 0.00E+00 0.000 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 0.00E+00 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
1.000 0.00000 0.000 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 7.0E+01 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 31.52 0.0 0.000 P100:50 
Step 2: 
Dilution to 
1E+9 c/µL 
 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 495 0.0 0.000 P1000:500 
Step 3: 
Dilution to 
1E+8 c/µL 
 
Aliquot (µL) 20 0.0 0.000 P20:10 
Diluted with (µL) RSS 180 0.0 0.000 P200:200 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 
100 ERCC 
solution 
 
Aliquot (µL) 1.5 0.02 0.012 P2:2 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 114.5 0.9 0.008 P200:200 
Diluted with (µL) ERCC-13 90 0.5 0.005 P100:100 
Diluted with (µL) ERCC-25 7.5 0.1 0.008 P10:10 
Diluted with (µL) ERCC-99 105 0.5 0.005 P200:100 
Diluted with (µL) ERCC-
113 
31.5 0.2 0.008 P100:50 
Diluted with (µL) ERCC-
171 
150 0.9 0.006 P200:200 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 4000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 116 0.5 0.004 P200:100 
Diluted with (µL) SaOS-2 735.00 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 2000 4.7 0.002 P1000:1000 
Diluted with (µL) Hs683 940 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 1.00E+03 7.1E+01 7.15E-02 
 
 
Expanded uncertainty 
 
1.4E+02 1.43E-01 
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ERCC-99 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 5.559E+11 0.00E+00 0.000 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 0.00E+00 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
0.986 0.00000 0.000 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 4.8E+03 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 22.79 0.0 0.000 P100:50 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 495 0.0 0.000 P1000:500 
Step 3: 
Dilution to 
1E+8 c/µL 
Aliquot (µL) 20 0.0 0.000 P20:10 
Diluted with (µL) RSS 180 0.0 0.000 P200:200 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 
100 ERCC 
solution 
Aliquot (µL) 105 0.5 0.005 P200:100 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 114.5 0.9 0.008 P200:200 
Diluted with (µL) ERCC-13 90 0.5 0.005 P100:100 
Diluted with (µL) ERCC-25 7.5 0.1 0.008 P10:10 
Diluted with (µL) ERCC-42 1.5 0.02 0.012 P2:2 
Diluted with (µL) ERCC-
113 
31.5 0.2 0.008 P100:50 
Diluted with (µL) ERCC-
171 
150 0.9 0.006 P200:200 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 4000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 116 0.5 0.004 P200:100 
Diluted with (µL) SaOS-2 735.00 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 2000 4.7 0.002 P1000:1000 
Diluted with (µL) Hs683 940 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 6.90E+04 4.9E+03 7.05E-02 
 
 
Expanded uncertainty 
 
9.7E+03 1.41E-01 
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ERCC-113 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 1.807E+12 0.00E+00 0.000 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 0.00E+00 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
0.938 0.00000 0.000 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 1.4E+03 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 85.34 0.0 0.000 P100:100 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 495 0.0 0.000 P1000:500 
Step 3: 
Dilution to 
1E+8 c/µL 
Aliquot (µL) 20 0.0 0.000 P20:10 
Diluted with (µL) RSS 180 0.0 0.000 P200:200 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 
100 ERCC 
solution 
Aliquot (µL) 31.5 0.2 0.008 P100:50 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 114.5 0.9 0.008 P200:200 
Diluted with (µL) ERCC-13 90 0.5 0.005 P100:100 
Diluted with (µL) ERCC-25 7.5 0.1 0.008 P10:10 
Diluted with (µL) ERCC-42 1.5 0.02 0.012 P2:2 
Diluted with (µL) ERCC-99 105 0.5 0.005 P200:100 
Diluted with (µL) ERCC-
171 
150 0.9 0.006 P200:200 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 4000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 116 0.5 0.004 P200:100 
Diluted with (µL) SaOS-2 735.00 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 2000 4.7 0.002 P1000:1000 
Diluted with (µL) Hs683 940 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 1.97E+04 1.4E+03 7.08E-02 
 
 
Expanded uncertainty 
 
2.8E+03 1.42E-01 
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ERCC-171 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 1.421E+12 0.00E+00 0.000 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 0.00E+00 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
0.939 0.00000 0.000 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 6.6E+03 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 66.05 0.0 0.000 P100:50 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 495 0.0 0.000 P1000:500 
Step 3: 
Dilution to 
1E+8 c/µL 
Aliquot (µL) 20 0.0 0.000 P20:10 
Diluted with (µL) RSS 180 0.0 0.000 P200:200 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 
100 ERCC 
solution 
Aliquot (µL) 150 0.9 0.006 P200:200 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 114.5 0.9 0.008 P200:200 
Diluted with (µL) ERCC-13 90 0.5 0.005 P100:100 
Diluted with (µL) ERCC-25 7.5 0.1 0.008 P10:10 
Diluted with (µL) ERCC-42 1.5 0.02 0.012 P2:2 
Diluted with (µL) ERCC-99 105 0.5 0.005 P200:100 
Diluted with (µL) ERCC-
113 
31.5 0.2 0.008 P100:50 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 4000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 116 0.5 0.004 P200:100 
Diluted with (µL) SaOS-2 735.00 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 2000 4.7 0.002 P1000:1000 
Diluted with (µL) Hs683 940 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 1000 1.8 0.002 P1000:200 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 9.39E+04 6.6E+03 7.06E-02 
 
 
Expanded uncertainty 
 
1.3E+04 1.41E-01 
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Figure 9.3 Unknown 1 Unit Measurement Uncertainty Contributing Factors. 
Measurement uncertainty components common to both Unknown 1 and Unknown 2 are not 
included in corresponding uncertainty budgets as these contributions cancel out in 
measurement of combined standard uncertainty of assigned ratios.   
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Table 9.9 Calculation of Unknown 2 assigned value and measurement uncertainty. 
Measurement uncertainty components common to both Unknown 1 and Unknown 2 are not 
included in corresponding uncertainty budgets as these contributions cancel out in 
measurement of combined standard uncertainty of assigned ratios. 
ERCC-13 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 1.018E+12 0.00E+00 0.000 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 0.00E+00 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
0.948 0.00000 0.000 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 6.0E+03 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 45.91 0.0 0.000 P100:50 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 495 0.0 0.000 P1000:500 
Step 3: 
Dilution to 
1E+8 c/µL 
Aliquot (µL) 20 0.0 0.000 P20:10 
Diluted with (µL) RSS 180 0.0 0.000 P200:200 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 
100 ERCC 
solution 
Aliquot (µL) 135 0.9 0.007 P200:200 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 100 0.5 0.005 P200:100 
Diluted with (µL) RSS 101.5 0.5 0.005 P200:100 
Diluted with (µL) ERCC-25 7.5 0.1 0.008 P10:10 
Diluted with (µL) ERCC-42 10.5 0.06 0.006 P20:10 
Diluted with (µL) ERCC-99 105 0.5 0.005 P200:100 
Diluted with (µL) ERCC-
113 
10.5 0.1 0.006 P20:10 
Diluted with (µL) ERCC-
171 
30 0.2 0.008 P100:50 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 5000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 1000 2.4 0.002 P1000:500 
Diluted with (µL) Hep-G2 600 2.4 0.004 P1000:500 
Diluted with (µL) Hep-G2 382.50 2.4 0.006 P1000:500 
Diluted with (µL) SaOS-2 735 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 73.5 0.5 0.006 P100:100 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 8.53E+04 6.0E+03 7.07E-02 
 
 
Expanded uncertainty 
 
1.2E+04 1.41E-01 
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ERCC-25 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 4.020E+11 0.00E+00 0.000 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 0.00E+00 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
1.000 0.00000 0.000 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 3.5E+02 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 15.1 0.0 0.000 P20:10 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 495 0.0 0.000 P1000:500 
Step 3: 
Dilution to 
1E+8 c/µL 
Aliquot (µL) 20 0.0 0.000 P20:10 
Diluted with (µL) RSS 180 0.0 0.000 P200:200 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 
100 ERCC 
solution 
Aliquot (µL) 7.5 0.1 0.008 P10:10 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 100 0.5 0.005 P200:100 
Diluted with (µL) RSS 101.5 0.5 0.005 P200:100 
Diluted with (µL) ERCC-13 135 0.5 0.004 P200:100 
Diluted with (µL) ERCC-42 10.5 0.06 0.006 P20:10 
Diluted with (µL) ERCC-99 105 0.5 0.005 P200:100 
Diluted with (µL) ERCC-
113 
10.5 0.1 0.006 P20:10 
Diluted with (µL) ERCC-
171 
30 0.2 0.008 P100:50 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 5000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 1000 2.4 0.002 P1000:500 
Diluted with (µL) Hep-G2 600 2.4 0.004 P1000:500 
Diluted with (µL) Hep-G2 382.50 2.4 0.006 P1000:500 
Diluted with (µL) SaOS-2 735 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 73.5 0.5 0.006 P100:100 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 5.00E+03 3.5E+02 7.09E-02 
 
 
Expanded uncertainty 
 
7.1E+02 1.42E-01 
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ERCC-42 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 7.305E+11 0.00E+00 0.000 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 0.00E+00 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
1.000 0.00000 0.000 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 4.9E+02 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 31.52 0.0 0.000 P100:50 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 495 0.0 0.000 P1000:500 
Step 3: 
Dilution to 
1E+8 c/µL 
Aliquot (µL) 20 0.0 0.000 P20:10 
Diluted with (µL) RSS 180 0.0 0.000 P200:200 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 
100 ERCC 
solution 
Aliquot (µL) 10.5 0.1 0.006 P20:10 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 100 0.5 0.005 P200:100 
Diluted with (µL) RSS 101.5 0.5 0.005 P200:100 
Diluted with (µL) ERCC-13 135 0.5 0.004 P200:100 
Diluted with (µL) ERCC-25 7.5 0.06 0.008 P10:10 
Diluted with (µL) ERCC-99 105 0.5 0.005 P200:100 
Diluted with (µL) ERCC-
113 
10.5 0.1 0.006 P20:10 
Diluted with (µL) ERCC-
171 
30 0.2 0.008 P100:50 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 5000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 1000 2.4 0.002 P1000:500 
Diluted with (µL) Hep-G2 600 2.4 0.004 P1000:500 
Diluted with (µL) Hep-G2 382.50 2.4 0.006 P1000:500 
Diluted with (µL) SaOS-2 735 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 73.5 0.5 0.006 P100:100 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 7.00E+03 4.9E+02 7.07E-02 
 
 
Expanded uncertainty 
 
9.9E+02 1.41E-01 
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ERCC-99 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 5.559E+11 0.00E+00 0.000 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 0.00E+00 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
0.986 0.00000 0.000 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 4.8E+03 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 22.79 0.0 0.000 P100:50 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 495 0.0 0.000 P1000:500 
Step 3: 
Dilution to 
1E+8 c/µL 
Aliquot (µL) 20 0.0 0.000 P20:10 
Diluted with (µL) RSS 180 0.0 0.000 P200:200 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 
100 ERCC 
solution 
Aliquot (µL) 105 0.5 0.005 P200:100 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 100 0.5 0.005 P200:100 
Diluted with (µL) RSS 101.5 0.5 0.005 P200:100 
Diluted with (µL) ERCC-13 135 0.5 0.004 P200:100 
Diluted with (µL) ERCC-25 7.5 0.06 0.008 P10:10 
Diluted with (µL) ERCC-42 10.5 0.1 0.006 P20:10 
Diluted with (µL) ERCC-
113 
10.5 0.1 0.006 P20:10 
Diluted with (µL) ERCC-
171 
30 0.2 0.008 P100:50 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 5000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 1000 2.4 0.002 P1000:500 
Diluted with (µL) Hep-G2 600 2.4 0.004 P1000:500 
Diluted with (µL) Hep-G2 382.50 2.4 0.006 P1000:500 
Diluted with (µL) SaOS-2 735 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 73.5 0.5 0.006 P100:100 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 6.90E+04 4.9E+03 7.05E-02 
 
 
Expanded uncertainty 
 
9.7E+03 1.41E-01 
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ERCC-113 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 1.807E+12 0.00E+00 0.000 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 0.00E+00 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
0.938 0.00000 0.000 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 4.6E+02 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 85.34 0.0 0.000 P100:100 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 495 0.0 0.000 P1000:500 
Step 3: 
Dilution to 
1E+8 c/µL 
Aliquot (µL) 20 0.0 0.000 P20:10 
Diluted with (µL) RSS 180 0.0 0.000 P200:200 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 
100 ERCC 
solution 
Aliquot (µL) 10.5 0.1 0.006 P20:10 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 100 0.5 0.005 P200:100 
Diluted with (µL) RSS 101.5 0.5 0.005 P200:100 
Diluted with (µL) ERCC-13 135 0.5 0.004 P200:100 
Diluted with (µL) ERCC-25 7.5 0.06 0.008 P10:10 
Diluted with (µL) ERCC-42 10.5 0.1 0.006 P20:10 
Diluted with (µL) ERCC-99 105 0.5 0.005 P200:100 
Diluted with (µL) ERCC-
171 
30 0.2 0.008 P100:50 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 5000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 1000 2.4 0.002 P1000:500 
Diluted with (µL) Hep-G2 600 2.4 0.004 P1000:500 
Diluted with (µL) Hep-G2 382.50 2.4 0.006 P1000:500 
Diluted with (µL) SaOS-2 735 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 73.5 0.5 0.006 P100:100 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 6.57E+03 4.6E+02 7.07E-02 
 
 
Expanded uncertainty 
 
9.3E+02 1.41E-01 
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ERCC-171 
Factor Term Value x u u'=(u/x)* Remark** 
Stock Estimated stock value (cp) 1.421E+12 0.00E+00 0.000 See Appendix 3, Table 9.7, ERCC-13 
Nanodrop 
Calibration 
Nanodrop Calibration (cp) 0 0.00E+00 0.042 See Appendix 3, Table 9.7, ERCC-13 
Material integrity: 
Impurity 
Estimated purity (mass 
fraction basis) 
0.939 0.00000 0.000 See Appendix 3, Table 9.7, ERCC-13 
Homogeneity Homogeneity (cp) 0 1.3E+03 0.070 See Appendix 3, Table 9.7, ERCC-13 
Stability Stability 0 0 n/a No allowance made 
Volumetric: (Based on manufacturer’s specifications) 
Step 1: 
Dilution to 
1E+11 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 66.05 0.0 0.000 P100:50 
Step 2: 
Dilution to 
1E+9 c/µL 
Aliquot (µL) 5 0.0 0.000 P10:10 
Diluted with (µL) RSS 495 0.0 0.000 P1000:500 
Step 3: 
Dilution to 
1E+8 c/µL 
Aliquot (µL) 20 0.0 0.000 P20:10 
Diluted with (µL) RSS 180 0.0 0.000 P200:200 
Step 4: 
Mixing of 
ERCC 
solutions to 
prepare 
100 ERCC 
solution 
Aliquot (µL) 30 0.2 0.008 P100:50 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 100 0.5 0.005 P200:100 
Diluted with (µL) RSS 101.5 0.5 0.005 P200:100 
Diluted with (µL) ERCC-13 135 0.5 0.004 P200:100 
Diluted with (µL) ERCC-25 7.5 0.06 0.008 P10:10 
Diluted with (µL) ERCC-42 10.5 0.1 0.006 P20:10 
Diluted with (µL) ERCC-99 105 0.5 0.005 P200:100 
Diluted with (µL) ERCC-
113 
10.5 0.1 0.006 P20:10 
Step 5: 
Preparation 
of units: 
Mixing of 
100 ERCC 
and Cell line 
solutions 
Aliquot (µL) 367.5 2.4 0.006 P1000:500 
Diluted with (µL) Hep-G2 5000.00 17.8 0.004 P5000:5000 
Diluted with (µL) Hep-G2 1000 2.4 0.002 P1000:500 
Diluted with (µL) Hep-G2 600 2.4 0.004 P1000:500 
Diluted with (µL) Hep-G2 382.50 2.4 0.006 P1000:500 
Diluted with (µL) SaOS-2 735 2.4 0.003 P1000:500 
Diluted with (µL) Hs683 73.5 0.5 0.006 P100:100 
Diluted with (µL) RSS 25000 87.1 0.003 P5000:25k 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 1000 4.7 0.005 P1000:1000 
Diluted with (µL) RSS 591.5 2.4 0.004 P1000:500 
 
Assigned value (cp): 1.88E+04 1.3E+03 7.08E-02 
 
 
Expanded uncertainty 
 
2.7E+03 1.42E-01 
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Figure 9.4 Unknown 2 Unit Measurement Uncertainty Contributing Factors. 
Measurement uncertainty components common to both Unknown 1 and Unknown 2 are not 
included in corresponding uncertainty budgets as these contributions cancel out in 
measurement of combined standard uncertainty of assigned ratios.   
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9.4  Appendix 4 – Pilot Reference Material Composition 
 
Table 9.10 Proportions of each cell line included in the pilot RMs. Hep-G2 and Hs683 total 
RNA was used at 250 ng/µL, and SaOS-2 total RNA was used at 100 ng/µL.  
 
 
 
Cell Line 
Proportions 
Calibrant Unknown 1 Unknown 2 
Hep-G2 total RNA 0.755 0.56 0.95 
SaOS-2 total RNA 0.04 0.04 0.04 
Hs683 total RNA 0.205 0.40 0.01 
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9.5 Appendix 5 – Typical dPCR Output Data 
A Ambion ERCC-25                Ambion ERCC-99            Ambion ERCC-25 & -99 (duplex)         Ambion ERCC-25 & -99 (NTC) 
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Invitrogen ERCC-25              Invitrogen ERCC-99         Invitrogen ERCC-25 & -99 (duplex)        Invitrogen ERCC-25 & -99 (NTC) 
           
           
 
Qiagen ERCC-25     Qiagen ERCC-99            Qiagen ERCC-25 & -99 (duplex)           Qiagen ERCC-25 & -99 (NTC) 
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B Ambion ERCC-25 & -99           Ambion MMP1 & UBC     Ambion ERCC-25 & UBC             Ambion NTC 
           
           
 
        Invitrogen ERCC-25 & -99        Invitrogen MMP1 & UBC   Invitrogen ERCC-25 & UBC            Invitrogen NTC 
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Qiagen ERCC-25 & -99          Qiagen MMP1 & UBC      Qiagen ERCC-25 & UBC   Qiagen NTC 
           
           
 
Figure 9.5 Typical dPCR output data from Chapter 4. Both amplification plots and heat maps are shown. Amplification plots display ΔRN versus 
cycle number. Heat maps are the corresponding schematic representations of positive partitions as detected by the Biomark instrument. Black = no 
amplification. Red = FAM amplification. Blue = HEX amplification. Threshold was adjusted to eliminate cross talk between the filters (FAM versus 
HEX). (A) One-Step RT-qPCR Kit Comparison by dPCR. (B) Endogenous versus Synthetic Targets.   
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9.6 Appendix 6 – Digital MIQE 
Table 9.11 dMIQE checklist for authors, reviewers and editors. All essential information 
(E) must be submitted with the manuscript. Desirable information (D) should be submitted if 
possible.  
ITEM TO CHECK IMPORTANCE Checklist Comments/Where? 
EXPERIMENTAL DESIGN 
 
  
Definition of experimental 
and control groups 
E Y Chapter 2 
Number within each group E Y Chapter 2 & Appendix 1 
Assay carried out by core 
lab or investigator's lab? 
D Y Investigator’s lab 
Power analysis D N - 
SAMPLE 
 
  
Description E Y Chapter 2 
     Volume or mass of 
sample processed 
E Y Chapter 2 & Appendix 1 
    Microdissection or 
macrodissection 
E N/A - 
Processing procedure E Y Chapter 2 
     If frozen - how and how 
quickly? 
E Y Chapter 2 
     If fixed - with what, how 
quickly? 
E N/A - 
Sample storage conditions 
and duration (especially 
for FFPE samples) 
E Y Chapter 2 
NUCLEIC ACID 
EXTRACTION  
  
Quantification - 
instrument/method 
E Y Chapter 2 
Storage conditions: 
temperature, 
concentration, duration, 
buffer 
E Y Chapter 2 
DNA or RNA quantification E Y Chapter 2 
Quality/integrity-
instrument/method; e.g. 
RIN/RQI and trace or 3’:5’ 
E Y Chapters 2-6 
Template structural 
information 
E Y Chapter 2 & 4 
Template modification 
(digestion, sonication, pre-
amplification etc.) 
E Y Chapters 2-6 
Template treatment 
(initial heating or chemical 
E Y Chapter 2 
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denaturation) 
Inhibition dilution or 
spike;  
E Y Chapter 2 
DNA contamination 
assessment of RNA sample 
E Y Chapter 2-3 
Details of DNase treatment 
where performed 
E Y Chapter 2-6 
Manufacturer of reagents 
used and catalogue 
number 
D Y Chapter 2 
Storage of nucleic acid: 
temperature, 
concentration, duration, 
buffer 
E Y Chapter 2 
REVERSE 
TRANSCRIPTION (If 
necessary) 
 
  
cDNA priming method + 
concentration 
E Y Chapter 2 
One or two step protocol E Y Chapter 2 & Appendix 1 
Amount of RNA used per 
reaction 
E Y Chapter 2 & Appendix 1 
Detailed reaction 
components and 
conditions 
E Y Chapter 2 
RT efficiency  D Y Chapter 3 
Estimated copies 
measured with and 
without addition of RT* 
D Y Alu PCR, Chapter 5 
Manufacturer of reagents 
used and catalogue 
number 
D Y Chapter 2 
Reaction volume (for two 
step reverse transcription 
reaction) 
D Y Chapter 2 
Storage of cDNA: 
temperature, 
concentration, duration, 
buffer 
D Y Chapter 2 
dPCR TARGET 
INFORMATION  
  
Sequence accession 
number 
E Y Appendix 1 
Location of amplicon D Y Appendix 1 
     Amplicon length  E Y Appendix 1 
     In silico specificity 
screen (BLAST, etc.) 
E Y Chapter 2 
     Pseudogenes, 
retropseudogenes or other 
homologs? 
D Y Chapter 2 
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     Sequence alignment D Y Chapter 2 
     Secondary structure 
analysis of amplicon and 
GC content 
D Y Chapter 2 & 4, Appendix 2 
Location of each primer by 
exon or intron (if 
applicable) 
E Y Appendix 1 
     Where appropriate, 
which splice variants are 
targeted? 
E Y Appendix 1 
dPCR 
OLIGONUCLEOTIDES 
   
Primer sequences and/or 
amplicon context 
sequence** 
E Y Appendix 1 
RTPrimerDB Identification 
Number  
D N/A - 
Probe sequences** D Y Appendix 1 
Location and identity of 
any modifications 
E N/A - 
Manufacturer of 
oligonucleotides 
D Y Chapter 2 
Purification method D Y Chapter 2 
dPCR PROTOCOL    
Complete reaction 
conditions 
E Y Chapter 2 
     Reaction volume and 
amount of 
RNA/cDNA/DNA 
E Y Chapter 2 & Appendix 1 
     Primer, (probe), Mg++ 
and dNTP concentrations 
E Y Chapter 2 
     Polymerase identity 
and concentration  
E Y Chapter 2 
     Buffer/kit Catalogue No 
and manufacturer 
E Y Chapter 2 
     Exact chemical 
constitution of the buffer 
D N/A Proprietary 
     Additives (SYBR Green 
I, DMSO, etc.) 
E Y Chapter 2 
Plates/tubes Catalogue No 
and manufacturer 
D Y Chapter 2 
Complete thermocycling 
parameters 
E Y Chapter 2 
Reaction setup D Y Chapter 2 
Gravimetric or volumetric 
dilutions 
(manual/robotic) 
D Y Chapter 2 
Total PCR reaction volume 
prepared 
D Y Chapter 2 
Partition number E Y Chapter 2 
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Individual partition 
volume 
E Y Chapter 2 
Total volume of the 
partitions measured 
(effective reaction size) 
E Y Chapter 2 
Partition volume 
variance/standard 
deviation 
D No - 
Comprehensive details 
and appropriate use of 
controls 
E Y Chapter 2 
Manufacturer of dPCR 
instrument 
E Y Chapter 2 
dPCR VALIDATION    
Optimisation data for the 
assay 
D Y Chapter 2 & 3 
Specificity (when 
measuring rare mutations, 
pathogen sequences etc.) 
E Y Chapter 3 
Limit of detection of 
calibration control 
D Y Chapter 2-4 
If multiplexing, 
comparison with 
singleplex assays 
E Y Chapter 2 & 4 
DATA ANALYSIS    
Average copies per 
partition (λ or equivalent)  
E Y Chapter 2-4 & 6 
dPCR analysis program 
(source, version) 
E Y Chapter 2 
Outlier identification and 
disposition 
E  Chapter 3-6 
Results of NTCs  E Y Chapter 2 
Examples of positive(s) 
and negative experimental 
results as supplemental 
data 
E Y Appendix 5 
Where appropriate, 
justification of number 
and choice of reference 
genes 
E Y Chapter 2-6 
Where appropriate, 
description of 
normalisation method 
E Y Chapter 1-6 
Number and concordance 
of biological replicates 
D Y Chapter 2-6 
Number and stage (RT or 
qPCR) of technical 
replicates 
E Y Chapter 2 & Appendix 1 
Repeatability (intra-assay 
variation) 
E Y Chapter 2-6 
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Reproducibility (inter-
assay/user/lab etc. 
variation) 
D Y Chapter 2-6 
Experimental variance or 
confidence interval*** 
E Y Chapter 2-6 
Statistical methods used 
for analysis  
E Y Chapter 2-6 
Data submission using 
RDML 
D N\A - 
* Assessing the absence of DNA using a no RT assay is essential when first extracting RNA. 
Once the sample has been validated as DNA-free, inclusion of a no-RT control is desirable, but 
no longer essential. 
** Disclosure of the primer and probe sequence is highly desirable and strongly encouraged. 
However, since not all commercial pre-designed assay vendors provide this information when 
it is not available assay context sequences must be submitted [55]. 
*** When single dPCR experiments are performed, the variation due to counting error alone 
should be calculated from the binomial (or suitable equivalent) distribution. 
 
